outcome_cleaner,outcome_category,significant,parameter_clean,author,year,doi,country,study_design,number_of_patients,extracorporeal,renal_function,patient_characteristics1,betalactam_studied
creatinine clearance,Physiological parameters,no,NA,Barreto,2023,https://dx.doi.org/10.1002/phar.2766,USA,prospective PK study,100,no,normal,general ICU,cefepime
SOFA,Disease severity score,no,NA,Abdul-Aziz,2016,https://dx.doi.org/10.1128/AAC.01543-15,Malaysia,prospective PK study,12,no,normal,sepsis,doripenem
weight,Patient characteristics,no,NA,Abdul-Aziz,2016,https://dx.doi.org/10.1128/AAC.01543-15,Malaysia,prospective PK study,12,no,normal,sepsis,doripenem
age,Patient characteristics,yes,Ke,Al-Shaer,2020,https://dx.doi.org/10.1128/AAC.00745-20,USA,retrospective PK study,230,no,normal,general ICU,cefepime
creatinine clearance,Physiological parameters,no,NA,Bue,2020,https://dx.doi.org/10.1016/j.ijid.2020.01.010,Denmark,prospective PK study,10,RRT,impaired,CRRT,piperacillin
weight,Patient characteristics,yes,"V, Ke",Al-Shaer,2020,https://dx.doi.org/10.1128/AAC.00745-20,USA,retrospective PK study,230,no,normal,general ICU,cefepime
sex,Patient characteristics,no,NA,Al-Shaer,2020,https://dx.doi.org/10.1128/AAC.00745-20,USA,retrospective PK study,230,no,normal,general ICU,cefepime
CRRT parameters,Extracorporeal parameters,yes,NA,Al-Shaer,2021,https://dx.doi.org/10.1128/AAC.00144-21,USA,prospective PK study,10,RRT,impaired,CRRT,cefepime
CRRT parameters,Extracorporeal parameters,yes,NA,Al-Shaer,2021,https://dx.doi.org/10.1128/AAC.00144-21,USA,prospective PK study,10,RRT,impaired,CRRT,cefepime
CRRT parameters,Extracorporeal parameters,no,NA,Al-Shaer,2021,https://dx.doi.org/10.1128/AAC.00144-21,USA,prospective PK study,10,RRT,impaired,CRRT,cefepime
CRRT parameters,Extracorporeal parameters,yes,NA,Al-Shaer,2021,https://dx.doi.org/10.1128/AAC.00144-21,USA,prospective PK study,10,RRT,impaired,CRRT,cefepime
CRRT parameters,Extracorporeal parameters,no,NA,Al-Shaer,2021,https://dx.doi.org/10.1128/AAC.00144-21,USA,prospective PK study,10,RRT,impaired,CRRT,cefepime
urine output,Physiological parameters,no,NA,Al-Shaer,2021,https://dx.doi.org/10.1128/AAC.00144-21,USA,prospective PK study,10,RRT,impaired,CRRT,cefepime
weight,Patient characteristics,no,NA,Al-Shaer,2021,https://dx.doi.org/10.1128/AAC.00144-21,USA,prospective PK study,10,RRT,impaired,CRRT,cefepime
creatinine clearance,Physiological parameters,no,NA,Dhaese,2019,https://dx.doi.org/10.1016/j.ijantimicag.2019.08.024,Belgium,prospective PK study,17,no,normal,general ICU,piperacillin
BMI,Patient characteristics,yes,V,Alobaid,2016,https://dx.doi.org/10.1128/AAC.00531-16,Australia,prospective PK study,19,no,normal,obesity,meropenem
age,Patient characteristics,no,NA,Alobaid,2016,https://dx.doi.org/10.1128/AAC.00531-16,Australia,prospective PK study,19,no,normal,obesity,meropenem
APACHE,Disease severity score,no,NA,Alobaid,2016,https://dx.doi.org/10.1128/AAC.00531-16,Australia,prospective PK study,19,no,normal,obesity,meropenem
serum albumin,Biomarkers,no,NA,Alobaid,2016,https://dx.doi.org/10.1128/AAC.00531-16,Australia,prospective PK study,19,no,normal,obesity,meropenem
serum creatinine,Biomarkers,no,NA,Alobaid,2016,https://dx.doi.org/10.1128/AAC.00531-16,Australia,prospective PK study,19,no,normal,obesity,meropenem
sex,Patient characteristics,no,NA,Alobaid,2016,https://dx.doi.org/10.1128/AAC.00531-16,Australia,prospective PK study,19,no,normal,obesity,meropenem
SOFA,Disease severity score,no,NA,Alobaid,2016,https://dx.doi.org/10.1128/AAC.00531-16,Australia,prospective PK study,19,no,normal,obesity,meropenem
weight,Patient characteristics,no,NA,Alobaid,2016,https://dx.doi.org/10.1128/AAC.00531-16,Australia,prospective PK study,19,no,normal,obesity,meropenem
weight,Patient characteristics,no,NA,Alobaid,2016,https://dx.doi.org/10.1128/AAC.00531-16,Australia,prospective PK study,19,no,normal,obesity,meropenem
weight,Patient characteristics,no,NA,Alobaid,2016,https://dx.doi.org/10.1128/AAC.00531-16,Australia,prospective PK study,19,no,normal,obesity,meropenem
creatinine clearance,Physiological parameters,no,NA,Dhaese,2019,https://dx.doi.org/10.1093/jac/dky434,Belgium,prospective PK study,68,no,normal,general ICU,meropenem
BMI,Patient characteristics,yes,V,Alobaid,2017,https://dx.doi.org/10.1128/AAC.01276-16,Australia,prospective PK study,37,no,normal,obesity,piperacillin
age,Patient characteristics,no,NA,Alobaid,2017,https://dx.doi.org/10.1128/AAC.01276-16,Australia,prospective PK study,37,no,normal,obesity,piperacillin
APACHE,Disease severity score,no,NA,Alobaid,2017,https://dx.doi.org/10.1128/AAC.01276-16,Australia,prospective PK study,37,no,normal,obesity,piperacillin
serum albumin,Biomarkers,no,NA,Alobaid,2017,https://dx.doi.org/10.1128/AAC.01276-16,Australia,prospective PK study,37,no,normal,obesity,piperacillin
serum creatinine,Biomarkers,no,NA,Alobaid,2017,https://dx.doi.org/10.1128/AAC.01276-16,Australia,prospective PK study,37,no,normal,obesity,piperacillin
sex,Patient characteristics,no,NA,Alobaid,2017,https://dx.doi.org/10.1128/AAC.01276-16,Australia,prospective PK study,37,no,normal,obesity,piperacillin
SOFA,Disease severity score,no,NA,Alobaid,2017,https://dx.doi.org/10.1128/AAC.01276-16,Australia,prospective PK study,37,no,normal,obesity,piperacillin
weight,Patient characteristics,no,NA,Alobaid,2017,https://dx.doi.org/10.1128/AAC.01276-16,Australia,prospective PK study,37,no,normal,obesity,piperacillin
weight,Patient characteristics,no,NA,Alobaid,2017,https://dx.doi.org/10.1128/AAC.01276-16,Australia,prospective PK study,37,no,normal,obesity,piperacillin
weight,Patient characteristics,no,NA,Alobaid,2017,https://dx.doi.org/10.1128/AAC.01276-16,Australia,prospective PK study,37,no,normal,obesity,piperacillin
creatinine clearance,Physiological parameters,no,CL,Dreesen,2022,https://dx.doi.org/10.1093/jac/dkac209,Belgium,prospective PK study,33,no,normal,pneumonia,ceftriaxone
CRRT,Organ dysfunction/support,yes,CL,An,2023,https://dx.doi.org/10.1128/aac.01312-22,USA,prospective PK study,130,no,normal,general ICU,meropenem
weight,Patient characteristics,yes,V,An,2023,https://dx.doi.org/10.1128/aac.01312-22,USA,prospective PK study,130,no,normal,general ICU,meropenem
age,Patient characteristics,no,NA,An,2023,https://dx.doi.org/10.1128/aac.01312-22,USA,prospective PK study,130,no,normal,general ICU,meropenem
AKI,Organ dysfunction/support,no,NA,An,2023,https://dx.doi.org/10.1128/aac.01312-22,USA,prospective PK study,130,no,normal,general ICU,meropenem
mechanical ventilation,Organ dysfunction/support,no,NA,An,2023,https://dx.doi.org/10.1128/aac.01312-22,USA,prospective PK study,130,no,normal,general ICU,meropenem
mortality,Other,no,NA,An,2023,https://dx.doi.org/10.1128/aac.01312-22,USA,prospective PK study,130,no,normal,general ICU,meropenem
sepsis,Organ dysfunction/support,no,NA,An,2023,https://dx.doi.org/10.1128/aac.01312-22,USA,prospective PK study,130,no,normal,general ICU,meropenem
sepsis,Organ dysfunction/support,no,NA,An,2023,https://dx.doi.org/10.1128/aac.01312-22,USA,prospective PK study,130,no,normal,general ICU,meropenem
sex,Patient characteristics,no,NA,An,2023,https://dx.doi.org/10.1128/aac.01312-22,USA,prospective PK study,130,no,normal,general ICU,meropenem
SOFA,Disease severity score,no,NA,An,2023,https://dx.doi.org/10.1128/aac.01312-22,USA,prospective PK study,130,no,normal,general ICU,meropenem
weight,Patient characteristics,no,NA,An,2023,https://dx.doi.org/10.1128/aac.01312-22,USA,prospective PK study,130,no,normal,general ICU,meropenem
creatinine clearance,Physiological parameters,no,NA,Ehmann,2019,https://dx.doi.org/10.1016/j.ijantimicag.2019.06.016,Germany,prospective PK study,48,"ECMO, RRT",impaired,sepsis,meropenem
weight,Patient characteristics,yes,V,Asin-Prieto,2014,https://dx.doi.org/10.1093/jac/dkt304,Spain,prospective PK study,16,RRT,impaired,CRRT,piperacillin
age,Patient characteristics,no,NA,Asin-Prieto,2014,https://dx.doi.org/10.1093/jac/dkt304,Spain,prospective PK study,16,RRT,impaired,CRRT,piperacillin
APACHE,Disease severity score,no,NA,Asin-Prieto,2014,https://dx.doi.org/10.1093/jac/dkt304,Spain,prospective PK study,16,RRT,impaired,CRRT,piperacillin
CRRT parameters,Extracorporeal parameters,no,NA,Asin-Prieto,2014,https://dx.doi.org/10.1093/jac/dkt304,Spain,prospective PK study,16,RRT,impaired,CRRT,piperacillin
CRRT parameters,Extracorporeal parameters,no,NA,Asin-Prieto,2014,https://dx.doi.org/10.1093/jac/dkt304,Spain,prospective PK study,16,RRT,impaired,CRRT,piperacillin
CRRT parameters,Extracorporeal parameters,no,NA,Asin-Prieto,2014,https://dx.doi.org/10.1093/jac/dkt304,Spain,prospective PK study,16,RRT,impaired,CRRT,piperacillin
drug sieving coefficient,Extracorporeal parameters,no,NA,Asin-Prieto,2014,https://dx.doi.org/10.1093/jac/dkt304,Spain,prospective PK study,16,RRT,impaired,CRRT,piperacillin
patient type,Patient characteristics,no,NA,Asin-Prieto,2014,https://dx.doi.org/10.1093/jac/dkt304,Spain,prospective PK study,16,RRT,impaired,CRRT,piperacillin
serum albumin,Biomarkers,no,NA,Asin-Prieto,2014,https://dx.doi.org/10.1093/jac/dkt304,Spain,prospective PK study,16,RRT,impaired,CRRT,piperacillin
serum bilirubin,Biomarkers,no,NA,Asin-Prieto,2014,https://dx.doi.org/10.1093/jac/dkt304,Spain,prospective PK study,16,RRT,impaired,CRRT,piperacillin
serum protein,Biomarkers,no,NA,Asin-Prieto,2014,https://dx.doi.org/10.1093/jac/dkt304,Spain,prospective PK study,16,RRT,impaired,CRRT,piperacillin
sex,Patient characteristics,no,NA,Asin-Prieto,2014,https://dx.doi.org/10.1093/jac/dkt304,Spain,prospective PK study,16,RRT,impaired,CRRT,piperacillin
SOFA,Disease severity score,no,NA,Asin-Prieto,2014,https://dx.doi.org/10.1093/jac/dkt304,Spain,prospective PK study,16,RRT,impaired,CRRT,piperacillin
unbound drug fraction,Other,no,NA,Asin-Prieto,2014,https://dx.doi.org/10.1093/jac/dkt304,Spain,prospective PK study,16,RRT,impaired,CRRT,piperacillin
GFR,Physiological parameters,yes,CL,Barreto,2023,https://dx.doi.org/10.1002/phar.2766,USA,prospective PK study,100,no,normal,general ICU,cefepime
weight,Patient characteristics,yes,V,Barreto,2023,https://dx.doi.org/10.1002/phar.2766,USA,prospective PK study,100,no,normal,general ICU,cefepime
age,Patient characteristics,no,NA,Barreto,2023,https://dx.doi.org/10.1002/phar.2766,USA,prospective PK study,100,no,normal,general ICU,cefepime
BSA,Patient characteristics,no,NA,Barreto,2023,https://dx.doi.org/10.1002/phar.2766,USA,prospective PK study,100,no,normal,general ICU,cefepime
creatinine clearance,Physiological parameters,no,NA,Eisert,2021,https://dx.doi.org/10.1016/j.ijantimicag.2021.106289,Germany,prospective PK study,32,RRT,impaired,septic shock,meropenem
ethnicity,Patient characteristics,no,NA,Barreto,2023,https://dx.doi.org/10.1002/phar.2766,USA,prospective PK study,100,no,normal,general ICU,cefepime
liver disease,Organ dysfunction/support,no,NA,Barreto,2023,https://dx.doi.org/10.1002/phar.2766,USA,prospective PK study,100,no,normal,general ICU,cefepime
sex,Patient characteristics,no,NA,Barreto,2023,https://dx.doi.org/10.1002/phar.2766,USA,prospective PK study,100,no,normal,general ICU,cefepime
creatinine clearance,Physiological parameters,no,NA,Fratoni,2022,https://dx.doi.org/10.1093/jac/dkac261,USA,prospective PK study,9,no,augmented,augmented renal clearance,imipenem
MELD score,Disease severity score,yes,CL,Bastida,2020,https://dx.doi.org/10.1093/jac/dkaa362,Spain,prospective PK study,54,no,unclear,liver failure,meropenem
liver disease,Organ dysfunction/support,yes,V,Bastida,2020,https://dx.doi.org/10.1093/jac/dkaa362,Spain,prospective PK study,54,no,unclear,liver failure,meropenem
age,Patient characteristics,no,NA,Benitez-Cano,2020,https://dx.doi.org/10.1186/s13054-020-2763-4,Spain,prospective randomised PK trial,31,no,normal,pneumonia,meropenem
APACHE,Disease severity score,no,NA,Benitez-Cano,2020,https://dx.doi.org/10.1186/s13054-020-2763-4,Spain,prospective randomised PK trial,31,no,normal,pneumonia,meropenem
CRP,Biomarkers,no,NA,Benitez-Cano,2020,https://dx.doi.org/10.1186/s13054-020-2763-4,Spain,prospective randomised PK trial,31,no,normal,pneumonia,meropenem
fluid balance,Physiological parameters,no,NA,Benitez-Cano,2020,https://dx.doi.org/10.1186/s13054-020-2763-4,Spain,prospective randomised PK trial,31,no,normal,pneumonia,meropenem
GFR,Physiological parameters,no,NA,Benitez-Cano,2020,https://dx.doi.org/10.1186/s13054-020-2763-4,Spain,prospective randomised PK trial,31,no,normal,pneumonia,meropenem
mechanical ventilation,Organ dysfunction/support,no,NA,Benitez-Cano,2020,https://dx.doi.org/10.1186/s13054-020-2763-4,Spain,prospective randomised PK trial,31,no,normal,pneumonia,meropenem
procalcitonin,Biomarkers,no,NA,Benitez-Cano,2020,https://dx.doi.org/10.1186/s13054-020-2763-4,Spain,prospective randomised PK trial,31,no,normal,pneumonia,meropenem
sepsis,Organ dysfunction/support,no,NA,Benitez-Cano,2020,https://dx.doi.org/10.1186/s13054-020-2763-4,Spain,prospective randomised PK trial,31,no,normal,pneumonia,meropenem
serum albumin,Biomarkers,no,NA,Benitez-Cano,2020,https://dx.doi.org/10.1186/s13054-020-2763-4,Spain,prospective randomised PK trial,31,no,normal,pneumonia,meropenem
serum creatinine,Biomarkers,no,NA,Benitez-Cano,2020,https://dx.doi.org/10.1186/s13054-020-2763-4,Spain,prospective randomised PK trial,31,no,normal,pneumonia,meropenem
serum protein,Biomarkers,no,NA,Benitez-Cano,2020,https://dx.doi.org/10.1186/s13054-020-2763-4,Spain,prospective randomised PK trial,31,no,normal,pneumonia,meropenem
serum urea,Biomarkers,no,NA,Benitez-Cano,2020,https://dx.doi.org/10.1186/s13054-020-2763-4,Spain,prospective randomised PK trial,31,no,normal,pneumonia,meropenem
sex,Patient characteristics,no,NA,Benitez-Cano,2020,https://dx.doi.org/10.1186/s13054-020-2763-4,Spain,prospective randomised PK trial,31,no,normal,pneumonia,meropenem
weight,Patient characteristics,no,NA,Benitez-Cano,2020,https://dx.doi.org/10.1186/s13054-020-2763-4,Spain,prospective randomised PK trial,31,no,normal,pneumonia,meropenem
creatinine clearance,Physiological parameters,no,NA,Fratoni,2022,https://dx.doi.org/10.1093/jac/dkac261,USA,prospective PK study,9,no,augmented,augmented renal clearance,imipenem
creatinine clearance,Physiological parameters,no,NA,Goncalves-Pereira,2014,https://dx.doi.org/10.1186/2050-6511-15-21,Portugal,prospective PK study,15,no,normal,sepsis,meropenem
serum albumin,Biomarkers,yes,V,Boonpeng,2022,https://dx.doi.org/10.1128/aac.00845-22,Thailand,prospective PK study,52,no,normal,general ICU,meropenem
shock,Organ dysfunction/support,yes,V,Boonpeng,2022,https://dx.doi.org/10.1128/aac.00845-22,Thailand,prospective PK study,52,no,normal,general ICU,meropenem
age,Patient characteristics,no,NA,Boonpeng,2022,https://dx.doi.org/10.1128/aac.00845-22,Thailand,prospective PK study,52,no,normal,general ICU,meropenem
AKI,Organ dysfunction/support,no,NA,Boonpeng,2022,https://dx.doi.org/10.1128/aac.00845-22,Thailand,prospective PK study,52,no,normal,general ICU,meropenem
APACHE,Disease severity score,no,NA,Boonpeng,2022,https://dx.doi.org/10.1128/aac.00845-22,Thailand,prospective PK study,52,no,normal,general ICU,meropenem
BMI,Patient characteristics,no,NA,Boonpeng,2022,https://dx.doi.org/10.1128/aac.00845-22,Thailand,prospective PK study,52,no,normal,general ICU,meropenem
fluid balance,Physiological parameters,no,NA,Boonpeng,2022,https://dx.doi.org/10.1128/aac.00845-22,Thailand,prospective PK study,52,no,normal,general ICU,meropenem
GFR,Physiological parameters,no,NA,Boonpeng,2022,https://dx.doi.org/10.1128/aac.00845-22,Thailand,prospective PK study,52,no,normal,general ICU,meropenem
mechanical ventilation,Organ dysfunction/support,no,NA,Boonpeng,2022,https://dx.doi.org/10.1128/aac.00845-22,Thailand,prospective PK study,52,no,normal,general ICU,meropenem
sepsis,Organ dysfunction/support,no,NA,Boonpeng,2022,https://dx.doi.org/10.1128/aac.00845-22,Thailand,prospective PK study,52,no,normal,general ICU,meropenem
sex,Patient characteristics,no,NA,Boonpeng,2022,https://dx.doi.org/10.1128/aac.00845-22,Thailand,prospective PK study,52,no,normal,general ICU,meropenem
SOFA,Disease severity score,no,NA,Boonpeng,2022,https://dx.doi.org/10.1128/aac.00845-22,Thailand,prospective PK study,52,no,normal,general ICU,meropenem
weight,Patient characteristics,no,NA,Boonpeng,2022,https://dx.doi.org/10.1128/aac.00845-22,Thailand,prospective PK study,52,no,normal,general ICU,meropenem
weight,Patient characteristics,no,NA,Boonpeng,2022,https://dx.doi.org/10.1128/aac.00845-22,Thailand,prospective PK study,52,no,normal,general ICU,meropenem
weight,Patient characteristics,no,NA,Boonpeng,2022,https://dx.doi.org/10.1128/aac.00845-22,Thailand,prospective PK study,52,no,normal,general ICU,meropenem
weight,Patient characteristics,no,NA,Boonpeng,2022,https://dx.doi.org/10.1128/aac.00845-22,Thailand,prospective PK study,52,no,normal,general ICU,meropenem
diuresis,Physiological parameters,yes,CL,Braune,2018,https://dx.doi.org/10.1186/s13054-018-1940-1,Germany,prospective PK study,19,RRT,impaired,CRRT,meropenem
CRRT parameters,Extracorporeal parameters,no,NA,Braune,2018,https://dx.doi.org/10.1186/s13054-018-1940-1,Germany,prospective PK study,19,RRT,impaired,CRRT,meropenem
CRRT parameters,Extracorporeal parameters,no,NA,Braune,2018,https://dx.doi.org/10.1186/s13054-018-1940-1,Germany,prospective PK study,19,RRT,impaired,CRRT,meropenem
CRRT parameters,Extracorporeal parameters,no,NA,Braune,2018,https://dx.doi.org/10.1186/s13054-018-1940-1,Germany,prospective PK study,19,RRT,impaired,CRRT,meropenem
weight,Patient characteristics,no,NA,Braune,2018,https://dx.doi.org/10.1186/s13054-018-1940-1,Germany,prospective PK study,19,RRT,impaired,CRRT,meropenem
age,Patient characteristics,no,NA,Bue,2020,https://dx.doi.org/10.1016/j.ijid.2020.01.010,Denmark,prospective PK study,10,RRT,impaired,CRRT,piperacillin
creatinine clearance,Physiological parameters,no,NA,Jacobs,2018,https://dx.doi.org/10.1128/AAC.02534-17,Belgium,retrospective PK study,215,no,augmented,augmented renal clearance,"meropenem, cefepime, ceftazidime, piperacillin"
serum albumin,Biomarkers,no,NA,Bue,2020,https://dx.doi.org/10.1016/j.ijid.2020.01.010,Denmark,prospective PK study,10,RRT,impaired,CRRT,piperacillin
weight,Patient characteristics,no,NA,Bue,2020,https://dx.doi.org/10.1016/j.ijid.2020.01.010,Denmark,prospective PK study,10,RRT,impaired,CRRT,piperacillin
comorbidity,Patient characteristics,yes,CL,Buning,2021,https://dx.doi.org/10.3390/antibiotics10060612,Netherlands,retrospective PK study,96,no,unclear,general ICU,ceftazidime
creatinine clearance,Physiological parameters,no,NA,Jager,2020,https://dx.doi.org/10.1093/jac/dkaa187,Australia,retrospective PK study,35,no,normal,hypoalbuminaemia,flucloxacillin
CRRT,Organ dysfunction/support,yes,CL,Buning,2021,https://dx.doi.org/10.3390/antibiotics10060612,Netherlands,retrospective PK study,96,no,unclear,general ICU,ceftazidime
age,Patient characteristics,no,NA,Buning,2021,https://dx.doi.org/10.3390/antibiotics10060612,Netherlands,retrospective PK study,96,no,unclear,general ICU,ceftazidime
BMI,Patient characteristics,no,NA,Buning,2021,https://dx.doi.org/10.3390/antibiotics10060612,Netherlands,retrospective PK study,96,no,unclear,general ICU,ceftazidime
diuretic use,Other,no,NA,Buning,2021,https://dx.doi.org/10.3390/antibiotics10060612,Netherlands,retrospective PK study,96,no,unclear,general ICU,ceftazidime
GFR,Physiological parameters,no,NA,Buning,2021,https://dx.doi.org/10.3390/antibiotics10060612,Netherlands,retrospective PK study,96,no,unclear,general ICU,ceftazidime
mechanical ventilation,Organ dysfunction/support,no,NA,Buning,2021,https://dx.doi.org/10.3390/antibiotics10060612,Netherlands,retrospective PK study,96,no,unclear,general ICU,ceftazidime
RIFLE score,Organ dysfunction/support,no,NA,Buning,2021,https://dx.doi.org/10.3390/antibiotics10060612,Netherlands,retrospective PK study,96,no,unclear,general ICU,ceftazidime
serum albumin,Biomarkers,no,NA,Buning,2021,https://dx.doi.org/10.3390/antibiotics10060612,Netherlands,retrospective PK study,96,no,unclear,general ICU,ceftazidime
serum creatinine,Biomarkers,no,NA,Buning,2021,https://dx.doi.org/10.3390/antibiotics10060612,Netherlands,retrospective PK study,96,no,unclear,general ICU,ceftazidime
serum sodium,Biomarkers,no,NA,Buning,2021,https://dx.doi.org/10.3390/antibiotics10060612,Netherlands,retrospective PK study,96,no,unclear,general ICU,ceftazidime
sex,Patient characteristics,no,NA,Buning,2021,https://dx.doi.org/10.3390/antibiotics10060612,Netherlands,retrospective PK study,96,no,unclear,general ICU,ceftazidime
site of infection,Other,no,NA,Buning,2021,https://dx.doi.org/10.3390/antibiotics10060612,Netherlands,retrospective PK study,96,no,unclear,general ICU,ceftazidime
vasopressor use,Organ dysfunction/support,no,NA,Buning,2021,https://dx.doi.org/10.3390/antibiotics10060612,Netherlands,retrospective PK study,96,no,unclear,general ICU,ceftazidime
weight,Patient characteristics,no,NA,Buning,2021,https://dx.doi.org/10.3390/antibiotics10060612,Netherlands,retrospective PK study,96,no,unclear,general ICU,ceftazidime
age,Patient characteristics,yes,CL,Burger,2018,https://dx.doi.org/10.1093/jac/dky370,Switzerland,prospective PK study,86,RRT,impaired,CRRT,meropenem
creatinine clearance,Physiological parameters,no,NA,Jonckheere,2016,http://dx.doi.org/10.1093/jac/dkw171,Belgium,prospective PK study,20,RRT,impaired,general ICU,cefepime
weight,Patient characteristics,yes,V,Burger,2018,https://dx.doi.org/10.1093/jac/dky370,Switzerland,prospective PK study,86,RRT,impaired,CRRT,meropenem
sex,Patient characteristics,no,NA,Burger,2018,https://dx.doi.org/10.1093/jac/dky370,Switzerland,prospective PK study,86,RRT,impaired,CRRT,meropenem
creatinine clearance,Physiological parameters,no,NA,Kang,2022,https://dx.doi.org/10.3390/jcm11226621,South Korea,prospective PK study,13,"ECMO, RRT",impaired,ECMO,meropenem
age,Patient characteristics,no,NA,Burkhardt,2007,https://dx.doi.org/10.1093/jac/dkl485,Germany,prospective PK study,17,no,normal,VAP,ertapenem
serum creatinine,Biomarkers,no,NA,Burkhardt,2007,https://dx.doi.org/10.1093/jac/dkl485,Germany,prospective PK study,17,no,normal,VAP,ertapenem
serum protein,Biomarkers,no,NA,Burkhardt,2007,https://dx.doi.org/10.1093/jac/dkl485,Germany,prospective PK study,17,no,normal,VAP,ertapenem
creatinine clearance,Physiological parameters,no,NA,Mattioli,2016,https://dx.doi.org/10.1007/s00228-016-2053-x,Italy,prospective PK study,27,no,normal,sepsis,meropenem
age,Patient characteristics,no,NA,Carlier,2013,https://dx.doi.org/10.1093/jac/dkt240,Belgium,prospective PK study,13,no,normal,general ICU,amoxicillin
APACHE,Disease severity score,no,NA,Carlier,2013,https://dx.doi.org/10.1093/jac/dkt240,Belgium,prospective PK study,13,no,normal,general ICU,amoxicillin
sex,Patient characteristics,no,NA,Carlier,2013,https://dx.doi.org/10.1093/jac/dkt240,Belgium,prospective PK study,13,no,normal,general ICU,amoxicillin
SOFA,Disease severity score,no,NA,Carlier,2013,https://dx.doi.org/10.1093/jac/dkt240,Belgium,prospective PK study,13,no,normal,general ICU,amoxicillin
weight,Patient characteristics,no,NA,Carlier,2013,https://dx.doi.org/10.1093/jac/dkt240,Belgium,prospective PK study,13,no,normal,general ICU,amoxicillin
creatinine clearance,Physiological parameters,no,NA,Niibe,2022,https://dx.doi.org/10.1016/j.jiac.2021.12.017,Japan,prospective PK study,12,no,normal,general ICU,meropenem
age,Patient characteristics,no,NA,Carlier,2014,https://dx.doi.org/10.1093/jac/dku195,Belgium,prospective PK study,20,no,normal,general ICU,cefuroxime
APACHE,Disease severity score,no,NA,Carlier,2014,https://dx.doi.org/10.1093/jac/dku195,Belgium,prospective PK study,20,no,normal,general ICU,cefuroxime
serum albumin,Biomarkers,no,NA,Carlier,2014,https://dx.doi.org/10.1093/jac/dku195,Belgium,prospective PK study,20,no,normal,general ICU,cefuroxime
sex,Patient characteristics,no,NA,Carlier,2014,https://dx.doi.org/10.1093/jac/dku195,Belgium,prospective PK study,20,no,normal,general ICU,cefuroxime
SOFA,Disease severity score,no,NA,Carlier,2014,https://dx.doi.org/10.1093/jac/dku195,Belgium,prospective PK study,20,no,normal,general ICU,cefuroxime
weight,Patient characteristics,no,NA,Carlier,2014,https://dx.doi.org/10.1093/jac/dku195,Belgium,prospective PK study,20,no,normal,general ICU,cefuroxime
creatinine clearance,Physiological parameters,no,NA,Por,2021,https://dx.doi.org/10.1002/jcph.1865,USA,prospective PK study,23,RRT,impaired,burns,imipenem
BMI,Patient characteristics,no,V,Chauzy,2019,https://dx.doi.org/10.1093/jac/dky489,France,prospective PK study,11,no,unclear,CNS infection,ceftaroline
weight,Patient characteristics,no,V,Chauzy,2019,https://dx.doi.org/10.1093/jac/dky489,France,prospective PK study,11,no,unclear,CNS infection,ceftaroline
creatinine clearance,Physiological parameters,no,NA,Sakka,2007,https://dx.doi.org/10.1128/AAC.01318-06,Germany,prospective randomised PK trial,20,no,normal,VAP,imipenem
age,Patient characteristics,no,NA,Chauzy,2022,https://dx.doi.org/10.1093/jac/dkac299,France,prospective PK study,18,no,augmented,pneumonia,ceftaroline
SAPS,Disease severity score,no,NA,Chauzy,2022,https://dx.doi.org/10.1093/jac/dkac299,France,prospective PK study,18,no,augmented,pneumonia,ceftaroline
serum albumin,Biomarkers,no,NA,Chauzy,2022,https://dx.doi.org/10.1093/jac/dkac299,France,prospective PK study,18,no,augmented,pneumonia,ceftaroline
serum protein,Biomarkers,no,NA,Chauzy,2022,https://dx.doi.org/10.1093/jac/dkac299,France,prospective PK study,18,no,augmented,pneumonia,ceftaroline
SOFA,Disease severity score,no,NA,Chauzy,2022,https://dx.doi.org/10.1093/jac/dkac299,France,prospective PK study,18,no,augmented,pneumonia,ceftaroline
weight,Patient characteristics,no,NA,Chauzy,2022,https://dx.doi.org/10.1093/jac/dkac299,France,prospective PK study,18,no,augmented,pneumonia,ceftaroline
creatinine clearance,Physiological parameters,no,NA,Ulldemolins,2010,https://dx.doi.org/10.1093/jac/dkq184,Australia,prospective PK study,10,no,normal,hypoalbuminaemia,flucloxacillin
weight,Patient characteristics,yes,V,Cheatham,2014,https://dx.doi.org/10.1002/jcph.196,USA,prospective PK study,9,no,normal,obesity,meropenem
BMI,Patient characteristics,no,NA,Cheatham,2014,https://dx.doi.org/10.1002/jcph.196,USA,prospective PK study,9,no,normal,obesity,meropenem
weight,Patient characteristics,no,NA,Cheatham,2014,https://dx.doi.org/10.1002/jcph.196,USA,prospective PK study,9,no,normal,obesity,meropenem
weight,Patient characteristics,no,NA,Cheatham,2014,https://dx.doi.org/10.1002/jcph.196,USA,prospective PK study,9,no,normal,obesity,meropenem
creatinine clearance,Physiological parameters,no,NA,Wallenburg,2021,https://dx.doi.org/10.1093/jac/dkab314,Netherlands,prospective PK study,33,RRT,impaired,general ICU,flucloxacillin
ECMO,Organ dysfunction/support,yes,CL,Chen,2020,https://dx.doi.org/10.1128/AAC.00385-20,China,retrospective PK study,247,ECMO,unclear,ECMO,imipenem
weight,Patient characteristics,yes,CL,Chen,2020,https://dx.doi.org/10.1128/AAC.00385-20,China,retrospective PK study,247,ECMO,unclear,ECMO,imipenem
age,Patient characteristics,no,NA,Chen,2020,https://dx.doi.org/10.1128/AAC.00385-20,China,retrospective PK study,247,ECMO,unclear,ECMO,imipenem
AST,Biomarkers,no,NA,Chen,2020,https://dx.doi.org/10.1128/AAC.00385-20,China,retrospective PK study,247,ECMO,unclear,ECMO,imipenem
CRRT,Organ dysfunction/support,no,NA,Chen,2020,https://dx.doi.org/10.1128/AAC.00385-20,China,retrospective PK study,247,ECMO,unclear,ECMO,imipenem
creatinine clearance,Physiological parameters,no,NA,Westermann,2021,https://dx.doi.org/10.1111/bcp.14846,Germany,prospective PK study,25,RRT,impaired,CRRT,meropenem
BMI,Patient characteristics,yes,V,Cheng,2021,https://dx.doi.org/10.1128/AAC.01438-21,International,prospective PK study,27,"ECMO, RRT",impaired,ECMO,piperacillin
age,Patient characteristics,no,NA,Cheng,2021,https://dx.doi.org/10.1128/AAC.01438-21,International,prospective PK study,27,"ECMO, RRT",impaired,ECMO,piperacillin
APACHE,Disease severity score,no,NA,Cheng,2021,https://dx.doi.org/10.1128/AAC.01438-21,International,prospective PK study,27,"ECMO, RRT",impaired,ECMO,piperacillin
ECMO parameters,Extracorporeal parameters,no,NA,Cheng,2021,https://dx.doi.org/10.1128/AAC.01438-21,International,prospective PK study,27,"ECMO, RRT",impaired,ECMO,piperacillin
ECMO parameters,Extracorporeal parameters,no,NA,Cheng,2021,https://dx.doi.org/10.1128/AAC.01438-21,International,prospective PK study,27,"ECMO, RRT",impaired,ECMO,piperacillin
serum creatinine,Biomarkers,no,NA,Cheng,2021,https://dx.doi.org/10.1128/AAC.01438-21,International,prospective PK study,27,"ECMO, RRT",impaired,ECMO,piperacillin
SOFA,Disease severity score,no,NA,Cheng,2021,https://dx.doi.org/10.1128/AAC.01438-21,International,prospective PK study,27,"ECMO, RRT",impaired,ECMO,piperacillin
weight,Patient characteristics,no,NA,Cheng,2021,https://dx.doi.org/10.1128/AAC.01438-21,International,prospective PK study,27,"ECMO, RRT",impaired,ECMO,piperacillin
creatinine clearance,Physiological parameters,NA,CL,Felton,2014,https://dx.doi.org/10.1128/AAC.02664-14,UK,retrospective PK study,146,no,unclear,general ICU,piperacillin
weight,Patient characteristics,yes,V,Cheng,2021,https://dx.doi.org/10.1016/j.ijantimicag.2021.106466,International,prospective PK study,6,ECMO,unclear,ECMO,cefepime
age,Patient characteristics,no,NA,Cheng,2021,https://dx.doi.org/10.1016/j.ijantimicag.2021.106466,International,prospective PK study,6,ECMO,unclear,ECMO,cefepime
APACHE,Disease severity score,no,NA,Cheng,2021,https://dx.doi.org/10.1016/j.ijantimicag.2021.106466,International,prospective PK study,6,ECMO,unclear,ECMO,cefepime
BMI,Patient characteristics,no,NA,Cheng,2021,https://dx.doi.org/10.1016/j.ijantimicag.2021.106466,International,prospective PK study,6,ECMO,unclear,ECMO,cefepime
ECMO parameters,Extracorporeal parameters,no,NA,Cheng,2021,https://dx.doi.org/10.1016/j.ijantimicag.2021.106466,International,prospective PK study,6,ECMO,unclear,ECMO,cefepime
serum creatinine,Biomarkers,no,NA,Cheng,2021,https://dx.doi.org/10.1016/j.ijantimicag.2021.106466,International,prospective PK study,6,ECMO,unclear,ECMO,cefepime
SOFA,Disease severity score,no,NA,Cheng,2021,https://dx.doi.org/10.1016/j.ijantimicag.2021.106466,International,prospective PK study,6,ECMO,unclear,ECMO,cefepime
creatinine clearance,Physiological parameters,yes,CL,Abdul-Aziz,2016,https://dx.doi.org/10.1128/AAC.01543-15,Malaysia,prospective PK study,12,no,normal,sepsis,doripenem
CRRT,Organ dysfunction/support,yes,CL,Cheng,2022,https://dx.doi.org/10.1007/s40262-021-01106-x,International,prospective PK study,14,"ECMO, RRT",impaired,ECMO,ceftriaxone
serum albumin,Biomarkers,yes,V,Cheng,2022,https://dx.doi.org/10.1007/s40262-021-01106-x,International,prospective PK study,14,"ECMO, RRT",impaired,ECMO,ceftriaxone
weight,Patient characteristics,yes,V,Cheng,2022,https://dx.doi.org/10.1007/s40262-021-01106-x,International,prospective PK study,14,"ECMO, RRT",impaired,ECMO,ceftriaxone
age,Patient characteristics,no,NA,Cheng,2022,https://dx.doi.org/10.1007/s40262-021-01106-x,International,prospective PK study,14,"ECMO, RRT",impaired,ECMO,ceftriaxone
APACHE,Disease severity score,no,NA,Cheng,2022,https://dx.doi.org/10.1007/s40262-021-01106-x,International,prospective PK study,14,"ECMO, RRT",impaired,ECMO,ceftriaxone
BMI,Patient characteristics,no,NA,Cheng,2022,https://dx.doi.org/10.1007/s40262-021-01106-x,International,prospective PK study,14,"ECMO, RRT",impaired,ECMO,ceftriaxone
ECMO parameters,Extracorporeal parameters,no,NA,Cheng,2022,https://dx.doi.org/10.1007/s40262-021-01106-x,International,prospective PK study,14,"ECMO, RRT",impaired,ECMO,ceftriaxone
ECMO parameters,Extracorporeal parameters,no,NA,Cheng,2022,https://dx.doi.org/10.1007/s40262-021-01106-x,International,prospective PK study,14,"ECMO, RRT",impaired,ECMO,ceftriaxone
serum creatinine,Biomarkers,no,NA,Cheng,2022,https://dx.doi.org/10.1007/s40262-021-01106-x,International,prospective PK study,14,"ECMO, RRT",impaired,ECMO,ceftriaxone
SOFA,Disease severity score,no,NA,Cheng,2022,https://dx.doi.org/10.1007/s40262-021-01106-x,International,prospective PK study,14,"ECMO, RRT",impaired,ECMO,ceftriaxone
creatinine clearance,Physiological parameters,yes,Ke,Al-Shaer,2020,https://dx.doi.org/10.1128/AAC.00745-20,USA,retrospective PK study,230,no,normal,general ICU,cefepime
location,Other,yes,V,Chung,2017,https://dx.doi.org/10.1177/1060028016676831,USA,prospective PK study,20,no,normal,obesity,doripenem
weight,Patient characteristics,yes,V,Chung,2017,https://dx.doi.org/10.1177/1060028016676831,USA,prospective PK study,20,no,normal,obesity,doripenem
age,Patient characteristics,no,NA,Chung,2017,https://dx.doi.org/10.1177/1060028016676831,USA,prospective PK study,20,no,normal,obesity,doripenem
BMI,Patient characteristics,no,NA,Chung,2017,https://dx.doi.org/10.1177/1060028016676831,USA,prospective PK study,20,no,normal,obesity,doripenem
sex,Patient characteristics,no,NA,Chung,2017,https://dx.doi.org/10.1177/1060028016676831,USA,prospective PK study,20,no,normal,obesity,doripenem
weight,Patient characteristics,no,NA,Chung,2017,https://dx.doi.org/10.1177/1060028016676831,USA,prospective PK study,20,no,normal,obesity,doripenem
weight,Patient characteristics,no,NA,Chung,2017,https://dx.doi.org/10.1177/1060028016676831,USA,prospective PK study,20,no,normal,obesity,doripenem
creatinine clearance,Physiological parameters,yes,CL,Alobaid,2016,https://dx.doi.org/10.1128/AAC.00531-16,Australia,prospective PK study,19,no,normal,obesity,meropenem
weight,Patient characteristics,yes,V,Cojutti,2021,https://dx.doi.org/10.3389/fphar.2021.781892,Italy,retrospective PK study,74,no,normal,general ICU,meropenem
height,Patient characteristics,no,NA,Cojutti,2021,https://dx.doi.org/10.3389/fphar.2021.781892,Italy,retrospective PK study,74,no,normal,general ICU,meropenem
sex,Patient characteristics,no,NA,Cojutti,2021,https://dx.doi.org/10.3389/fphar.2021.781892,Italy,retrospective PK study,74,no,normal,general ICU,meropenem
creatinine clearance,Physiological parameters,yes,CL,Alobaid,2017,https://dx.doi.org/10.1128/AAC.01276-16,Australia,prospective PK study,37,no,normal,obesity,piperacillin
mechanical ventilation,Organ dysfunction/support,yes,V,Conil,2007,https://dx.doi.org/10.1111/j.1365-2125.2007.02857.x,France,prospective PK study,50,no,unclear,burns,ceftazidime
serum creatinine,Biomarkers,yes,V,Conil,2007,https://dx.doi.org/10.1111/j.1365-2125.2007.02857.x,France,prospective PK study,50,no,unclear,burns,ceftazidime
sex,Patient characteristics,yes,V,Conil,2007,https://dx.doi.org/10.1111/j.1365-2125.2007.02857.x,France,prospective PK study,50,no,unclear,burns,ceftazidime
age,Patient characteristics,no,NA,Conil,2007,https://dx.doi.org/10.1111/j.1365-2125.2007.02857.x,France,prospective PK study,50,no,unclear,burns,ceftazidime
alkaline reserve,Other,no,NA,Conil,2007,https://dx.doi.org/10.1111/j.1365-2125.2007.02857.x,France,prospective PK study,50,no,unclear,burns,ceftazidime
ALP,Biomarkers,no,NA,Conil,2007,https://dx.doi.org/10.1111/j.1365-2125.2007.02857.x,France,prospective PK study,50,no,unclear,burns,ceftazidime
ALT,Biomarkers,no,NA,Conil,2007,https://dx.doi.org/10.1111/j.1365-2125.2007.02857.x,France,prospective PK study,50,no,unclear,burns,ceftazidime
Baux index,Other,no,NA,Conil,2007,https://dx.doi.org/10.1111/j.1365-2125.2007.02857.x,France,prospective PK study,50,no,unclear,burns,ceftazidime
BUN,Biomarkers,no,NA,Conil,2007,https://dx.doi.org/10.1111/j.1365-2125.2007.02857.x,France,prospective PK study,50,no,unclear,burns,ceftazidime
oxygenation,Organ dysfunction/support,no,NA,Conil,2007,https://dx.doi.org/10.1111/j.1365-2125.2007.02857.x,France,prospective PK study,50,no,unclear,burns,ceftazidime
pCO2,Biomarkers,no,NA,Conil,2007,https://dx.doi.org/10.1111/j.1365-2125.2007.02857.x,France,prospective PK study,50,no,unclear,burns,ceftazidime
serum protein,Biomarkers,no,NA,Conil,2007,https://dx.doi.org/10.1111/j.1365-2125.2007.02857.x,France,prospective PK study,50,no,unclear,burns,ceftazidime
serum sodium,Biomarkers,no,NA,Conil,2007,https://dx.doi.org/10.1111/j.1365-2125.2007.02857.x,France,prospective PK study,50,no,unclear,burns,ceftazidime
TBSA,Patient characteristics,no,NA,Conil,2007,https://dx.doi.org/10.1111/j.1365-2125.2007.02857.x,France,prospective PK study,50,no,unclear,burns,ceftazidime
Tobiasen index,Other,no,NA,Conil,2007,https://dx.doi.org/10.1111/j.1365-2125.2007.02857.x,France,prospective PK study,50,no,unclear,burns,ceftazidime
weight,Patient characteristics,no,NA,Conil,2007,https://dx.doi.org/10.1111/j.1365-2125.2007.02857.x,France,prospective PK study,50,no,unclear,burns,ceftazidime
creatinine clearance,Physiological parameters,yes,CL,An,2023,https://dx.doi.org/10.1128/aac.01312-22,USA,prospective PK study,130,no,normal,general ICU,meropenem
serum albumin,Biomarkers,yes,V,Couffignal,2014,https://dx.doi.org/10.1111/bcp.12435,France,prospective PK study,63,no,normal,VAP,imipenem
weight,Patient characteristics,yes,V,Couffignal,2014,https://dx.doi.org/10.1111/bcp.12435,France,prospective PK study,63,no,normal,VAP,imipenem
age,Patient characteristics,no,NA,Couffignal,2014,https://dx.doi.org/10.1111/bcp.12435,France,prospective PK study,63,no,normal,VAP,imipenem
oedema,Other,no,NA,Couffignal,2014,https://dx.doi.org/10.1111/bcp.12435,France,prospective PK study,63,no,normal,VAP,imipenem
oxygenation,Organ dysfunction/support,no,NA,Couffignal,2014,https://dx.doi.org/10.1111/bcp.12435,France,prospective PK study,63,no,normal,VAP,imipenem
PEEP,Organ dysfunction/support,no,NA,Couffignal,2014,https://dx.doi.org/10.1111/bcp.12435,France,prospective PK study,63,no,normal,VAP,imipenem
SAPS,Disease severity score,no,NA,Couffignal,2014,https://dx.doi.org/10.1111/bcp.12435,France,prospective PK study,63,no,normal,VAP,imipenem
sepsis,Organ dysfunction/support,no,NA,Couffignal,2014,https://dx.doi.org/10.1111/bcp.12435,France,prospective PK study,63,no,normal,VAP,imipenem
sex,Patient characteristics,no,NA,Couffignal,2014,https://dx.doi.org/10.1111/bcp.12435,France,prospective PK study,63,no,normal,VAP,imipenem
SOFA,Disease severity score,no,NA,Couffignal,2014,https://dx.doi.org/10.1111/bcp.12435,France,prospective PK study,63,no,normal,VAP,imipenem
weight,Patient characteristics,no,NA,Couffignal,2014,https://dx.doi.org/10.1111/bcp.12435,France,prospective PK study,63,no,normal,VAP,imipenem
creatinine clearance,Physiological parameters,yes,CL,Asin-Prieto,2014,https://dx.doi.org/10.1093/jac/dkt304,Spain,prospective PK study,16,RRT,impaired,CRRT,piperacillin
weight,Patient characteristics,yes,V,Crandon,2011,https://dx.doi.org/10.1007/s00134-010-2105-0,USA,prospective PK study,26,no,unclear,general ICU,meropenem
age,Patient characteristics,no,NA,Crandon,2011,https://dx.doi.org/10.1007/s00134-010-2105-0,USA,prospective PK study,26,no,unclear,general ICU,meropenem
APACHE,Disease severity score,no,NA,Crandon,2011,https://dx.doi.org/10.1007/s00134-010-2105-0,USA,prospective PK study,26,no,unclear,general ICU,meropenem
ethnicity,Patient characteristics,no,NA,Crandon,2011,https://dx.doi.org/10.1007/s00134-010-2105-0,USA,prospective PK study,26,no,unclear,general ICU,meropenem
sex,Patient characteristics,no,NA,Crandon,2011,https://dx.doi.org/10.1007/s00134-010-2105-0,USA,prospective PK study,26,no,unclear,general ICU,meropenem
GFR,Physiological parameters,yes,Ke,de Velde,2020,https://dx.doi.org/10.1007/s40262-020-00859-1,Switzerland,retrospective PK study,26,no,normal,severe bacterial infection,imipenem
weight,Patient characteristics,no,NA,de Velde,2020,https://dx.doi.org/10.1007/s40262-020-00859-1,Switzerland,retrospective PK study,26,no,normal,severe bacterial infection,imipenem
weight,Patient characteristics,no,NA,de Velde,2020,https://dx.doi.org/10.1007/s40262-020-00859-1,Switzerland,retrospective PK study,26,no,normal,severe bacterial infection,imipenem
weight,Patient characteristics,no,NA,de Velde,2020,https://dx.doi.org/10.1007/s40262-020-00859-1,Switzerland,retrospective PK study,26,no,normal,severe bacterial infection,imipenem
amikacin,Other,no,CL,Delattre,2012,https://dx.doi.org/10.1016/j.clinbiochem.2012.03.030,Belgium,prospective PK study,88,no,normal,sepsis,"piperacillin, ceftazidime, cefepime, meropenem"
amikacin,Other,no,CL,Delattre,2012,https://dx.doi.org/10.1016/j.clinbiochem.2012.03.030,Belgium,prospective PK study,88,no,normal,sepsis,"piperacillin, ceftazidime, cefepime, meropenem"
renal function,Physiological parameters,no,CL,Delattre,2012,https://dx.doi.org/10.1016/j.clinbiochem.2012.03.030,Belgium,prospective PK study,88,no,normal,sepsis,"piperacillin, ceftazidime, cefepime, meropenem"
amikacin,Other,no,V,Delattre,2012,https://dx.doi.org/10.1016/j.clinbiochem.2012.03.030,Belgium,prospective PK study,88,no,normal,sepsis,"piperacillin, ceftazidime, cefepime, meropenem"
amikacin,Other,no,V,Delattre,2012,https://dx.doi.org/10.1016/j.clinbiochem.2012.03.030,Belgium,prospective PK study,88,no,normal,sepsis,"piperacillin, ceftazidime, cefepime, meropenem"
creatinine clearance,Physiological parameters,yes,CL,Bastida,2020,https://dx.doi.org/10.1093/jac/dkaa362,Spain,prospective PK study,54,no,unclear,liver failure,meropenem
APACHE,Disease severity score,no,NA,Dhaese,2018,https://dx.doi.org/10.1016/j.ijantimicag.2017.12.015,Belgium,prospective PK study,110,no,normal,general ICU,piperacillin
serum albumin,Biomarkers,no,NA,Dhaese,2018,https://dx.doi.org/10.1016/j.ijantimicag.2017.12.015,Belgium,prospective PK study,110,no,normal,general ICU,piperacillin
serum bilirubin,Biomarkers,no,NA,Dhaese,2018,https://dx.doi.org/10.1016/j.ijantimicag.2017.12.015,Belgium,prospective PK study,110,no,normal,general ICU,piperacillin
SOFA,Disease severity score,no,NA,Dhaese,2018,https://dx.doi.org/10.1016/j.ijantimicag.2017.12.015,Belgium,prospective PK study,110,no,normal,general ICU,piperacillin
weight,Patient characteristics,no,NA,Dhaese,2018,https://dx.doi.org/10.1016/j.ijantimicag.2017.12.015,Belgium,prospective PK study,110,no,normal,general ICU,piperacillin
creatinine clearance,Physiological parameters,yes,CL,Bhalodi,2013,https://dx.doi.org/10.1345/aph.1R789,USA,prospective PK study,25,no,normal,general ICU,doripenem
creatinine clearance,Physiological parameters,yes,CL,Boonpeng,2022,https://dx.doi.org/10.1128/aac.00845-22,Thailand,prospective PK study,52,no,normal,general ICU,meropenem
GFR,Physiological parameters,no,NA,Dhaese,2019,https://dx.doi.org/10.1016/j.ijantimicag.2019.08.024,Belgium,prospective PK study,17,no,normal,general ICU,piperacillin
serum albumin,Biomarkers,no,NA,Dhaese,2019,https://dx.doi.org/10.1016/j.ijantimicag.2019.08.024,Belgium,prospective PK study,17,no,normal,general ICU,piperacillin
SOFA,Disease severity score,no,NA,Dhaese,2019,https://dx.doi.org/10.1016/j.ijantimicag.2019.08.024,Belgium,prospective PK study,17,no,normal,general ICU,piperacillin
weight,Patient characteristics,no,NA,Dhaese,2019,https://dx.doi.org/10.1016/j.ijantimicag.2019.08.024,Belgium,prospective PK study,17,no,normal,general ICU,piperacillin
creatinine clearance,Physiological parameters,yes,CL,Buning,2021,https://dx.doi.org/10.3390/antibiotics10060612,Netherlands,retrospective PK study,96,no,unclear,general ICU,ceftazidime
age,Patient characteristics,no,NA,Dhaese,2019,https://dx.doi.org/10.1093/jac/dky434,Belgium,prospective PK study,68,no,normal,general ICU,meropenem
APACHE,Disease severity score,no,NA,Dhaese,2019,https://dx.doi.org/10.1093/jac/dky434,Belgium,prospective PK study,68,no,normal,general ICU,meropenem
BMI,Patient characteristics,no,NA,Dhaese,2019,https://dx.doi.org/10.1093/jac/dky434,Belgium,prospective PK study,68,no,normal,general ICU,meropenem
creatinine clearance,Physiological parameters,yes,CL,Burger,2018,https://dx.doi.org/10.1093/jac/dky370,Switzerland,prospective PK study,86,RRT,impaired,CRRT,meropenem
serum albumin,Biomarkers,no,NA,Dhaese,2019,https://dx.doi.org/10.1093/jac/dky434,Belgium,prospective PK study,68,no,normal,general ICU,meropenem
sex,Patient characteristics,no,NA,Dhaese,2019,https://dx.doi.org/10.1093/jac/dky434,Belgium,prospective PK study,68,no,normal,general ICU,meropenem
SOFA,Disease severity score,no,NA,Dhaese,2019,https://dx.doi.org/10.1093/jac/dky434,Belgium,prospective PK study,68,no,normal,general ICU,meropenem
weight,Patient characteristics,no,NA,Dhaese,2019,https://dx.doi.org/10.1093/jac/dky434,Belgium,prospective PK study,68,no,normal,general ICU,meropenem
creatinine clearance,Physiological parameters,yes,CL,Burkhardt,2007,https://dx.doi.org/10.1093/jac/dkl485,Germany,prospective PK study,17,no,normal,VAP,ertapenem
age,Patient characteristics,no,NA,Dinh,2022,https://dx.doi.org/10.2147/IDR.S373348,Vietnam,prospective PK study,24,no,normal,general ICU,imipenem
location,Other,no,NA,Dinh,2022,https://dx.doi.org/10.2147/IDR.S373348,Vietnam,prospective PK study,24,no,normal,general ICU,imipenem
mechanical ventilation,Organ dysfunction/support,no,NA,Dinh,2022,https://dx.doi.org/10.2147/IDR.S373348,Vietnam,prospective PK study,24,no,normal,general ICU,imipenem
serum albumin,Biomarkers,no,NA,Dinh,2022,https://dx.doi.org/10.2147/IDR.S373348,Vietnam,prospective PK study,24,no,normal,general ICU,imipenem
sex,Patient characteristics,no,NA,Dinh,2022,https://dx.doi.org/10.2147/IDR.S373348,Vietnam,prospective PK study,24,no,normal,general ICU,imipenem
vasopressor use,Organ dysfunction/support,no,NA,Dinh,2022,https://dx.doi.org/10.2147/IDR.S373348,Vietnam,prospective PK study,24,no,normal,general ICU,imipenem
weight,Patient characteristics,no,NA,Dinh,2022,https://dx.doi.org/10.2147/IDR.S373348,Vietnam,prospective PK study,24,no,normal,general ICU,imipenem
ARC,Physiological parameters,no,CL,Dreesen,2022,https://dx.doi.org/10.1093/jac/dkac209,Belgium,prospective PK study,33,no,normal,pneumonia,ceftriaxone
ARC,Physiological parameters,yes,CL,Dreesen,2022,https://dx.doi.org/10.1093/jac/dkac209,Belgium,prospective PK study,33,no,normal,pneumonia,ceftriaxone
creatinine clearance,Physiological parameters,yes,CL,Carlier,2013,https://dx.doi.org/10.1093/jac/dkt240,Belgium,prospective PK study,13,no,normal,general ICU,amoxicillin
GFR,Physiological parameters,yes,CL,Dreesen,2022,https://dx.doi.org/10.1093/jac/dkac209,Belgium,prospective PK study,33,no,normal,pneumonia,ceftriaxone
serum creatinine,Biomarkers,no,CL,Dreesen,2022,https://dx.doi.org/10.1093/jac/dkac209,Belgium,prospective PK study,33,no,normal,pneumonia,ceftriaxone
weight,Patient characteristics,no,"CL, V",Dreesen,2022,https://dx.doi.org/10.1093/jac/dkac209,Belgium,prospective PK study,33,no,normal,pneumonia,ceftriaxone
serum albumin,Biomarkers,no,protein binding,Dreesen,2022,https://dx.doi.org/10.1093/jac/dkac209,Belgium,prospective PK study,33,no,normal,pneumonia,ceftriaxone
age,Patient characteristics,yes,CL,Economou,2019,https://dx.doi.org/10.1016/j.ijantimicag.2019.06.027,Australia,prospective PK study,6,RRT,impaired,CRRT,ticarcillin
creatinine clearance,Physiological parameters,yes,CL,Carlier,2014,https://dx.doi.org/10.1093/jac/dku195,Belgium,prospective PK study,20,no,normal,general ICU,cefuroxime
serum creatinine,Biomarkers,yes,CL,Economou,2019,https://dx.doi.org/10.1016/j.ijantimicag.2019.06.027,Australia,prospective PK study,6,RRT,impaired,CRRT,ticarcillin
CRRT,Organ dysfunction/support,no,NA,Economou,2019,https://dx.doi.org/10.1016/j.ijantimicag.2019.06.027,Australia,prospective PK study,6,RRT,impaired,CRRT,ticarcillin
sex,Patient characteristics,no,NA,Economou,2019,https://dx.doi.org/10.1016/j.ijantimicag.2019.06.027,Australia,prospective PK study,6,RRT,impaired,CRRT,ticarcillin
weight,Patient characteristics,no,NA,Economou,2019,https://dx.doi.org/10.1016/j.ijantimicag.2019.06.027,Australia,prospective PK study,6,RRT,impaired,CRRT,ticarcillin
cholinesterase,Biomarkers,yes,CL,Ehmann,2019,https://dx.doi.org/10.1016/j.ijantimicag.2019.06.016,Germany,prospective PK study,48,"ECMO, RRT",impaired,sepsis,meropenem
creatinine clearance,Physiological parameters,yes,CL,Chauzy,2019,https://dx.doi.org/10.1093/jac/dky489,France,prospective PK study,11,no,unclear,CNS infection,ceftaroline
factor V,Biomarkers,yes,CL,Ehmann,2019,https://dx.doi.org/10.1016/j.ijantimicag.2019.06.016,Germany,prospective PK study,48,"ECMO, RRT",impaired,sepsis,meropenem
HR,Vital signs,yes,CL,Ehmann,2019,https://dx.doi.org/10.1016/j.ijantimicag.2019.06.016,Germany,prospective PK study,48,"ECMO, RRT",impaired,sepsis,meropenem
hydrogencarbonate,Biomarkers,yes,CL,Ehmann,2019,https://dx.doi.org/10.1016/j.ijantimicag.2019.06.016,Germany,prospective PK study,48,"ECMO, RRT",impaired,sepsis,meropenem
serum urea,Biomarkers,yes,CL,Ehmann,2019,https://dx.doi.org/10.1016/j.ijantimicag.2019.06.016,Germany,prospective PK study,48,"ECMO, RRT",impaired,sepsis,meropenem
age,Patient characteristics,yes,V,Ehmann,2019,https://dx.doi.org/10.1016/j.ijantimicag.2019.06.016,Germany,prospective PK study,48,"ECMO, RRT",impaired,sepsis,meropenem
lactate,Biomarkers,yes,V,Ehmann,2019,https://dx.doi.org/10.1016/j.ijantimicag.2019.06.016,Germany,prospective PK study,48,"ECMO, RRT",impaired,sepsis,meropenem
sex,Patient characteristics,yes,V,Ehmann,2019,https://dx.doi.org/10.1016/j.ijantimicag.2019.06.016,Germany,prospective PK study,48,"ECMO, RRT",impaired,sepsis,meropenem
weight,Patient characteristics,yes,V,Ehmann,2019,https://dx.doi.org/10.1016/j.ijantimicag.2019.06.016,Germany,prospective PK study,48,"ECMO, RRT",impaired,sepsis,meropenem
cardiovascular system,Vital signs,yes,"V, CL",Ehmann,2019,https://dx.doi.org/10.1016/j.ijantimicag.2019.06.016,Germany,prospective PK study,48,"ECMO, RRT",impaired,sepsis,meropenem
serum bilirubin,Biomarkers,yes,V,Ehmann,2019,https://dx.doi.org/10.1016/j.ijantimicag.2019.06.016,Germany,prospective PK study,48,"ECMO, RRT",impaired,sepsis,meropenem
CRP,Biomarkers,yes,V,Ehmann,2019,https://dx.doi.org/10.1016/j.ijantimicag.2019.06.016,Germany,prospective PK study,48,"ECMO, RRT",impaired,sepsis,meropenem
pH,Biomarkers,yes,V,Ehmann,2019,https://dx.doi.org/10.1016/j.ijantimicag.2019.06.016,Germany,prospective PK study,48,"ECMO, RRT",impaired,sepsis,meropenem
serum albumin,Biomarkers,yes,V,Ehmann,2019,https://dx.doi.org/10.1016/j.ijantimicag.2019.06.016,Germany,prospective PK study,48,"ECMO, RRT",impaired,sepsis,meropenem
antithrombin,Biomarkers,no,NA,Ehmann,2019,https://dx.doi.org/10.1016/j.ijantimicag.2019.06.016,Germany,prospective PK study,48,"ECMO, RRT",impaired,sepsis,meropenem
ARDS,Organ dysfunction/support,no,NA,Ehmann,2019,https://dx.doi.org/10.1016/j.ijantimicag.2019.06.016,Germany,prospective PK study,48,"ECMO, RRT",impaired,sepsis,meropenem
BP,Vital signs,no,NA,Ehmann,2019,https://dx.doi.org/10.1016/j.ijantimicag.2019.06.016,Germany,prospective PK study,48,"ECMO, RRT",impaired,sepsis,meropenem
CD64 index,Biomarkers,no,NA,Ehmann,2019,https://dx.doi.org/10.1016/j.ijantimicag.2019.06.016,Germany,prospective PK study,48,"ECMO, RRT",impaired,sepsis,meropenem
creatinine clearance,Physiological parameters,yes,CL,Chauzy,2022,https://dx.doi.org/10.1093/jac/dkac299,France,prospective PK study,18,no,augmented,pneumonia,ceftaroline
ECMO,Organ dysfunction/support,no,NA,Ehmann,2019,https://dx.doi.org/10.1016/j.ijantimicag.2019.06.016,Germany,prospective PK study,48,"ECMO, RRT",impaired,sepsis,meropenem
fibrinogen,Biomarkers,no,NA,Ehmann,2019,https://dx.doi.org/10.1016/j.ijantimicag.2019.06.016,Germany,prospective PK study,48,"ECMO, RRT",impaired,sepsis,meropenem
IL-6,Biomarkers,no,NA,Ehmann,2019,https://dx.doi.org/10.1016/j.ijantimicag.2019.06.016,Germany,prospective PK study,48,"ECMO, RRT",impaired,sepsis,meropenem
lung transplant,Organ dysfunction/support,no,NA,Ehmann,2019,https://dx.doi.org/10.1016/j.ijantimicag.2019.06.016,Germany,prospective PK study,48,"ECMO, RRT",impaired,sepsis,meropenem
peritonitis,Organ dysfunction/support,no,NA,Ehmann,2019,https://dx.doi.org/10.1016/j.ijantimicag.2019.06.016,Germany,prospective PK study,48,"ECMO, RRT",impaired,sepsis,meropenem
serum creatinine,Biomarkers,no,NA,Ehmann,2019,https://dx.doi.org/10.1016/j.ijantimicag.2019.06.016,Germany,prospective PK study,48,"ECMO, RRT",impaired,sepsis,meropenem
serum sodium,Biomarkers,no,NA,Ehmann,2019,https://dx.doi.org/10.1016/j.ijantimicag.2019.06.016,Germany,prospective PK study,48,"ECMO, RRT",impaired,sepsis,meropenem
creatinine clearance,Physiological parameters,yes,CL,Cheatham,2014,https://dx.doi.org/10.1002/jcph.196,USA,prospective PK study,9,no,normal,obesity,meropenem
creatinine clearance,Physiological parameters,yes,CL,Chen,2020,https://dx.doi.org/10.1128/AAC.00385-20,China,retrospective PK study,247,ECMO,unclear,ECMO,imipenem
infusion volume,Other,no,NA,Eisert,2021,https://dx.doi.org/10.1016/j.ijantimicag.2021.106289,Germany,prospective PK study,32,RRT,impaired,septic shock,meropenem
study site,Other,no,NA,Eisert,2021,https://dx.doi.org/10.1016/j.ijantimicag.2021.106289,Germany,prospective PK study,32,RRT,impaired,septic shock,meropenem
weight,Patient characteristics,no,NA,Eisert,2021,https://dx.doi.org/10.1016/j.ijantimicag.2021.106289,Germany,prospective PK study,32,RRT,impaired,septic shock,meropenem
weight,Patient characteristics,no,NA,Eisert,2021,https://dx.doi.org/10.1016/j.ijantimicag.2021.106289,Germany,prospective PK study,32,RRT,impaired,septic shock,meropenem
age,Patient characteristics,NA,"CL, V",Eyler,2014,https://dx.doi.org/10.1128/AAC.02090-12,USA,prospective PK study,8,RRT,impaired,CRRT,ertapenem
weight,Patient characteristics,NA,"CL, V",Eyler,2014,https://dx.doi.org/10.1128/AAC.02090-12,USA,prospective PK study,8,RRT,impaired,CRRT,ertapenem
creatinine clearance,Physiological parameters,yes,CL,Cheng,2021,https://dx.doi.org/10.1128/AAC.01438-21,International,prospective PK study,27,"ECMO, RRT",impaired,ECMO,piperacillin
weight,Patient characteristics,NA,V,Felton,2014,https://dx.doi.org/10.1128/AAC.02664-14,UK,retrospective PK study,146,no,unclear,general ICU,piperacillin
creatinine clearance,Physiological parameters,yes,CL,Cheng,2021,https://dx.doi.org/10.1016/j.ijantimicag.2021.106466,International,prospective PK study,6,ECMO,unclear,ECMO,cefepime
ECMO,Organ dysfunction/support,no,NA,Fillatre,2021,https://dx.doi.org/10.1093/jac/dkab031,France,prospective PK study,42,"ECMO, RRT",impaired,ECMO,piperacillin
creatinine clearance,Physiological parameters,yes,CL,Cheng,2022,https://dx.doi.org/10.1007/s40262-021-01106-x,International,prospective PK study,14,"ECMO, RRT",impaired,ECMO,ceftriaxone
weight,Patient characteristics,yes,V,Fournier,2018,https://dx.doi.org/10.1128/AAC.00505-18,Switzerland,prospective PK study,21,no,unclear,burns,amoxicillin
serum albumin,Biomarkers,no,NA,Fournier,2018,https://dx.doi.org/10.1128/AAC.00505-18,Switzerland,prospective PK study,21,no,unclear,burns,amoxicillin
serum creatinine,Biomarkers,no,NA,Fournier,2018,https://dx.doi.org/10.1128/AAC.00505-18,Switzerland,prospective PK study,21,no,unclear,burns,amoxicillin
sex,Patient characteristics,no,NA,Fournier,2018,https://dx.doi.org/10.1128/AAC.00505-18,Switzerland,prospective PK study,21,no,unclear,burns,amoxicillin
TBSA,Patient characteristics,no,NA,Fournier,2018,https://dx.doi.org/10.1128/AAC.00505-18,Switzerland,prospective PK study,21,no,unclear,burns,amoxicillin
weight,Patient characteristics,no,NA,Fournier,2018,https://dx.doi.org/10.1128/AAC.00505-18,Switzerland,prospective PK study,21,no,unclear,burns,amoxicillin
weight,Patient characteristics,no,NA,Fournier,2018,https://dx.doi.org/10.1128/AAC.00505-18,Switzerland,prospective PK study,21,no,unclear,burns,amoxicillin
weight,Patient characteristics,no,NA,Fournier,2018,https://dx.doi.org/10.1128/AAC.00505-18,Switzerland,prospective PK study,21,no,unclear,burns,amoxicillin
body size,Patient characteristics,no,NA,Fratoni,2022,https://dx.doi.org/10.1093/jac/dkac261,USA,prospective PK study,9,no,augmented,augmented renal clearance,imipenem
creatinine clearance,Physiological parameters,yes,CL,Chung,2017,https://dx.doi.org/10.1177/1060028016676831,USA,prospective PK study,20,no,normal,obesity,doripenem
creatinine clearance,Physiological parameters,yes,CL,Cojutti,2021,https://dx.doi.org/10.3389/fphar.2021.781892,Italy,retrospective PK study,74,no,normal,general ICU,meropenem
creatinine clearance,Physiological parameters,yes,CL,Conil,2007,https://dx.doi.org/10.1111/j.1365-2125.2007.02857.x,France,prospective PK study,50,no,unclear,burns,ceftazidime
weight,Patient characteristics,yes,V,Frippiat,2015,https://dx.doi.org/10.1093/jac/dku354,Belgium,prospective PK study,55,RRT,impaired,pneumonia,meropenem
age,Patient characteristics,no,NA,Frippiat,2015,https://dx.doi.org/10.1093/jac/dku354,Belgium,prospective PK study,55,RRT,impaired,pneumonia,meropenem
bacteraemia,Other,no,NA,Frippiat,2015,https://dx.doi.org/10.1093/jac/dku354,Belgium,prospective PK study,55,RRT,impaired,pneumonia,meropenem
cirrhosis,Organ dysfunction/support,no,NA,Frippiat,2015,https://dx.doi.org/10.1093/jac/dku354,Belgium,prospective PK study,55,RRT,impaired,pneumonia,meropenem
SAPS,Disease severity score,no,NA,Frippiat,2015,https://dx.doi.org/10.1093/jac/dku354,Belgium,prospective PK study,55,RRT,impaired,pneumonia,meropenem
sepsis,Organ dysfunction/support,no,NA,Frippiat,2015,https://dx.doi.org/10.1093/jac/dku354,Belgium,prospective PK study,55,RRT,impaired,pneumonia,meropenem
sepsis,Organ dysfunction/support,no,NA,Frippiat,2015,https://dx.doi.org/10.1093/jac/dku354,Belgium,prospective PK study,55,RRT,impaired,pneumonia,meropenem
sex,Patient characteristics,no,NA,Frippiat,2015,https://dx.doi.org/10.1093/jac/dku354,Belgium,prospective PK study,55,RRT,impaired,pneumonia,meropenem
SOFA,Disease severity score,no,NA,Frippiat,2015,https://dx.doi.org/10.1093/jac/dku354,Belgium,prospective PK study,55,RRT,impaired,pneumonia,meropenem
surgical drain,Other,no,NA,Frippiat,2015,https://dx.doi.org/10.1093/jac/dku354,Belgium,prospective PK study,55,RRT,impaired,pneumonia,meropenem
creatinine clearance,Physiological parameters,yes,CL,Couffignal,2014,https://dx.doi.org/10.1111/bcp.12435,France,prospective PK study,63,no,normal,VAP,imipenem
age,Patient characteristics,no,NA,Garot,2011,https://dx.doi.org/10.1111/j.1365-2125.2011.04005.x,France,prospective PK study,54,RRT,impaired,sepsis,ceftriaxone
CRRT,Organ dysfunction/support,no,NA,Garot,2011,https://dx.doi.org/10.1111/j.1365-2125.2011.04005.x,France,prospective PK study,54,RRT,impaired,sepsis,ceftriaxone
fluid balance,Physiological parameters,no,NA,Garot,2011,https://dx.doi.org/10.1111/j.1365-2125.2011.04005.x,France,prospective PK study,54,RRT,impaired,sepsis,ceftriaxone
haematocrit,Biomarkers,no,NA,Garot,2011,https://dx.doi.org/10.1111/j.1365-2125.2011.04005.x,France,prospective PK study,54,RRT,impaired,sepsis,ceftriaxone
mechanical ventilation,Organ dysfunction/support,no,NA,Garot,2011,https://dx.doi.org/10.1111/j.1365-2125.2011.04005.x,France,prospective PK study,54,RRT,impaired,sepsis,ceftriaxone
SAPS,Disease severity score,no,NA,Garot,2011,https://dx.doi.org/10.1111/j.1365-2125.2011.04005.x,France,prospective PK study,54,RRT,impaired,sepsis,ceftriaxone
sepsis,Organ dysfunction/support,no,NA,Garot,2011,https://dx.doi.org/10.1111/j.1365-2125.2011.04005.x,France,prospective PK study,54,RRT,impaired,sepsis,ceftriaxone
sepsis,Organ dysfunction/support,no,NA,Garot,2011,https://dx.doi.org/10.1111/j.1365-2125.2011.04005.x,France,prospective PK study,54,RRT,impaired,sepsis,ceftriaxone
sepsis,Organ dysfunction/support,no,NA,Garot,2011,https://dx.doi.org/10.1111/j.1365-2125.2011.04005.x,France,prospective PK study,54,RRT,impaired,sepsis,ceftriaxone
serum albumin,Biomarkers,no,NA,Garot,2011,https://dx.doi.org/10.1111/j.1365-2125.2011.04005.x,France,prospective PK study,54,RRT,impaired,sepsis,ceftriaxone
serum bilirubin,Biomarkers,no,NA,Garot,2011,https://dx.doi.org/10.1111/j.1365-2125.2011.04005.x,France,prospective PK study,54,RRT,impaired,sepsis,ceftriaxone
serum creatinine,Biomarkers,no,NA,Garot,2011,https://dx.doi.org/10.1111/j.1365-2125.2011.04005.x,France,prospective PK study,54,RRT,impaired,sepsis,ceftriaxone
SOFA,Disease severity score,no,NA,Garot,2011,https://dx.doi.org/10.1111/j.1365-2125.2011.04005.x,France,prospective PK study,54,RRT,impaired,sepsis,ceftriaxone
vasopressor use,Organ dysfunction/support,no,NA,Garot,2011,https://dx.doi.org/10.1111/j.1365-2125.2011.04005.x,France,prospective PK study,54,RRT,impaired,sepsis,ceftriaxone
weight,Patient characteristics,no,NA,Garot,2011,https://dx.doi.org/10.1111/j.1365-2125.2011.04005.x,France,prospective PK study,54,RRT,impaired,sepsis,ceftriaxone
creatinine clearance,Physiological parameters,yes,CL,Crandon,2011,https://dx.doi.org/10.1007/s00134-010-2105-0,USA,prospective PK study,26,no,unclear,general ICU,meropenem
SAPS,Disease severity score,yes,CL,Georges,2009,https://dx.doi.org/10.1128/AAC.00430-09,France,prospective randomised PK trial,72,no,unclear,pneumonia,ceftazidime
mechanical ventilation,Organ dysfunction/support,yes,"CL, V",Georges,2009,https://dx.doi.org/10.1128/AAC.00430-09,France,prospective randomised PK trial,72,no,unclear,pneumonia,ceftazidime
diagnosis,Patient characteristics,yes,"CL, V",Georges,2009,https://dx.doi.org/10.1128/AAC.00430-09,France,prospective randomised PK trial,72,no,unclear,pneumonia,ceftazidime
age,Patient characteristics,no,NA,Georges,2009,https://dx.doi.org/10.1128/AAC.00430-09,France,prospective randomised PK trial,72,no,unclear,pneumonia,ceftazidime
BUN,Biomarkers,no,NA,Georges,2009,https://dx.doi.org/10.1128/AAC.00430-09,France,prospective randomised PK trial,72,no,unclear,pneumonia,ceftazidime
CRP,Biomarkers,no,NA,Georges,2009,https://dx.doi.org/10.1128/AAC.00430-09,France,prospective randomised PK trial,72,no,unclear,pneumonia,ceftazidime
haemoglobin,Biomarkers,no,NA,Georges,2009,https://dx.doi.org/10.1128/AAC.00430-09,France,prospective randomised PK trial,72,no,unclear,pneumonia,ceftazidime
height,Patient characteristics,no,NA,Georges,2009,https://dx.doi.org/10.1128/AAC.00430-09,France,prospective randomised PK trial,72,no,unclear,pneumonia,ceftazidime
SAPS,Disease severity score,no,NA,Georges,2009,https://dx.doi.org/10.1128/AAC.00430-09,France,prospective randomised PK trial,72,no,unclear,pneumonia,ceftazidime
serum creatinine,Biomarkers,no,NA,Georges,2009,https://dx.doi.org/10.1128/AAC.00430-09,France,prospective randomised PK trial,72,no,unclear,pneumonia,ceftazidime
serum protein,Biomarkers,no,NA,Georges,2009,https://dx.doi.org/10.1128/AAC.00430-09,France,prospective randomised PK trial,72,no,unclear,pneumonia,ceftazidime
sex,Patient characteristics,no,NA,Georges,2009,https://dx.doi.org/10.1128/AAC.00430-09,France,prospective randomised PK trial,72,no,unclear,pneumonia,ceftazidime
weight,Patient characteristics,no,NA,Georges,2009,https://dx.doi.org/10.1128/AAC.00430-09,France,prospective randomised PK trial,72,no,unclear,pneumonia,ceftazidime
white cell count,Biomarkers,no,NA,Georges,2009,https://dx.doi.org/10.1128/AAC.00430-09,France,prospective randomised PK trial,72,no,unclear,pneumonia,ceftazidime
creatinine clearance,Physiological parameters,yes,CL,Dhaese,2018,https://dx.doi.org/10.1016/j.ijantimicag.2017.12.015,Belgium,prospective PK study,110,no,normal,general ICU,piperacillin
age,Patient characteristics,no,NA,Gijsen,2022,https://dx.doi.org/10.2147/IDR.S343264,Belgium,prospective PK study,58,no,augmented,augmented renal clearance,meropenem
APACHE,Disease severity score,no,NA,Gijsen,2022,https://dx.doi.org/10.2147/IDR.S343264,Belgium,prospective PK study,58,no,augmented,augmented renal clearance,meropenem
ARC,Physiological parameters,no,NA,Gijsen,2022,https://dx.doi.org/10.2147/IDR.S343264,Belgium,prospective PK study,58,no,augmented,augmented renal clearance,meropenem
BMI,Patient characteristics,no,NA,Gijsen,2022,https://dx.doi.org/10.2147/IDR.S343264,Belgium,prospective PK study,58,no,augmented,augmented renal clearance,meropenem
fluid balance,Physiological parameters,no,NA,Gijsen,2022,https://dx.doi.org/10.2147/IDR.S343264,Belgium,prospective PK study,58,no,augmented,augmented renal clearance,meropenem
GFR,Physiological parameters,no,NA,Gijsen,2022,https://dx.doi.org/10.2147/IDR.S343264,Belgium,prospective PK study,58,no,augmented,augmented renal clearance,meropenem
serum creatinine,Biomarkers,no,NA,Gijsen,2022,https://dx.doi.org/10.2147/IDR.S343264,Belgium,prospective PK study,58,no,augmented,augmented renal clearance,meropenem
SOFA,Disease severity score,no,NA,Gijsen,2022,https://dx.doi.org/10.2147/IDR.S343264,Belgium,prospective PK study,58,no,augmented,augmented renal clearance,meropenem
weight,Patient characteristics,no,NA,Gijsen,2022,https://dx.doi.org/10.2147/IDR.S343264,Belgium,prospective PK study,58,no,augmented,augmented renal clearance,meropenem
weight,Patient characteristics,no,NA,Gijsen,2022,https://dx.doi.org/10.2147/IDR.S343264,Belgium,prospective PK study,58,no,augmented,augmented renal clearance,meropenem
weight,Patient characteristics,no,NA,Gijsen,2022,https://dx.doi.org/10.2147/IDR.S343264,Belgium,prospective PK study,58,no,augmented,augmented renal clearance,meropenem
Charlson comorbidity index,Patient characteristics,no,NA,Goncalves-Pereira,2014,https://dx.doi.org/10.1186/2050-6511-15-21,Portugal,prospective PK study,15,no,normal,sepsis,meropenem
creatinine clearance,Physiological parameters,yes,CL,Dhaese,2019,https://dx.doi.org/10.1016/j.ijantimicag.2019.08.024,Belgium,prospective PK study,17,no,normal,general ICU,piperacillin
SOFA,Disease severity score,no,NA,Goncalves-Pereira,2014,https://dx.doi.org/10.1186/2050-6511-15-21,Portugal,prospective PK study,15,no,normal,sepsis,meropenem
creatinine clearance,Physiological parameters,yes,CL,Dhaese,2019,https://dx.doi.org/10.1093/jac/dky434,Belgium,prospective PK study,68,no,normal,general ICU,meropenem
ECMO,Organ dysfunction/support,yes,CL,Hahn,2021,https://dx.doi.org/10.1128/Spectrum.00633-21,South Korea,prospective PK study,26,"ECMO, RRT",impaired,ECMO,piperacillin
CRRT,Organ dysfunction/support,yes,V,Hahn,2021,https://dx.doi.org/10.1128/Spectrum.00633-21,South Korea,prospective PK study,26,"ECMO, RRT",impaired,ECMO,piperacillin
serum bilirubin,Biomarkers,yes,V,Hahn,2021,https://dx.doi.org/10.1128/Spectrum.00633-21,South Korea,prospective PK study,26,"ECMO, RRT",impaired,ECMO,piperacillin
age,Patient characteristics,no,NA,Hahn,2021,https://dx.doi.org/10.1128/Spectrum.00633-21,South Korea,prospective PK study,26,"ECMO, RRT",impaired,ECMO,piperacillin
BUN,Biomarkers,no,NA,Hahn,2021,https://dx.doi.org/10.1128/Spectrum.00633-21,South Korea,prospective PK study,26,"ECMO, RRT",impaired,ECMO,piperacillin
CRRT parameters,Extracorporeal parameters,no,NA,Hahn,2021,https://dx.doi.org/10.1128/Spectrum.00633-21,South Korea,prospective PK study,26,"ECMO, RRT",impaired,ECMO,piperacillin
CRRT parameters,Extracorporeal parameters,no,NA,Hahn,2021,https://dx.doi.org/10.1128/Spectrum.00633-21,South Korea,prospective PK study,26,"ECMO, RRT",impaired,ECMO,piperacillin
CRRT parameters,Extracorporeal parameters,no,NA,Hahn,2021,https://dx.doi.org/10.1128/Spectrum.00633-21,South Korea,prospective PK study,26,"ECMO, RRT",impaired,ECMO,piperacillin
ECMO parameters,Extracorporeal parameters,no,NA,Hahn,2021,https://dx.doi.org/10.1128/Spectrum.00633-21,South Korea,prospective PK study,26,"ECMO, RRT",impaired,ECMO,piperacillin
ECMO parameters,Extracorporeal parameters,no,NA,Hahn,2021,https://dx.doi.org/10.1128/Spectrum.00633-21,South Korea,prospective PK study,26,"ECMO, RRT",impaired,ECMO,piperacillin
ECMO parameters,Extracorporeal parameters,no,NA,Hahn,2021,https://dx.doi.org/10.1128/Spectrum.00633-21,South Korea,prospective PK study,26,"ECMO, RRT",impaired,ECMO,piperacillin
GFR,Physiological parameters,no,NA,Hahn,2021,https://dx.doi.org/10.1128/Spectrum.00633-21,South Korea,prospective PK study,26,"ECMO, RRT",impaired,ECMO,piperacillin
serum creatinine,Biomarkers,no,NA,Hahn,2021,https://dx.doi.org/10.1128/Spectrum.00633-21,South Korea,prospective PK study,26,"ECMO, RRT",impaired,ECMO,piperacillin
serum protein,Biomarkers,no,NA,Hahn,2021,https://dx.doi.org/10.1128/Spectrum.00633-21,South Korea,prospective PK study,26,"ECMO, RRT",impaired,ECMO,piperacillin
sex,Patient characteristics,no,NA,Hahn,2021,https://dx.doi.org/10.1128/Spectrum.00633-21,South Korea,prospective PK study,26,"ECMO, RRT",impaired,ECMO,piperacillin
weight,Patient characteristics,no,NA,Hahn,2021,https://dx.doi.org/10.1128/Spectrum.00633-21,South Korea,prospective PK study,26,"ECMO, RRT",impaired,ECMO,piperacillin
creatinine clearance,Physiological parameters,yes,CL,Dinh,2022,https://dx.doi.org/10.2147/IDR.S373348,Vietnam,prospective PK study,24,no,normal,general ICU,imipenem
age,Patient characteristics,no,NA,Hanberg,2018,https://dx.doi.org/10.1128/AAC.02390-17,Denmark,prospective PK study,10,"ECMO, RRT",impaired,ECMO,meropenem
CRRT,Organ dysfunction/support,no,NA,Hanberg,2018,https://dx.doi.org/10.1128/AAC.02390-17,Denmark,prospective PK study,10,"ECMO, RRT",impaired,ECMO,meropenem
serum albumin,Biomarkers,no,NA,Hanberg,2018,https://dx.doi.org/10.1128/AAC.02390-17,Denmark,prospective PK study,10,"ECMO, RRT",impaired,ECMO,meropenem
sex,Patient characteristics,no,NA,Hanberg,2018,https://dx.doi.org/10.1128/AAC.02390-17,Denmark,prospective PK study,10,"ECMO, RRT",impaired,ECMO,meropenem
weight,Patient characteristics,no,NA,Hanberg,2018,https://dx.doi.org/10.1128/AAC.02390-17,Denmark,prospective PK study,10,"ECMO, RRT",impaired,ECMO,meropenem
creatinine clearance,Physiological parameters,yes,CL,Economou,2019,https://dx.doi.org/10.1016/j.ijantimicag.2019.06.027,Australia,prospective PK study,6,RRT,impaired,CRRT,ticarcillin
age,Patient characteristics,no,NA,Heffernan,2022,https://dx.doi.org/10.1128/aac.02189-21,Australia,retrospective PK study,36,no,normal,sepsis,ceftriaxone
serum albumin,Biomarkers,no,NA,Heffernan,2022,https://dx.doi.org/10.1128/aac.02189-21,Australia,retrospective PK study,36,no,normal,sepsis,ceftriaxone
sex,Patient characteristics,no,NA,Heffernan,2022,https://dx.doi.org/10.1128/aac.02189-21,Australia,retrospective PK study,36,no,normal,sepsis,ceftriaxone
weight,Patient characteristics,no,NA,Heffernan,2022,https://dx.doi.org/10.1128/aac.02189-21,Australia,retrospective PK study,36,no,normal,sepsis,ceftriaxone
creatinine clearance,Physiological parameters,yes,CL,Ehmann,2019,https://dx.doi.org/10.1016/j.ijantimicag.2019.06.016,Germany,prospective PK study,48,"ECMO, RRT",impaired,sepsis,meropenem
BMI,Patient characteristics,no,NA,Idoate Grijalba,2019,https://dx.doi.org/10.1007/s00228-019-02716-y,France,retrospective PK study,80,no,normal,general ICU,meropenem
BSA,Patient characteristics,no,NA,Idoate Grijalba,2019,https://dx.doi.org/10.1007/s00228-019-02716-y,France,retrospective PK study,80,no,normal,general ICU,meropenem
CKD,Organ dysfunction/support,no,NA,Idoate Grijalba,2019,https://dx.doi.org/10.1007/s00228-019-02716-y,France,retrospective PK study,80,no,normal,general ICU,meropenem
comorbidity,Patient characteristics,no,NA,Idoate Grijalba,2019,https://dx.doi.org/10.1007/s00228-019-02716-y,France,retrospective PK study,80,no,normal,general ICU,meropenem
CRP,Biomarkers,no,NA,Idoate Grijalba,2019,https://dx.doi.org/10.1007/s00228-019-02716-y,France,retrospective PK study,80,no,normal,general ICU,meropenem
days in ICU,Other,no,NA,Idoate Grijalba,2019,https://dx.doi.org/10.1007/s00228-019-02716-y,France,retrospective PK study,80,no,normal,general ICU,meropenem
diagnosis,Patient characteristics,no,NA,Idoate Grijalba,2019,https://dx.doi.org/10.1007/s00228-019-02716-y,France,retrospective PK study,80,no,normal,general ICU,meropenem
height,Patient characteristics,no,NA,Idoate Grijalba,2019,https://dx.doi.org/10.1007/s00228-019-02716-y,France,retrospective PK study,80,no,normal,general ICU,meropenem
liver disease,Organ dysfunction/support,no,NA,Idoate Grijalba,2019,https://dx.doi.org/10.1007/s00228-019-02716-y,France,retrospective PK study,80,no,normal,general ICU,meropenem
mechanical ventilation,Organ dysfunction/support,no,NA,Idoate Grijalba,2019,https://dx.doi.org/10.1007/s00228-019-02716-y,France,retrospective PK study,80,no,normal,general ICU,meropenem
mortality,Other,no,NA,Idoate Grijalba,2019,https://dx.doi.org/10.1007/s00228-019-02716-y,France,retrospective PK study,80,no,normal,general ICU,meropenem
procalcitonin,Biomarkers,no,NA,Idoate Grijalba,2019,https://dx.doi.org/10.1007/s00228-019-02716-y,France,retrospective PK study,80,no,normal,general ICU,meropenem
re-admission,Other,no,NA,Idoate Grijalba,2019,https://dx.doi.org/10.1007/s00228-019-02716-y,France,retrospective PK study,80,no,normal,general ICU,meropenem
SAPS,Disease severity score,no,NA,Idoate Grijalba,2019,https://dx.doi.org/10.1007/s00228-019-02716-y,France,retrospective PK study,80,no,normal,general ICU,meropenem
serum creatinine,Biomarkers,no,NA,Idoate Grijalba,2019,https://dx.doi.org/10.1007/s00228-019-02716-y,France,retrospective PK study,80,no,normal,general ICU,meropenem
sex,Patient characteristics,no,NA,Idoate Grijalba,2019,https://dx.doi.org/10.1007/s00228-019-02716-y,France,retrospective PK study,80,no,normal,general ICU,meropenem
SOFA,Disease severity score,no,NA,Idoate Grijalba,2019,https://dx.doi.org/10.1007/s00228-019-02716-y,France,retrospective PK study,80,no,normal,general ICU,meropenem
SOFA,Disease severity score,no,NA,Idoate Grijalba,2019,https://dx.doi.org/10.1007/s00228-019-02716-y,France,retrospective PK study,80,no,normal,general ICU,meropenem
vasopressor use,Organ dysfunction/support,no,NA,Idoate Grijalba,2019,https://dx.doi.org/10.1007/s00228-019-02716-y,France,retrospective PK study,80,no,normal,general ICU,meropenem
weight,Patient characteristics,no,NA,Idoate Grijalba,2019,https://dx.doi.org/10.1007/s00228-019-02716-y,France,retrospective PK study,80,no,normal,general ICU,meropenem
white cell count,Biomarkers,no,NA,Idoate Grijalba,2019,https://dx.doi.org/10.1007/s00228-019-02716-y,France,retrospective PK study,80,no,normal,general ICU,meropenem
creatinine clearance,Physiological parameters,yes,CL,Eisert,2021,https://dx.doi.org/10.1016/j.ijantimicag.2021.106289,Germany,prospective PK study,32,RRT,impaired,septic shock,meropenem
CRRT parameters,Extracorporeal parameters,yes,CL,Isla,2008,https://dx.doi.org/10.2165/00003088-200847030-00003,Spain,prospective PK study,20,RRT,impaired,CRRT,meropenem
patient type,Patient characteristics,yes,"CL, V",Isla,2008,https://dx.doi.org/10.2165/00003088-200847030-00003,Spain,prospective PK study,20,RRT,impaired,CRRT,meropenem
age,Patient characteristics,no,NA,Isla,2008,https://dx.doi.org/10.2165/00003088-200847030-00003,Spain,prospective PK study,20,RRT,impaired,CRRT,meropenem
CRRT parameters,Extracorporeal parameters,no,NA,Isla,2008,https://dx.doi.org/10.2165/00003088-200847030-00003,Spain,prospective PK study,20,RRT,impaired,CRRT,meropenem
CRRT parameters,Extracorporeal parameters,no,NA,Isla,2008,https://dx.doi.org/10.2165/00003088-200847030-00003,Spain,prospective PK study,20,RRT,impaired,CRRT,meropenem
unbound drug fraction,Other,no,NA,Isla,2008,https://dx.doi.org/10.2165/00003088-200847030-00003,Spain,prospective PK study,20,RRT,impaired,CRRT,meropenem
weight,Patient characteristics,no,NA,Isla,2008,https://dx.doi.org/10.2165/00003088-200847030-00003,Spain,prospective PK study,20,RRT,impaired,CRRT,meropenem
creatinine clearance,Physiological parameters,yes,CL,Felton,2018,https://dx.doi.org/10.1093/jac/dkx541,UK,retrospective PK study,53,no,normal,VAP,piperacillin
serum albumin,Biomarkers,yes,Bmax,Jager,2020,https://dx.doi.org/10.1093/jac/dkaa187,Australia,retrospective PK study,35,no,normal,hypoalbuminaemia,flucloxacillin
GFR,Physiological parameters,yes,CL,Jager,2020,https://dx.doi.org/10.1093/jac/dkaa187,Australia,retrospective PK study,35,no,normal,hypoalbuminaemia,flucloxacillin
age,Patient characteristics,no,NA,Jager,2020,https://dx.doi.org/10.1093/jac/dkaa187,Australia,retrospective PK study,35,no,normal,hypoalbuminaemia,flucloxacillin
BMI,Patient characteristics,no,NA,Jager,2020,https://dx.doi.org/10.1093/jac/dkaa187,Australia,retrospective PK study,35,no,normal,hypoalbuminaemia,flucloxacillin
creatinine clearance,Physiological parameters,yes,CL,Fournier,2018,https://dx.doi.org/10.1128/AAC.00505-18,Switzerland,prospective PK study,21,no,unclear,burns,amoxicillin
CRRT,Organ dysfunction/support,no,NA,Jager,2020,https://dx.doi.org/10.1093/jac/dkaa187,Australia,retrospective PK study,35,no,normal,hypoalbuminaemia,flucloxacillin
serum creatinine,Biomarkers,no,NA,Jager,2020,https://dx.doi.org/10.1093/jac/dkaa187,Australia,retrospective PK study,35,no,normal,hypoalbuminaemia,flucloxacillin
sex,Patient characteristics,no,NA,Jager,2020,https://dx.doi.org/10.1093/jac/dkaa187,Australia,retrospective PK study,35,no,normal,hypoalbuminaemia,flucloxacillin
weight,Patient characteristics,no,NA,Jager,2020,https://dx.doi.org/10.1093/jac/dkaa187,Australia,retrospective PK study,35,no,normal,hypoalbuminaemia,flucloxacillin
creatinine clearance,Physiological parameters,yes,CL,Frippiat,2015,https://dx.doi.org/10.1093/jac/dku354,Belgium,prospective PK study,55,RRT,impaired,pneumonia,meropenem
age,Patient characteristics,no,NA,Jaruratanasirikul,2015,https://dx.doi.org/10.1128/AAC.04166-14,Thailand,prospective PK study,9,no,normal,sepsis,meropenem
APACHE,Disease severity score,no,NA,Jaruratanasirikul,2015,https://dx.doi.org/10.1128/AAC.04166-14,Thailand,prospective PK study,9,no,normal,sepsis,meropenem
BMI,Patient characteristics,no,NA,Jaruratanasirikul,2015,https://dx.doi.org/10.1128/AAC.04166-14,Thailand,prospective PK study,9,no,normal,sepsis,meropenem
BP,Vital signs,no,NA,Jaruratanasirikul,2015,https://dx.doi.org/10.1128/AAC.04166-14,Thailand,prospective PK study,9,no,normal,sepsis,meropenem
BP,Vital signs,no,NA,Jaruratanasirikul,2015,https://dx.doi.org/10.1128/AAC.04166-14,Thailand,prospective PK study,9,no,normal,sepsis,meropenem
BUN,Biomarkers,no,NA,Jaruratanasirikul,2015,https://dx.doi.org/10.1128/AAC.04166-14,Thailand,prospective PK study,9,no,normal,sepsis,meropenem
fluid balance,Physiological parameters,no,NA,Jaruratanasirikul,2015,https://dx.doi.org/10.1128/AAC.04166-14,Thailand,prospective PK study,9,no,normal,sepsis,meropenem
pH,Biomarkers,no,NA,Jaruratanasirikul,2015,https://dx.doi.org/10.1128/AAC.04166-14,Thailand,prospective PK study,9,no,normal,sepsis,meropenem
serum albumin,Biomarkers,no,NA,Jaruratanasirikul,2015,https://dx.doi.org/10.1128/AAC.04166-14,Thailand,prospective PK study,9,no,normal,sepsis,meropenem
serum creatinine,Biomarkers,no,NA,Jaruratanasirikul,2015,https://dx.doi.org/10.1128/AAC.04166-14,Thailand,prospective PK study,9,no,normal,sepsis,meropenem
SOFA,Disease severity score,no,NA,Jaruratanasirikul,2015,https://dx.doi.org/10.1128/AAC.04166-14,Thailand,prospective PK study,9,no,normal,sepsis,meropenem
urine output,Physiological parameters,no,NA,Jaruratanasirikul,2015,https://dx.doi.org/10.1128/AAC.04166-14,Thailand,prospective PK study,9,no,normal,sepsis,meropenem
weight,Patient characteristics,no,NA,Jaruratanasirikul,2015,https://dx.doi.org/10.1128/AAC.04166-14,Thailand,prospective PK study,9,no,normal,sepsis,meropenem
APACHE,Disease severity score,yes,"CL, K10",Jaruratanasirikul,2019,https://dx.doi.org/10.1007/s40261-019-00796-3,Thailand,prospective PK study,10,ECMO,unclear,ECMO,imipenem
creatinine clearance,Physiological parameters,yes,CL,Garot,2011,https://dx.doi.org/10.1111/j.1365-2125.2011.04005.x,France,prospective PK study,54,RRT,impaired,sepsis,ceftriaxone
SOFA,Disease severity score,yes,"t1/2β, K10, Cmin",Jaruratanasirikul,2019,https://dx.doi.org/10.1007/s40261-019-00796-3,Thailand,prospective PK study,10,ECMO,unclear,ECMO,imipenem
age,Patient characteristics,no,NA,Jaruratanasirikul,2019,https://dx.doi.org/10.1007/s40261-019-00796-3,Thailand,prospective PK study,10,ECMO,unclear,ECMO,imipenem
BMI,Patient characteristics,no,NA,Jaruratanasirikul,2019,https://dx.doi.org/10.1007/s40261-019-00796-3,Thailand,prospective PK study,10,ECMO,unclear,ECMO,imipenem
concomitant medications,Other,no,NA,Jaruratanasirikul,2019,https://dx.doi.org/10.1007/s40261-019-00796-3,Thailand,prospective PK study,10,ECMO,unclear,ECMO,imipenem
ECMO parameters,Extracorporeal parameters,no,NA,Jaruratanasirikul,2019,https://dx.doi.org/10.1007/s40261-019-00796-3,Thailand,prospective PK study,10,ECMO,unclear,ECMO,imipenem
fluid balance,Physiological parameters,no,NA,Jaruratanasirikul,2019,https://dx.doi.org/10.1007/s40261-019-00796-3,Thailand,prospective PK study,10,ECMO,unclear,ECMO,imipenem
serum albumin,Biomarkers,no,NA,Jaruratanasirikul,2019,https://dx.doi.org/10.1007/s40261-019-00796-3,Thailand,prospective PK study,10,ECMO,unclear,ECMO,imipenem
sex,Patient characteristics,no,NA,Jaruratanasirikul,2019,https://dx.doi.org/10.1007/s40261-019-00796-3,Thailand,prospective PK study,10,ECMO,unclear,ECMO,imipenem
weight,Patient characteristics,no,NA,Jaruratanasirikul,2019,https://dx.doi.org/10.1007/s40261-019-00796-3,Thailand,prospective PK study,10,ECMO,unclear,ECMO,imipenem
creatinine clearance,Physiological parameters,yes,CL,Georges,2009,https://dx.doi.org/10.1128/AAC.00430-09,France,prospective randomised PK trial,72,no,unclear,pneumonia,ceftazidime
day after burn injury,Other,yes,CL,Jeon,2014,https://dx.doi.org/10.1128/AAC.02089-13,South Korea,prospective PK study,50,no,unclear,burns,piperacillin
sepsis,Organ dysfunction/support,yes,V,Jeon,2014,https://dx.doi.org/10.1128/AAC.02089-13,South Korea,prospective PK study,50,no,unclear,burns,piperacillin
abbreviated burn severity index,Disease severity score,no,NA,Jeon,2014,https://dx.doi.org/10.1128/AAC.02089-13,South Korea,prospective PK study,50,no,unclear,burns,piperacillin
age,Patient characteristics,no,NA,Jeon,2014,https://dx.doi.org/10.1128/AAC.02089-13,South Korea,prospective PK study,50,no,unclear,burns,piperacillin
APACHE,Disease severity score,no,NA,Jeon,2014,https://dx.doi.org/10.1128/AAC.02089-13,South Korea,prospective PK study,50,no,unclear,burns,piperacillin
CRRT,Organ dysfunction/support,no,NA,Jeon,2014,https://dx.doi.org/10.1128/AAC.02089-13,South Korea,prospective PK study,50,no,unclear,burns,piperacillin
dehydration,Patient characteristics,no,NA,Jeon,2014,https://dx.doi.org/10.1128/AAC.02089-13,South Korea,prospective PK study,50,no,unclear,burns,piperacillin
oedema,Patient characteristics,no,NA,Jeon,2014,https://dx.doi.org/10.1128/AAC.02089-13,South Korea,prospective PK study,50,no,unclear,burns,piperacillin
serum albumin,Biomarkers,no,NA,Jeon,2014,https://dx.doi.org/10.1128/AAC.02089-13,South Korea,prospective PK study,50,no,unclear,burns,piperacillin
serum creatinine,Biomarkers,no,NA,Jeon,2014,https://dx.doi.org/10.1128/AAC.02089-13,South Korea,prospective PK study,50,no,unclear,burns,piperacillin
sex,Patient characteristics,no,NA,Jeon,2014,https://dx.doi.org/10.1128/AAC.02089-13,South Korea,prospective PK study,50,no,unclear,burns,piperacillin
TBSA,Patient characteristics,no,NA,Jeon,2014,https://dx.doi.org/10.1128/AAC.02089-13,South Korea,prospective PK study,50,no,unclear,burns,piperacillin
weight,Patient characteristics,no,NA,Jeon,2014,https://dx.doi.org/10.1128/AAC.02089-13,South Korea,prospective PK study,50,no,unclear,burns,piperacillin
creatinine clearance,Physiological parameters,yes,CL,Gijsen,2022,https://dx.doi.org/10.2147/IDR.S343264,Belgium,prospective PK study,58,no,augmented,augmented renal clearance,meropenem
age,Patient characteristics,no,NA,Jonckheere,2016,http://dx.doi.org/10.1093/jac/dkw171,Belgium,prospective PK study,20,RRT,impaired,general ICU,cefepime
creatinine clearance,Physiological parameters,yes,CL,Hahn,2021,https://dx.doi.org/10.1128/Spectrum.00633-21,South Korea,prospective PK study,26,"ECMO, RRT",impaired,ECMO,piperacillin
cystatin C,Biomarkers,no,NA,Jonckheere,2016,http://dx.doi.org/10.1093/jac/dkw171,Belgium,prospective PK study,20,RRT,impaired,general ICU,cefepime
KIM-1,Biomarkers,no,NA,Jonckheere,2016,http://dx.doi.org/10.1093/jac/dkw171,Belgium,prospective PK study,20,RRT,impaired,general ICU,cefepime
serum albumin,Biomarkers,no,NA,Jonckheere,2016,http://dx.doi.org/10.1093/jac/dkw171,Belgium,prospective PK study,20,RRT,impaired,general ICU,cefepime
serum creatinine,Biomarkers,no,NA,Jonckheere,2016,http://dx.doi.org/10.1093/jac/dkw171,Belgium,prospective PK study,20,RRT,impaired,general ICU,cefepime
serum urea,Biomarkers,no,NA,Jonckheere,2016,http://dx.doi.org/10.1093/jac/dkw171,Belgium,prospective PK study,20,RRT,impaired,general ICU,cefepime
uromodulin,Biomarkers,no,NA,Jonckheere,2016,http://dx.doi.org/10.1093/jac/dkw171,Belgium,prospective PK study,20,RRT,impaired,general ICU,cefepime
weight,Patient characteristics,no,NA,Jonckheere,2016,http://dx.doi.org/10.1093/jac/dkw171,Belgium,prospective PK study,20,RRT,impaired,general ICU,cefepime
CRRT,Organ dysfunction/support,yes,CL,Kang,2022,https://dx.doi.org/10.3390/jcm11226621,South Korea,prospective PK study,13,"ECMO, RRT",impaired,ECMO,meropenem
age,Patient characteristics,no,NA,Kang,2022,https://dx.doi.org/10.3390/jcm11226621,South Korea,prospective PK study,13,"ECMO, RRT",impaired,ECMO,meropenem
alcohol use,Patient characteristics,no,NA,Kang,2022,https://dx.doi.org/10.3390/jcm11226621,South Korea,prospective PK study,13,"ECMO, RRT",impaired,ECMO,meropenem
ALT,Biomarkers,no,NA,Kang,2022,https://dx.doi.org/10.3390/jcm11226621,South Korea,prospective PK study,13,"ECMO, RRT",impaired,ECMO,meropenem
AST,Biomarkers,no,NA,Kang,2022,https://dx.doi.org/10.3390/jcm11226621,South Korea,prospective PK study,13,"ECMO, RRT",impaired,ECMO,meropenem
BP,Vital signs,no,NA,Kang,2022,https://dx.doi.org/10.3390/jcm11226621,South Korea,prospective PK study,13,"ECMO, RRT",impaired,ECMO,meropenem
BUN,Biomarkers,no,NA,Kang,2022,https://dx.doi.org/10.3390/jcm11226621,South Korea,prospective PK study,13,"ECMO, RRT",impaired,ECMO,meropenem
creatinine clearance,Physiological parameters,yes,CL,Hanberg,2018,https://dx.doi.org/10.1128/AAC.02390-17,Denmark,prospective PK study,10,"ECMO, RRT",impaired,ECMO,meropenem
CRP,Biomarkers,no,NA,Kang,2022,https://dx.doi.org/10.3390/jcm11226621,South Korea,prospective PK study,13,"ECMO, RRT",impaired,ECMO,meropenem
CRRT,Organ dysfunction/support,no,NA,Kang,2022,https://dx.doi.org/10.3390/jcm11226621,South Korea,prospective PK study,13,"ECMO, RRT",impaired,ECMO,meropenem
CRRT parameters,Extracorporeal parameters,no,NA,Kang,2022,https://dx.doi.org/10.3390/jcm11226621,South Korea,prospective PK study,13,"ECMO, RRT",impaired,ECMO,meropenem
CRRT parameters,Extracorporeal parameters,no,NA,Kang,2022,https://dx.doi.org/10.3390/jcm11226621,South Korea,prospective PK study,13,"ECMO, RRT",impaired,ECMO,meropenem
ECMO,Organ dysfunction/support,no,NA,Kang,2022,https://dx.doi.org/10.3390/jcm11226621,South Korea,prospective PK study,13,"ECMO, RRT",impaired,ECMO,meropenem
ECMO parameters,Extracorporeal parameters,no,NA,Kang,2022,https://dx.doi.org/10.3390/jcm11226621,South Korea,prospective PK study,13,"ECMO, RRT",impaired,ECMO,meropenem
ECMO parameters,Extracorporeal parameters,no,NA,Kang,2022,https://dx.doi.org/10.3390/jcm11226621,South Korea,prospective PK study,13,"ECMO, RRT",impaired,ECMO,meropenem
ECMO parameters,Extracorporeal parameters,no,NA,Kang,2022,https://dx.doi.org/10.3390/jcm11226621,South Korea,prospective PK study,13,"ECMO, RRT",impaired,ECMO,meropenem
GFR,Physiological parameters,no,NA,Kang,2022,https://dx.doi.org/10.3390/jcm11226621,South Korea,prospective PK study,13,"ECMO, RRT",impaired,ECMO,meropenem
haemoglobin,Biomarkers,no,NA,Kang,2022,https://dx.doi.org/10.3390/jcm11226621,South Korea,prospective PK study,13,"ECMO, RRT",impaired,ECMO,meropenem
height,Patient characteristics,no,NA,Kang,2022,https://dx.doi.org/10.3390/jcm11226621,South Korea,prospective PK study,13,"ECMO, RRT",impaired,ECMO,meropenem
platelets,Biomarkers,no,NA,Kang,2022,https://dx.doi.org/10.3390/jcm11226621,South Korea,prospective PK study,13,"ECMO, RRT",impaired,ECMO,meropenem
procalcitonin,Biomarkers,no,NA,Kang,2022,https://dx.doi.org/10.3390/jcm11226621,South Korea,prospective PK study,13,"ECMO, RRT",impaired,ECMO,meropenem
red cell count,Biomarkers,no,NA,Kang,2022,https://dx.doi.org/10.3390/jcm11226621,South Korea,prospective PK study,13,"ECMO, RRT",impaired,ECMO,meropenem
serum bilirubin,Biomarkers,no,NA,Kang,2022,https://dx.doi.org/10.3390/jcm11226621,South Korea,prospective PK study,13,"ECMO, RRT",impaired,ECMO,meropenem
serum creatinine,Biomarkers,no,NA,Kang,2022,https://dx.doi.org/10.3390/jcm11226621,South Korea,prospective PK study,13,"ECMO, RRT",impaired,ECMO,meropenem
sex,Patient characteristics,no,NA,Kang,2022,https://dx.doi.org/10.3390/jcm11226621,South Korea,prospective PK study,13,"ECMO, RRT",impaired,ECMO,meropenem
smoking,Patient characteristics,no,NA,Kang,2022,https://dx.doi.org/10.3390/jcm11226621,South Korea,prospective PK study,13,"ECMO, RRT",impaired,ECMO,meropenem
temperature,Vital signs,no,NA,Kang,2022,https://dx.doi.org/10.3390/jcm11226621,South Korea,prospective PK study,13,"ECMO, RRT",impaired,ECMO,meropenem
weight,Patient characteristics,no,NA,Kang,2022,https://dx.doi.org/10.3390/jcm11226621,South Korea,prospective PK study,13,"ECMO, RRT",impaired,ECMO,meropenem
white cell count,Biomarkers,no,NA,Kang,2022,https://dx.doi.org/10.3390/jcm11226621,South Korea,prospective PK study,13,"ECMO, RRT",impaired,ECMO,meropenem
CRRT,Organ dysfunction/support,yes,CL,Kanji,2018,https://dx.doi.org/10.1177/1060028018773771,Canada,prospective PK study,34,RRT,impaired,CRRT,piperacillin
age,Patient characteristics,no,NA,Kanji,2018,https://dx.doi.org/10.1177/1060028018773771,Canada,prospective PK study,34,RRT,impaired,CRRT,piperacillin
CRRT parameters,Extracorporeal parameters,no,NA,Kanji,2018,https://dx.doi.org/10.1177/1060028018773771,Canada,prospective PK study,34,RRT,impaired,CRRT,piperacillin
CRRT parameters,Extracorporeal parameters,no,NA,Kanji,2018,https://dx.doi.org/10.1177/1060028018773771,Canada,prospective PK study,34,RRT,impaired,CRRT,piperacillin
height,Patient characteristics,no,NA,Kanji,2018,https://dx.doi.org/10.1177/1060028018773771,Canada,prospective PK study,34,RRT,impaired,CRRT,piperacillin
serum creatinine,Biomarkers,no,NA,Kanji,2018,https://dx.doi.org/10.1177/1060028018773771,Canada,prospective PK study,34,RRT,impaired,CRRT,piperacillin
sex,Patient characteristics,no,NA,Kanji,2018,https://dx.doi.org/10.1177/1060028018773771,Canada,prospective PK study,34,RRT,impaired,CRRT,piperacillin
weight,Patient characteristics,no,NA,Kanji,2018,https://dx.doi.org/10.1177/1060028018773771,Canada,prospective PK study,34,RRT,impaired,CRRT,piperacillin
creatinine clearance,Physiological parameters,yes,CL,Heffernan,2022,https://dx.doi.org/10.1128/aac.02189-21,Australia,retrospective PK study,36,no,normal,sepsis,ceftriaxone
creatinine clearance,Physiological parameters,yes,CL,Idoate Grijalba,2019,https://dx.doi.org/10.1007/s00228-019-02716-y,France,retrospective PK study,80,no,normal,general ICU,meropenem
cystatin C,Biomarkers,yes,CL,Kees,2016,https://dx.doi.org/10.1002/jcph.600,Germany,prospective PK study,32,no,normal,general ICU,meropenem
GFR,Physiological parameters,yes,CL,Kees,2016,https://dx.doi.org/10.1002/jcph.600,Germany,prospective PK study,32,no,normal,general ICU,meropenem
age,Patient characteristics,no,NA,Kees,2016,https://dx.doi.org/10.1002/jcph.600,Germany,prospective PK study,32,no,normal,general ICU,meropenem
serum creatinine,Biomarkers,no,NA,Kees,2016,https://dx.doi.org/10.1002/jcph.600,Germany,prospective PK study,32,no,normal,general ICU,meropenem
sex,Patient characteristics,no,NA,Kees,2016,https://dx.doi.org/10.1002/jcph.600,Germany,prospective PK study,32,no,normal,general ICU,meropenem
weight,Patient characteristics,no,NA,Kees,2016,https://dx.doi.org/10.1002/jcph.600,Germany,prospective PK study,32,no,normal,general ICU,meropenem
GFR,Physiological parameters,yes,CL,Kim,2022,https://dx.doi.org/10.1093/jac/dkac059,South Korea,prospective PK study,38,"ECMO, RRT",impaired,ECMO,piperacillin
ECMO,Organ dysfunction/support,yes,V,Kim,2022,https://dx.doi.org/10.1093/jac/dkac059,South Korea,prospective PK study,38,"ECMO, RRT",impaired,ECMO,piperacillin
age,Patient characteristics,no,NA,Kim,2022,https://dx.doi.org/10.1093/jac/dkac059,South Korea,prospective PK study,38,"ECMO, RRT",impaired,ECMO,piperacillin
BSA,Patient characteristics,no,NA,Kim,2022,https://dx.doi.org/10.1093/jac/dkac059,South Korea,prospective PK study,38,"ECMO, RRT",impaired,ECMO,piperacillin
comorbidity,Patient characteristics,no,NA,Kim,2022,https://dx.doi.org/10.1093/jac/dkac059,South Korea,prospective PK study,38,"ECMO, RRT",impaired,ECMO,piperacillin
cystatin C,Biomarkers,no,NA,Kim,2022,https://dx.doi.org/10.1093/jac/dkac059,South Korea,prospective PK study,38,"ECMO, RRT",impaired,ECMO,piperacillin
diagnosis,Patient characteristics,no,NA,Kim,2022,https://dx.doi.org/10.1093/jac/dkac059,South Korea,prospective PK study,38,"ECMO, RRT",impaired,ECMO,piperacillin
ECMO parameters,Extracorporeal parameters,no,NA,Kim,2022,https://dx.doi.org/10.1093/jac/dkac059,South Korea,prospective PK study,38,"ECMO, RRT",impaired,ECMO,piperacillin
ECMO parameters,Extracorporeal parameters,no,NA,Kim,2022,https://dx.doi.org/10.1093/jac/dkac059,South Korea,prospective PK study,38,"ECMO, RRT",impaired,ECMO,piperacillin
ECMO parameters,Extracorporeal parameters,no,NA,Kim,2022,https://dx.doi.org/10.1093/jac/dkac059,South Korea,prospective PK study,38,"ECMO, RRT",impaired,ECMO,piperacillin
height,Patient characteristics,no,NA,Kim,2022,https://dx.doi.org/10.1093/jac/dkac059,South Korea,prospective PK study,38,"ECMO, RRT",impaired,ECMO,piperacillin
serum albumin,Biomarkers,no,NA,Kim,2022,https://dx.doi.org/10.1093/jac/dkac059,South Korea,prospective PK study,38,"ECMO, RRT",impaired,ECMO,piperacillin
serum creatinine,Biomarkers,no,NA,Kim,2022,https://dx.doi.org/10.1093/jac/dkac059,South Korea,prospective PK study,38,"ECMO, RRT",impaired,ECMO,piperacillin
serum protein,Biomarkers,no,NA,Kim,2022,https://dx.doi.org/10.1093/jac/dkac059,South Korea,prospective PK study,38,"ECMO, RRT",impaired,ECMO,piperacillin
sex,Patient characteristics,no,NA,Kim,2022,https://dx.doi.org/10.1093/jac/dkac059,South Korea,prospective PK study,38,"ECMO, RRT",impaired,ECMO,piperacillin
creatinine clearance,Physiological parameters,yes,CL,Isla,2008,https://dx.doi.org/10.2165/00003088-200847030-00003,Spain,prospective PK study,20,RRT,impaired,CRRT,meropenem
age,Patient characteristics,no,NA,Klastrup,2020,https://dx.doi.org/10.1128/AAC.02556-19,Denmark,prospective PK study,78,no,normal,general ICU,piperacillin
serum creatinine,Biomarkers,no,NA,Klastrup,2020,https://dx.doi.org/10.1128/AAC.02556-19,Denmark,prospective PK study,78,no,normal,general ICU,piperacillin
sex,Patient characteristics,no,NA,Klastrup,2020,https://dx.doi.org/10.1128/AAC.02556-19,Denmark,prospective PK study,78,no,normal,general ICU,piperacillin
weight,Patient characteristics,no,NA,Klastrup,2020,https://dx.doi.org/10.1128/AAC.02556-19,Denmark,prospective PK study,78,no,normal,general ICU,piperacillin
weight,Patient characteristics,yes,V,Konig,2017,https://dx.doi.org/10.1093/jac/dkw592,Germany,prospective PK study,16,RRT,impaired,CRRT,ceftazidime
CRRT,Organ dysfunction/support,no,NA,Konig,2017,https://dx.doi.org/10.1093/jac/dkw592,Germany,prospective PK study,16,RRT,impaired,CRRT,ceftazidime
age,Patient characteristics,yes,NA,Kumta,2022,https://dx.doi.org/10.1128/aac.00142-22,International,prospective PK study,8,no,normal,CNS infection,meropenem
ALT,Biomarkers,no,NA,Kumta,2022,https://dx.doi.org/10.1128/aac.00142-22,International,prospective PK study,8,no,normal,CNS infection,meropenem
APACHE,Disease severity score,no,NA,Kumta,2022,https://dx.doi.org/10.1128/aac.00142-22,International,prospective PK study,8,no,normal,CNS infection,meropenem
BMI,Patient characteristics,no,NA,Kumta,2022,https://dx.doi.org/10.1128/aac.00142-22,International,prospective PK study,8,no,normal,CNS infection,meropenem
creatinine clearance,Physiological parameters,yes,CL,Jaruratanasirikul,2015,https://dx.doi.org/10.1128/AAC.04166-14,Thailand,prospective PK study,9,no,normal,sepsis,meropenem
CSF,Other,no,NA,Kumta,2022,https://dx.doi.org/10.1128/aac.00142-22,International,prospective PK study,8,no,normal,CNS infection,meropenem
CSF,Other,no,NA,Kumta,2022,https://dx.doi.org/10.1128/aac.00142-22,International,prospective PK study,8,no,normal,CNS infection,meropenem
CSF,Other,no,NA,Kumta,2022,https://dx.doi.org/10.1128/aac.00142-22,International,prospective PK study,8,no,normal,CNS infection,meropenem
height,Patient characteristics,no,NA,Kumta,2022,https://dx.doi.org/10.1128/aac.00142-22,International,prospective PK study,8,no,normal,CNS infection,meropenem
serum albumin,Biomarkers,no,NA,Kumta,2022,https://dx.doi.org/10.1128/aac.00142-22,International,prospective PK study,8,no,normal,CNS infection,meropenem
sex,Patient characteristics,no,NA,Kumta,2022,https://dx.doi.org/10.1128/aac.00142-22,International,prospective PK study,8,no,normal,CNS infection,meropenem
SOFA,Disease severity score,no,NA,Kumta,2022,https://dx.doi.org/10.1128/aac.00142-22,International,prospective PK study,8,no,normal,CNS infection,meropenem
weight,Patient characteristics,no,NA,Kumta,2022,https://dx.doi.org/10.1128/aac.00142-22,International,prospective PK study,8,no,normal,CNS infection,meropenem
creatinine clearance,Physiological parameters,yes,"CL, K10",Jaruratanasirikul,2019,https://dx.doi.org/10.1007/s40261-019-00796-3,Thailand,prospective PK study,10,ECMO,unclear,ECMO,imipenem
BSA,Patient characteristics,no,NA,Layios,2022,https://dx.doi.org/10.1128/AAC.02052-21,Belgium,prospective PK study,32,no,normal,VAP,temocillin
weight,Patient characteristics,no,NA,Layios,2022,https://dx.doi.org/10.1128/AAC.02052-21,Belgium,prospective PK study,32,no,normal,VAP,temocillin
renal function,Physiological parameters,yes,CL,Lee,2021,https://dx.doi.org/10.3389/fphar.2021.768912,South Korea,prospective PK study,30,"ECMO, RRT",impaired,ECMO,meropenem
ECMO parameters,Extracorporeal parameters,yes,V,Lee,2021,https://dx.doi.org/10.3389/fphar.2021.768912,South Korea,prospective PK study,30,"ECMO, RRT",impaired,ECMO,meropenem
age,Patient characteristics,no,NA,Lee,2021,https://dx.doi.org/10.3389/fphar.2021.768912,South Korea,prospective PK study,30,"ECMO, RRT",impaired,ECMO,meropenem
APACHE,Disease severity score,no,NA,Lee,2021,https://dx.doi.org/10.3389/fphar.2021.768912,South Korea,prospective PK study,30,"ECMO, RRT",impaired,ECMO,meropenem
BSA,Patient characteristics,no,NA,Lee,2021,https://dx.doi.org/10.3389/fphar.2021.768912,South Korea,prospective PK study,30,"ECMO, RRT",impaired,ECMO,meropenem
comorbidity,Patient characteristics,no,NA,Lee,2021,https://dx.doi.org/10.3389/fphar.2021.768912,South Korea,prospective PK study,30,"ECMO, RRT",impaired,ECMO,meropenem
CRRT,Organ dysfunction/support,no,NA,Lee,2021,https://dx.doi.org/10.3389/fphar.2021.768912,South Korea,prospective PK study,30,"ECMO, RRT",impaired,ECMO,meropenem
diagnosis,Patient characteristics,no,NA,Lee,2021,https://dx.doi.org/10.3389/fphar.2021.768912,South Korea,prospective PK study,30,"ECMO, RRT",impaired,ECMO,meropenem
ECMO parameters,Extracorporeal parameters,no,NA,Lee,2021,https://dx.doi.org/10.3389/fphar.2021.768912,South Korea,prospective PK study,30,"ECMO, RRT",impaired,ECMO,meropenem
height,Patient characteristics,no,NA,Lee,2021,https://dx.doi.org/10.3389/fphar.2021.768912,South Korea,prospective PK study,30,"ECMO, RRT",impaired,ECMO,meropenem
serum albumin,Biomarkers,no,NA,Lee,2021,https://dx.doi.org/10.3389/fphar.2021.768912,South Korea,prospective PK study,30,"ECMO, RRT",impaired,ECMO,meropenem
serum creatinine,Biomarkers,no,NA,Lee,2021,https://dx.doi.org/10.3389/fphar.2021.768912,South Korea,prospective PK study,30,"ECMO, RRT",impaired,ECMO,meropenem
serum protein,Biomarkers,no,NA,Lee,2021,https://dx.doi.org/10.3389/fphar.2021.768912,South Korea,prospective PK study,30,"ECMO, RRT",impaired,ECMO,meropenem
sex,Patient characteristics,no,NA,Lee,2021,https://dx.doi.org/10.3389/fphar.2021.768912,South Korea,prospective PK study,30,"ECMO, RRT",impaired,ECMO,meropenem
SOFA,Disease severity score,no,NA,Lee,2021,https://dx.doi.org/10.3389/fphar.2021.768912,South Korea,prospective PK study,30,"ECMO, RRT",impaired,ECMO,meropenem
weight,Patient characteristics,no,NA,Lee,2021,https://dx.doi.org/10.3389/fphar.2021.768912,South Korea,prospective PK study,30,"ECMO, RRT",impaired,ECMO,meropenem
renal function,Physiological parameters,yes,CL,Lee,2021,https://dx.doi.org/10.3390/pharmaceutics13111861,South Korea,prospective PK study,26,"ECMO, RRT",impaired,ECMO,meropenem
age,Patient characteristics,no,NA,Lee,2021,https://dx.doi.org/10.3390/pharmaceutics13111861,South Korea,prospective PK study,26,"ECMO, RRT",impaired,ECMO,meropenem
BSA,Patient characteristics,no,NA,Lee,2021,https://dx.doi.org/10.3390/pharmaceutics13111861,South Korea,prospective PK study,26,"ECMO, RRT",impaired,ECMO,meropenem
comorbidity,Patient characteristics,no,NA,Lee,2021,https://dx.doi.org/10.3390/pharmaceutics13111861,South Korea,prospective PK study,26,"ECMO, RRT",impaired,ECMO,meropenem
cystatin C,Biomarkers,no,NA,Lee,2021,https://dx.doi.org/10.3390/pharmaceutics13111861,South Korea,prospective PK study,26,"ECMO, RRT",impaired,ECMO,meropenem
diagnosis,Patient characteristics,no,NA,Lee,2021,https://dx.doi.org/10.3390/pharmaceutics13111861,South Korea,prospective PK study,26,"ECMO, RRT",impaired,ECMO,meropenem
ECMO parameters,Extracorporeal parameters,no,NA,Lee,2021,https://dx.doi.org/10.3390/pharmaceutics13111861,South Korea,prospective PK study,26,"ECMO, RRT",impaired,ECMO,meropenem
ECMO parameters,Extracorporeal parameters,no,NA,Lee,2021,https://dx.doi.org/10.3390/pharmaceutics13111861,South Korea,prospective PK study,26,"ECMO, RRT",impaired,ECMO,meropenem
height,Patient characteristics,no,NA,Lee,2021,https://dx.doi.org/10.3390/pharmaceutics13111861,South Korea,prospective PK study,26,"ECMO, RRT",impaired,ECMO,meropenem
serum albumin,Biomarkers,no,NA,Lee,2021,https://dx.doi.org/10.3390/pharmaceutics13111861,South Korea,prospective PK study,26,"ECMO, RRT",impaired,ECMO,meropenem
serum creatinine,Biomarkers,no,NA,Lee,2021,https://dx.doi.org/10.3390/pharmaceutics13111861,South Korea,prospective PK study,26,"ECMO, RRT",impaired,ECMO,meropenem
serum protein,Biomarkers,no,NA,Lee,2021,https://dx.doi.org/10.3390/pharmaceutics13111861,South Korea,prospective PK study,26,"ECMO, RRT",impaired,ECMO,meropenem
sex,Patient characteristics,no,NA,Lee,2021,https://dx.doi.org/10.3390/pharmaceutics13111861,South Korea,prospective PK study,26,"ECMO, RRT",impaired,ECMO,meropenem
weight,Patient characteristics,no,NA,Lee,2021,https://dx.doi.org/10.3390/pharmaceutics13111861,South Korea,prospective PK study,26,"ECMO, RRT",impaired,ECMO,meropenem
serum albumin,Biomarkers,yes,Bmax,Leegwater,2020,https://dx.doi.org/10.1093/jac/dkaa067,Netherlands,prospective PK study,55,no,normal,general ICU,ceftriaxone
creatinine clearance,Physiological parameters,yes,CL,Jeon,2014,https://dx.doi.org/10.1128/AAC.02089-13,South Korea,prospective PK study,50,no,unclear,burns,piperacillin
mode of administration,Other,yes,V,Leegwater,2020,https://dx.doi.org/10.1093/jac/dkaa067,Netherlands,prospective PK study,55,no,normal,general ICU,ceftriaxone
age,Patient characteristics,no,NA,Leegwater,2020,https://dx.doi.org/10.1093/jac/dkaa067,Netherlands,prospective PK study,55,no,normal,general ICU,ceftriaxone
APACHE,Disease severity score,no,NA,Leegwater,2020,https://dx.doi.org/10.1093/jac/dkaa067,Netherlands,prospective PK study,55,no,normal,general ICU,ceftriaxone
BMI,Patient characteristics,no,NA,Leegwater,2020,https://dx.doi.org/10.1093/jac/dkaa067,Netherlands,prospective PK study,55,no,normal,general ICU,ceftriaxone
fluid balance,Physiological parameters,no,NA,Leegwater,2020,https://dx.doi.org/10.1093/jac/dkaa067,Netherlands,prospective PK study,55,no,normal,general ICU,ceftriaxone
SAPS,Disease severity score,no,NA,Leegwater,2020,https://dx.doi.org/10.1093/jac/dkaa067,Netherlands,prospective PK study,55,no,normal,general ICU,ceftriaxone
serum bilirubin,Biomarkers,no,NA,Leegwater,2020,https://dx.doi.org/10.1093/jac/dkaa067,Netherlands,prospective PK study,55,no,normal,general ICU,ceftriaxone
sex,Patient characteristics,no,NA,Leegwater,2020,https://dx.doi.org/10.1093/jac/dkaa067,Netherlands,prospective PK study,55,no,normal,general ICU,ceftriaxone
weight,Patient characteristics,no,NA,Leegwater,2020,https://dx.doi.org/10.1093/jac/dkaa067,Netherlands,prospective PK study,55,no,normal,general ICU,ceftriaxone
diuresis,Physiological parameters,yes,CL,Li,2019,https://dx.doi.org/10.1016/j.ijantimicag.2018.10.006,Belgium,retrospective PK study,20,RRT,impaired,burns,imipenem
patient type,Patient characteristics,yes,CL,Li,2019,https://dx.doi.org/10.1016/j.ijantimicag.2018.10.006,Belgium,retrospective PK study,20,RRT,impaired,burns,imipenem
age,Patient characteristics,no,NA,Li,2019,https://dx.doi.org/10.1016/j.ijantimicag.2018.10.006,Belgium,retrospective PK study,20,RRT,impaired,burns,imipenem
APACHE,Disease severity score,no,NA,Li,2019,https://dx.doi.org/10.1016/j.ijantimicag.2018.10.006,Belgium,retrospective PK study,20,RRT,impaired,burns,imipenem
burns,Patient characteristics,no,NA,Li,2019,https://dx.doi.org/10.1016/j.ijantimicag.2018.10.006,Belgium,retrospective PK study,20,RRT,impaired,burns,imipenem
sex,Patient characteristics,no,NA,Li,2019,https://dx.doi.org/10.1016/j.ijantimicag.2018.10.006,Belgium,retrospective PK study,20,RRT,impaired,burns,imipenem
urine output,Physiological parameters,no,NA,Li,2019,https://dx.doi.org/10.1016/j.ijantimicag.2018.10.006,Belgium,retrospective PK study,20,RRT,impaired,burns,imipenem
weight,Patient characteristics,no,NA,Li,2019,https://dx.doi.org/10.1016/j.ijantimicag.2018.10.006,Belgium,retrospective PK study,20,RRT,impaired,burns,imipenem
creatinine clearance,Physiological parameters,yes,CL,Jonckheere,2016,http://dx.doi.org/10.1093/jac/dkw171,Belgium,prospective PK study,20,RRT,impaired,general ICU,cefepime
CRRT parameters,Extracorporeal parameters,yes,CL,Li,2020,https://dx.doi.org/10.1016/j.clinthera.2020.06.010,China,prospective PK study,30,RRT,impaired,CRRT,imipenem
age,Patient characteristics,no,NA,Li,2020,https://dx.doi.org/10.1016/j.clinthera.2020.06.010,China,prospective PK study,30,RRT,impaired,CRRT,imipenem
AKI,Organ dysfunction/support,no,NA,Li,2020,https://dx.doi.org/10.1016/j.clinthera.2020.06.010,China,prospective PK study,30,RRT,impaired,CRRT,imipenem
APACHE,Disease severity score,no,NA,Li,2020,https://dx.doi.org/10.1016/j.clinthera.2020.06.010,China,prospective PK study,30,RRT,impaired,CRRT,imipenem
course of treatment,Other,no,NA,Li,2020,https://dx.doi.org/10.1016/j.clinthera.2020.06.010,China,prospective PK study,30,RRT,impaired,CRRT,imipenem
CRRT parameters,Extracorporeal parameters,no,NA,Li,2020,https://dx.doi.org/10.1016/j.clinthera.2020.06.010,China,prospective PK study,30,RRT,impaired,CRRT,imipenem
CRRT parameters,Extracorporeal parameters,no,NA,Li,2020,https://dx.doi.org/10.1016/j.clinthera.2020.06.010,China,prospective PK study,30,RRT,impaired,CRRT,imipenem
mechanical ventilation,Organ dysfunction/support,no,NA,Li,2020,https://dx.doi.org/10.1016/j.clinthera.2020.06.010,China,prospective PK study,30,RRT,impaired,CRRT,imipenem
sepsis,Organ dysfunction/support,no,NA,Li,2020,https://dx.doi.org/10.1016/j.clinthera.2020.06.010,China,prospective PK study,30,RRT,impaired,CRRT,imipenem
sepsis,Organ dysfunction/support,no,NA,Li,2020,https://dx.doi.org/10.1016/j.clinthera.2020.06.010,China,prospective PK study,30,RRT,impaired,CRRT,imipenem
serum creatinine,Biomarkers,no,NA,Li,2020,https://dx.doi.org/10.1016/j.clinthera.2020.06.010,China,prospective PK study,30,RRT,impaired,CRRT,imipenem
sex,Patient characteristics,no,NA,Li,2020,https://dx.doi.org/10.1016/j.clinthera.2020.06.010,China,prospective PK study,30,RRT,impaired,CRRT,imipenem
SOFA,Disease severity score,no,NA,Li,2020,https://dx.doi.org/10.1016/j.clinthera.2020.06.010,China,prospective PK study,30,RRT,impaired,CRRT,imipenem
weight,Patient characteristics,no,NA,Li,2020,https://dx.doi.org/10.1016/j.clinthera.2020.06.010,China,prospective PK study,30,RRT,impaired,CRRT,imipenem
creatinine clearance,Physiological parameters,yes,CL,Kees,2016,https://dx.doi.org/10.1002/jcph.600,Germany,prospective PK study,32,no,normal,general ICU,meropenem
weight,Patient characteristics,NA,V,Liebchen,2021,https://dx.doi.org/10.3390/antibiotics10040468,Germany,retrospective PK study,155,no,normal,general ICU,meropenem
serum albumin,Biomarkers,yes,V,Liebchen,2021,https://dx.doi.org/10.3390/antibiotics10040468,Germany,retrospective PK study,155,no,normal,general ICU,meropenem
creatinine clearance,Physiological parameters,yes,CL,Kees,2016,https://dx.doi.org/10.1002/jcph.600,Germany,prospective PK study,32,no,normal,general ICU,meropenem
weight,Patient characteristics,yes,V,Mathew,2016,https://dx.doi.org/10.1097/FTD.0000000000000323,India,prospective PK study,35,no,normal,sepsis,meropenem
age,Patient characteristics,no,NA,Mathew,2016,https://dx.doi.org/10.1097/FTD.0000000000000323,India,prospective PK study,35,no,normal,sepsis,meropenem
sex,Patient characteristics,no,NA,Mathew,2016,https://dx.doi.org/10.1097/FTD.0000000000000323,India,prospective PK study,35,no,normal,sepsis,meropenem
sepsis,Organ dysfunction/support,yes,CL,Mattioli,2016,https://dx.doi.org/10.1007/s00228-016-2053-x,Italy,prospective PK study,27,no,normal,sepsis,meropenem
sex,Patient characteristics,yes,CL,Mattioli,2016,https://dx.doi.org/10.1007/s00228-016-2053-x,Italy,prospective PK study,27,no,normal,sepsis,meropenem
age,Patient characteristics,yes,V,Mattioli,2016,https://dx.doi.org/10.1007/s00228-016-2053-x,Italy,prospective PK study,27,no,normal,sepsis,meropenem
serum albumin,Biomarkers,yes,V,Mattioli,2016,https://dx.doi.org/10.1007/s00228-016-2053-x,Italy,prospective PK study,27,no,normal,sepsis,meropenem
BMI,Patient characteristics,no,NA,Mattioli,2016,https://dx.doi.org/10.1007/s00228-016-2053-x,Italy,prospective PK study,27,no,normal,sepsis,meropenem
creatinine clearance,Physiological parameters,yes,CL,Klastrup,2020,https://dx.doi.org/10.1128/AAC.02556-19,Denmark,prospective PK study,78,no,normal,general ICU,piperacillin
height,Patient characteristics,no,NA,Mattioli,2016,https://dx.doi.org/10.1007/s00228-016-2053-x,Italy,prospective PK study,27,no,normal,sepsis,meropenem
serum creatinine,Biomarkers,no,NA,Mattioli,2016,https://dx.doi.org/10.1007/s00228-016-2053-x,Italy,prospective PK study,27,no,normal,sepsis,meropenem
weight,Patient characteristics,no,NA,Mattioli,2016,https://dx.doi.org/10.1007/s00228-016-2053-x,Italy,prospective PK study,27,no,normal,sepsis,meropenem
creatinine clearance,Physiological parameters,yes,NA,Kumta,2022,https://dx.doi.org/10.1128/aac.00142-22,International,prospective PK study,8,no,normal,CNS infection,meropenem
CNS infection,Other,yes,CL,Murinova,2022,https://dx.doi.org/10.1136/ejhpharm-2022-003535,Czech Republic,retrospective PK study,144,no,normal,sepsis,meropenem
GFR,Physiological parameters,yes,CL,Murinova,2022,https://dx.doi.org/10.1136/ejhpharm-2022-003535,Czech Republic,retrospective PK study,144,no,normal,sepsis,meropenem
age,Patient characteristics,no,NA,Murinova,2022,https://dx.doi.org/10.1136/ejhpharm-2022-003535,Czech Republic,retrospective PK study,144,no,normal,sepsis,meropenem
BMI,Patient characteristics,no,NA,Murinova,2022,https://dx.doi.org/10.1136/ejhpharm-2022-003535,Czech Republic,retrospective PK study,144,no,normal,sepsis,meropenem
height,Patient characteristics,no,NA,Murinova,2022,https://dx.doi.org/10.1136/ejhpharm-2022-003535,Czech Republic,retrospective PK study,144,no,normal,sepsis,meropenem
serum creatinine,Biomarkers,no,NA,Murinova,2022,https://dx.doi.org/10.1136/ejhpharm-2022-003535,Czech Republic,retrospective PK study,144,no,normal,sepsis,meropenem
sex,Patient characteristics,no,NA,Murinova,2022,https://dx.doi.org/10.1136/ejhpharm-2022-003535,Czech Republic,retrospective PK study,144,no,normal,sepsis,meropenem
weight,Patient characteristics,no,NA,Murinova,2022,https://dx.doi.org/10.1136/ejhpharm-2022-003535,Czech Republic,retrospective PK study,144,no,normal,sepsis,meropenem
ethnicity,Patient characteristics,yes,CL,Nandy,2010,https://dx.doi.org/10.1128/AAC.01649-09,USA,retrospective PK study,285,no,unclear,sepsis,doripenem
creatinine clearance,Physiological parameters,yes,CL,Layios,2022,https://dx.doi.org/10.1128/AAC.02052-21,Belgium,prospective PK study,32,no,normal,VAP,temocillin
weight,Patient characteristics,yes,"Q, V",Nandy,2010,https://dx.doi.org/10.1128/AAC.01649-09,USA,retrospective PK study,285,no,unclear,sepsis,doripenem
age,Patient characteristics,yes,V,Nandy,2010,https://dx.doi.org/10.1128/AAC.01649-09,USA,retrospective PK study,285,no,unclear,sepsis,doripenem
ALP,Biomarkers,no,NA,Nandy,2010,https://dx.doi.org/10.1128/AAC.01649-09,USA,retrospective PK study,285,no,unclear,sepsis,doripenem
ALT,Biomarkers,no,NA,Nandy,2010,https://dx.doi.org/10.1128/AAC.01649-09,USA,retrospective PK study,285,no,unclear,sepsis,doripenem
AST,Biomarkers,no,NA,Nandy,2010,https://dx.doi.org/10.1128/AAC.01649-09,USA,retrospective PK study,285,no,unclear,sepsis,doripenem
BMI,Patient characteristics,no,NA,Nandy,2010,https://dx.doi.org/10.1128/AAC.01649-09,USA,retrospective PK study,285,no,unclear,sepsis,doripenem
BSA,Patient characteristics,no,NA,Nandy,2010,https://dx.doi.org/10.1128/AAC.01649-09,USA,retrospective PK study,285,no,unclear,sepsis,doripenem
concomitant medications,Other,no,NA,Nandy,2010,https://dx.doi.org/10.1128/AAC.01649-09,USA,retrospective PK study,285,no,unclear,sepsis,doripenem
GGT,Biomarkers,no,NA,Nandy,2010,https://dx.doi.org/10.1128/AAC.01649-09,USA,retrospective PK study,285,no,unclear,sepsis,doripenem
health status,Patient characteristics,no,NA,Nandy,2010,https://dx.doi.org/10.1128/AAC.01649-09,USA,retrospective PK study,285,no,unclear,sepsis,doripenem
height,Patient characteristics,no,NA,Nandy,2010,https://dx.doi.org/10.1128/AAC.01649-09,USA,retrospective PK study,285,no,unclear,sepsis,doripenem
LDH,Biomarkers,no,NA,Nandy,2010,https://dx.doi.org/10.1128/AAC.01649-09,USA,retrospective PK study,285,no,unclear,sepsis,doripenem
occasion number,Other,no,NA,Nandy,2010,https://dx.doi.org/10.1128/AAC.01649-09,USA,retrospective PK study,285,no,unclear,sepsis,doripenem
renal function,Physiological parameters,no,NA,Nandy,2010,https://dx.doi.org/10.1128/AAC.01649-09,USA,retrospective PK study,285,no,unclear,sepsis,doripenem
serum bilirubin,Biomarkers,no,NA,Nandy,2010,https://dx.doi.org/10.1128/AAC.01649-09,USA,retrospective PK study,285,no,unclear,sepsis,doripenem
serum creatinine,Biomarkers,no,NA,Nandy,2010,https://dx.doi.org/10.1128/AAC.01649-09,USA,retrospective PK study,285,no,unclear,sepsis,doripenem
serum protein,Biomarkers,no,NA,Nandy,2010,https://dx.doi.org/10.1128/AAC.01649-09,USA,retrospective PK study,285,no,unclear,sepsis,doripenem
sex,Patient characteristics,no,NA,Nandy,2010,https://dx.doi.org/10.1128/AAC.01649-09,USA,retrospective PK study,285,no,unclear,sepsis,doripenem
study phase,Other,no,NA,Nandy,2010,https://dx.doi.org/10.1128/AAC.01649-09,USA,retrospective PK study,285,no,unclear,sepsis,doripenem
treatment,Other,no,NA,Nandy,2010,https://dx.doi.org/10.1128/AAC.01649-09,USA,retrospective PK study,285,no,unclear,sepsis,doripenem
weight,Patient characteristics,no,NA,Nandy,2010,https://dx.doi.org/10.1128/AAC.01649-09,USA,retrospective PK study,285,no,unclear,sepsis,doripenem
creatinine clearance,Physiological parameters,yes,CL,Leegwater,2020,https://dx.doi.org/10.1093/jac/dkaa067,Netherlands,prospective PK study,55,no,normal,general ICU,ceftriaxone
weight,Patient characteristics,yes,V,Nicasio,2009,https://dx.doi.org/10.1128/AAC.01141-08,USA,prospective PK study,26,no,normal,VAP,cefepime
age,Patient characteristics,no,NA,Nicasio,2009,https://dx.doi.org/10.1128/AAC.01141-08,USA,prospective PK study,26,no,normal,VAP,cefepime
APACHE,Disease severity score,no,NA,Nicasio,2009,https://dx.doi.org/10.1128/AAC.01141-08,USA,prospective PK study,26,no,normal,VAP,cefepime
ethnicity,Patient characteristics,no,NA,Nicasio,2009,https://dx.doi.org/10.1128/AAC.01141-08,USA,prospective PK study,26,no,normal,VAP,cefepime
sex,Patient characteristics,no,NA,Nicasio,2009,https://dx.doi.org/10.1128/AAC.01141-08,USA,prospective PK study,26,no,normal,VAP,cefepime
GFR,Physiological parameters,yes,CL,Niibe,2020,https://dx.doi.org/10.1097/FTD.0000000000000741,Japan,prospective PK study,21,RRT,impaired,CRRT,meropenem
age,Patient characteristics,no,NA,Niibe,2020,https://dx.doi.org/10.1097/FTD.0000000000000741,Japan,prospective PK study,21,RRT,impaired,CRRT,meropenem
APACHE,Disease severity score,no,NA,Niibe,2020,https://dx.doi.org/10.1097/FTD.0000000000000741,Japan,prospective PK study,21,RRT,impaired,CRRT,meropenem
CHDF hemofilter,Extracorporeal parameters,no,NA,Niibe,2020,https://dx.doi.org/10.1097/FTD.0000000000000741,Japan,prospective PK study,21,RRT,impaired,CRRT,meropenem
CHDF intensity,Extracorporeal parameters,no,NA,Niibe,2020,https://dx.doi.org/10.1097/FTD.0000000000000741,Japan,prospective PK study,21,RRT,impaired,CRRT,meropenem
CRP,Biomarkers,no,NA,Niibe,2020,https://dx.doi.org/10.1097/FTD.0000000000000741,Japan,prospective PK study,21,RRT,impaired,CRRT,meropenem
IL-6,Biomarkers,no,NA,Niibe,2020,https://dx.doi.org/10.1097/FTD.0000000000000741,Japan,prospective PK study,21,RRT,impaired,CRRT,meropenem
serum albumin,Biomarkers,no,NA,Niibe,2020,https://dx.doi.org/10.1097/FTD.0000000000000741,Japan,prospective PK study,21,RRT,impaired,CRRT,meropenem
sex,Patient characteristics,no,NA,Niibe,2020,https://dx.doi.org/10.1097/FTD.0000000000000741,Japan,prospective PK study,21,RRT,impaired,CRRT,meropenem
SOFA,Disease severity score,no,NA,Niibe,2020,https://dx.doi.org/10.1097/FTD.0000000000000741,Japan,prospective PK study,21,RRT,impaired,CRRT,meropenem
urine output,Physiological parameters,no,NA,Niibe,2020,https://dx.doi.org/10.1097/FTD.0000000000000741,Japan,prospective PK study,21,RRT,impaired,CRRT,meropenem
weight,Patient characteristics,no,NA,Niibe,2020,https://dx.doi.org/10.1097/FTD.0000000000000741,Japan,prospective PK study,21,RRT,impaired,CRRT,meropenem
white cell count,Biomarkers,no,NA,Niibe,2020,https://dx.doi.org/10.1097/FTD.0000000000000741,Japan,prospective PK study,21,RRT,impaired,CRRT,meropenem
CRP,Biomarkers,yes,CL,Niibe,2022,https://dx.doi.org/10.1016/j.jiac.2021.12.017,Japan,prospective PK study,12,no,normal,general ICU,meropenem
age,Patient characteristics,no,NA,Niibe,2022,https://dx.doi.org/10.1016/j.jiac.2021.12.017,Japan,prospective PK study,12,no,normal,general ICU,meropenem
APACHE,Disease severity score,no,NA,Niibe,2022,https://dx.doi.org/10.1016/j.jiac.2021.12.017,Japan,prospective PK study,12,no,normal,general ICU,meropenem
creatinine clearance,Physiological parameters,yes,CL,Li,2020,https://dx.doi.org/10.1016/j.clinthera.2020.06.010,China,prospective PK study,30,RRT,impaired,CRRT,imipenem
patient type,Patient characteristics,no,NA,Niibe,2022,https://dx.doi.org/10.1016/j.jiac.2021.12.017,Japan,prospective PK study,12,no,normal,general ICU,meropenem
serum albumin,Biomarkers,no,NA,Niibe,2022,https://dx.doi.org/10.1016/j.jiac.2021.12.017,Japan,prospective PK study,12,no,normal,general ICU,meropenem
sex,Patient characteristics,no,NA,Niibe,2022,https://dx.doi.org/10.1016/j.jiac.2021.12.017,Japan,prospective PK study,12,no,normal,general ICU,meropenem
SOFA,Disease severity score,no,NA,Niibe,2022,https://dx.doi.org/10.1016/j.jiac.2021.12.017,Japan,prospective PK study,12,no,normal,general ICU,meropenem
urine output,Physiological parameters,no,NA,Niibe,2022,https://dx.doi.org/10.1016/j.jiac.2021.12.017,Japan,prospective PK study,12,no,normal,general ICU,meropenem
weight,Patient characteristics,no,NA,Niibe,2022,https://dx.doi.org/10.1016/j.jiac.2021.12.017,Japan,prospective PK study,12,no,normal,general ICU,meropenem
creatinine clearance,Physiological parameters,yes,CL,Liebchen,2021,https://dx.doi.org/10.3390/antibiotics10040468,Germany,retrospective PK study,155,no,normal,general ICU,meropenem
serum albumin,Biomarkers,no,NA,Nonoshita,2020,https://dx.doi.org/10.1038/s41598-020-79076-6,Japan,prospective PK study,21,RRT,impaired,general ICU,doripenem
weight,Patient characteristics,no,NA,Nonoshita,2020,https://dx.doi.org/10.1038/s41598-020-79076-6,Japan,prospective PK study,21,RRT,impaired,general ICU,doripenem
dialysis,Organ dysfunction/support,yes,CL,O'Jeanson,2021,https://dx.doi.org/10.1007/s13318-021-00709-w,France,retrospective PK study,58,RRT,impaired,general ICU,meropenem
diuresis,Physiological parameters,yes,CL,O'Jeanson,2021,https://dx.doi.org/10.1007/s13318-021-00709-w,France,retrospective PK study,58,RRT,impaired,general ICU,meropenem
GFR,Physiological parameters,yes,CL,O'Jeanson,2021,https://dx.doi.org/10.1007/s13318-021-00709-w,France,retrospective PK study,58,RRT,impaired,general ICU,meropenem
renal function,Physiological parameters,yes,CL,O'Jeanson,2021,https://dx.doi.org/10.1007/s13318-021-00709-w,France,retrospective PK study,58,RRT,impaired,general ICU,meropenem
BMI,Patient characteristics,no,NA,O'Jeanson,2021,https://dx.doi.org/10.1007/s13318-021-00709-w,France,retrospective PK study,58,RRT,impaired,general ICU,meropenem
BSA,Patient characteristics,no,NA,O'Jeanson,2021,https://dx.doi.org/10.1007/s13318-021-00709-w,France,retrospective PK study,58,RRT,impaired,general ICU,meropenem
weight,Patient characteristics,no,NA,O'Jeanson,2021,https://dx.doi.org/10.1007/s13318-021-00709-w,France,retrospective PK study,58,RRT,impaired,general ICU,meropenem
creatinine clearance,Physiological parameters,yes,Ke,Mathew,2016,https://dx.doi.org/10.1097/FTD.0000000000000323,India,prospective PK study,35,no,normal,sepsis,meropenem
age,Patient characteristics,no,NA,Ollivier,2019,https://dx.doi.org/10.1128/AAC.02134-18,France,prospective PK study,21,no,normal,sepsis,ceftriaxone
serum albumin,Biomarkers,no,NA,Ollivier,2019,https://dx.doi.org/10.1128/AAC.02134-18,France,prospective PK study,21,no,normal,sepsis,ceftriaxone
sex,Patient characteristics,no,NA,Ollivier,2019,https://dx.doi.org/10.1128/AAC.02134-18,France,prospective PK study,21,no,normal,sepsis,ceftriaxone
weight,Patient characteristics,no,NA,Ollivier,2019,https://dx.doi.org/10.1128/AAC.02134-18,France,prospective PK study,21,no,normal,sepsis,ceftriaxone
serum albumin,Biomarkers,yes,V,Onichimowski,2020,https://dx.doi.org/10.1007/s43440-020-00104-3,Poland,prospective PK study,19,RRT,impaired,CRRT,meropenem
age,Patient characteristics,no,NA,Onichimowski,2020,https://dx.doi.org/10.1007/s43440-020-00104-3,Poland,prospective PK study,19,RRT,impaired,CRRT,meropenem
anticoagulation,Extracorporeal parameters,no,NA,Onichimowski,2020,https://dx.doi.org/10.1007/s43440-020-00104-3,Poland,prospective PK study,19,RRT,impaired,CRRT,meropenem
APACHE,Disease severity score,no,NA,Onichimowski,2020,https://dx.doi.org/10.1007/s43440-020-00104-3,Poland,prospective PK study,19,RRT,impaired,CRRT,meropenem
CRRT parameters,Extracorporeal parameters,no,NA,Onichimowski,2020,https://dx.doi.org/10.1007/s43440-020-00104-3,Poland,prospective PK study,19,RRT,impaired,CRRT,meropenem
CRRT parameters,Extracorporeal parameters,no,NA,Onichimowski,2020,https://dx.doi.org/10.1007/s43440-020-00104-3,Poland,prospective PK study,19,RRT,impaired,CRRT,meropenem
CRRT parameters,Extracorporeal parameters,no,NA,Onichimowski,2020,https://dx.doi.org/10.1007/s43440-020-00104-3,Poland,prospective PK study,19,RRT,impaired,CRRT,meropenem
CRRT parameters,Extracorporeal parameters,no,NA,Onichimowski,2020,https://dx.doi.org/10.1007/s43440-020-00104-3,Poland,prospective PK study,19,RRT,impaired,CRRT,meropenem
day of antibiotic therapy,Other,no,NA,Onichimowski,2020,https://dx.doi.org/10.1007/s43440-020-00104-3,Poland,prospective PK study,19,RRT,impaired,CRRT,meropenem
diuresis,Physiological parameters,no,NA,Onichimowski,2020,https://dx.doi.org/10.1007/s43440-020-00104-3,Poland,prospective PK study,19,RRT,impaired,CRRT,meropenem
GFR,Physiological parameters,no,NA,Onichimowski,2020,https://dx.doi.org/10.1007/s43440-020-00104-3,Poland,prospective PK study,19,RRT,impaired,CRRT,meropenem
sepsis,Organ dysfunction/support,no,NA,Onichimowski,2020,https://dx.doi.org/10.1007/s43440-020-00104-3,Poland,prospective PK study,19,RRT,impaired,CRRT,meropenem
serum creatinine,Biomarkers,no,NA,Onichimowski,2020,https://dx.doi.org/10.1007/s43440-020-00104-3,Poland,prospective PK study,19,RRT,impaired,CRRT,meropenem
sex,Patient characteristics,no,NA,Onichimowski,2020,https://dx.doi.org/10.1007/s43440-020-00104-3,Poland,prospective PK study,19,RRT,impaired,CRRT,meropenem
SOFA,Disease severity score,no,NA,Onichimowski,2020,https://dx.doi.org/10.1007/s43440-020-00104-3,Poland,prospective PK study,19,RRT,impaired,CRRT,meropenem
weight,Patient characteristics,no,NA,Onichimowski,2020,https://dx.doi.org/10.1007/s43440-020-00104-3,Poland,prospective PK study,19,RRT,impaired,CRRT,meropenem
age,Patient characteristics,no,NA,Padulles Zamora,2019,https://dx.doi.org/10.1093/jac/dkz299,Spain,prospective PK study,12,RRT,impaired,CRRT,meropenem
CRRT parameters,Extracorporeal parameters,no,NA,Padulles Zamora,2019,https://dx.doi.org/10.1093/jac/dkz299,Spain,prospective PK study,12,RRT,impaired,CRRT,meropenem
CRRT parameters,Extracorporeal parameters,no,NA,Padulles Zamora,2019,https://dx.doi.org/10.1093/jac/dkz299,Spain,prospective PK study,12,RRT,impaired,CRRT,meropenem
sex,Patient characteristics,no,NA,Padulles Zamora,2019,https://dx.doi.org/10.1093/jac/dkz299,Spain,prospective PK study,12,RRT,impaired,CRRT,meropenem
weight,Patient characteristics,no,NA,Padulles Zamora,2019,https://dx.doi.org/10.1093/jac/dkz299,Spain,prospective PK study,12,RRT,impaired,CRRT,meropenem
creatinine clearance,Physiological parameters,yes,CL,Minichmayr,2018,https://dx.doi.org/10.1093/jac/dkx526,Germany,retrospective PK study,195,no,normal,general ICU,meropenem
age,Patient characteristics,no,NA,Pokem,2022,https://dx.doi.org/10.3390/antibiotics11070898,Belgium,prospective PK study,19,no,unclear,septic shock,temocillin
APACHE,Disease severity score,no,NA,Pokem,2022,https://dx.doi.org/10.3390/antibiotics11070898,Belgium,prospective PK study,19,no,unclear,septic shock,temocillin
ascitic fluid albumin,Biomarkers,no,NA,Pokem,2022,https://dx.doi.org/10.3390/antibiotics11070898,Belgium,prospective PK study,19,no,unclear,septic shock,temocillin
BMI,Patient characteristics,no,NA,Pokem,2022,https://dx.doi.org/10.3390/antibiotics11070898,Belgium,prospective PK study,19,no,unclear,septic shock,temocillin
CRP,Biomarkers,no,NA,Pokem,2022,https://dx.doi.org/10.3390/antibiotics11070898,Belgium,prospective PK study,19,no,unclear,septic shock,temocillin
height,Patient characteristics,no,NA,Pokem,2022,https://dx.doi.org/10.3390/antibiotics11070898,Belgium,prospective PK study,19,no,unclear,septic shock,temocillin
serum albumin,Biomarkers,no,NA,Pokem,2022,https://dx.doi.org/10.3390/antibiotics11070898,Belgium,prospective PK study,19,no,unclear,septic shock,temocillin
SOFA,Disease severity score,no,NA,Pokem,2022,https://dx.doi.org/10.3390/antibiotics11070898,Belgium,prospective PK study,19,no,unclear,septic shock,temocillin
weight,Patient characteristics,no,NA,Pokem,2022,https://dx.doi.org/10.3390/antibiotics11070898,Belgium,prospective PK study,19,no,unclear,septic shock,temocillin
weight,Patient characteristics,yes,CL,Por,2021,https://dx.doi.org/10.1002/jcph.1865,USA,prospective PK study,23,RRT,impaired,burns,imipenem
weight,Patient characteristics,yes,"CL, V",Por,2021,https://dx.doi.org/10.1002/jcph.1865,USA,prospective PK study,23,RRT,impaired,burns,imipenem
serum albumin,Biomarkers,yes,V,Por,2021,https://dx.doi.org/10.1002/jcph.1865,USA,prospective PK study,23,RRT,impaired,burns,imipenem
age,Patient characteristics,no,NA,Por,2021,https://dx.doi.org/10.1002/jcph.1865,USA,prospective PK study,23,RRT,impaired,burns,imipenem
burns,Patient characteristics,no,NA,Por,2021,https://dx.doi.org/10.1002/jcph.1865,USA,prospective PK study,23,RRT,impaired,burns,imipenem
burns,Patient characteristics,no,NA,Por,2021,https://dx.doi.org/10.1002/jcph.1865,USA,prospective PK study,23,RRT,impaired,burns,imipenem
burns,Patient characteristics,no,NA,Por,2021,https://dx.doi.org/10.1002/jcph.1865,USA,prospective PK study,23,RRT,impaired,burns,imipenem
creatinine clearance,Physiological parameters,yes,"CL, V",Nandy,2010,https://dx.doi.org/10.1128/AAC.01649-09,USA,retrospective PK study,285,no,unclear,sepsis,doripenem
CRRT,Organ dysfunction/support,no,NA,Por,2021,https://dx.doi.org/10.1002/jcph.1865,USA,prospective PK study,23,RRT,impaired,burns,imipenem
urine output,Physiological parameters,no,NA,Por,2021,https://dx.doi.org/10.1002/jcph.1865,USA,prospective PK study,23,RRT,impaired,burns,imipenem
creatinine clearance,Physiological parameters,yes,K10,Nicasio,2009,https://dx.doi.org/10.1128/AAC.01141-08,USA,prospective PK study,26,no,normal,VAP,cefepime
age,Patient characteristics,no,NA,Roberts,2009,https://dx.doi.org/10.1093/jac/dkp139,Australia,prospective PK study,10,no,unclear,sepsis,meropenem
BMI,Patient characteristics,no,NA,Roberts,2009,https://dx.doi.org/10.1093/jac/dkp139,Australia,prospective PK study,10,no,unclear,sepsis,meropenem
serum creatinine,Biomarkers,no,NA,Roberts,2009,https://dx.doi.org/10.1093/jac/dkp139,Australia,prospective PK study,10,no,unclear,sepsis,meropenem
SOFA,Disease severity score,no,NA,Roberts,2009,https://dx.doi.org/10.1093/jac/dkp139,Australia,prospective PK study,10,no,unclear,sepsis,meropenem
weight,Patient characteristics,no,NA,Roberts,2009,https://dx.doi.org/10.1093/jac/dkp139,Australia,prospective PK study,10,no,unclear,sepsis,meropenem
weight,Patient characteristics,no,NA,Roberts,2009,https://dx.doi.org/10.1093/jac/dkp139,Australia,prospective PK study,10,no,unclear,sepsis,meropenem
weight,Patient characteristics,yes,CL,Roberts,2010,https://dx.doi.org/10.1016/j.ijantimicag.2009.10.008,Australia,prospective randomised PK trial,16,no,normal,sepsis,piperacillin
creatinine clearance,Physiological parameters,yes,CL,Nonoshita,2020,https://dx.doi.org/10.1038/s41598-020-79076-6,Japan,prospective PK study,21,RRT,impaired,general ICU,doripenem
SOFA,Disease severity score,no,NA,Roberts,2011,https://doi.org/10.1128%2FAAC.01543-15,Malaysia,prospective PK study,12,no,normal,sepsis,doripenem
weight,Patient characteristics,no,NA,Roberts,2011,https://doi.org/10.1128%2FAAC.01543-15,Malaysia,prospective PK study,12,no,normal,sepsis,doripenem
creatinine clearance,Physiological parameters,yes,CL,Ollivier,2019,https://dx.doi.org/10.1128/AAC.02134-18,France,prospective PK study,21,no,normal,sepsis,ceftriaxone
weight,Patient characteristics,yes,V,Roberts,2013,https://dx.doi.org/10.1097/CCM.0b013e31826ab4c4,International,retrospective PK study,31,no,augmented,pneumonia,doripenem
age,Patient characteristics,no,NA,Roberts,2013,https://dx.doi.org/10.1097/CCM.0b013e31826ab4c4,International,retrospective PK study,31,no,augmented,pneumonia,doripenem
height,Patient characteristics,no,NA,Roberts,2013,https://dx.doi.org/10.1097/CCM.0b013e31826ab4c4,International,retrospective PK study,31,no,augmented,pneumonia,doripenem
serum creatinine,Biomarkers,no,NA,Roberts,2013,https://dx.doi.org/10.1097/CCM.0b013e31826ab4c4,International,retrospective PK study,31,no,augmented,pneumonia,doripenem
sex,Patient characteristics,no,NA,Roberts,2013,https://dx.doi.org/10.1097/CCM.0b013e31826ab4c4,International,retrospective PK study,31,no,augmented,pneumonia,doripenem
age,Patient characteristics,no,NA,Roberts,2014,https://dx.doi.org/10.1093/jac/dku177,Australia,prospective PK study,12,RRT,impaired,CRRT,doripenem
CRRT parameters,Extracorporeal parameters,yes,NA,Roberts,2014,https://dx.doi.org/10.1093/jac/dku177,Australia,prospective PK study,12,RRT,impaired,CRRT,doripenem
sex,Patient characteristics,no,NA,Roberts,2014,https://dx.doi.org/10.1093/jac/dku177,Australia,prospective PK study,12,RRT,impaired,CRRT,doripenem
weight,Patient characteristics,no,NA,Roberts,2014,https://dx.doi.org/10.1093/jac/dku177,Australia,prospective PK study,12,RRT,impaired,CRRT,doripenem
weight,Patient characteristics,yes,"CL, V",Roberts,2015,https://dx.doi.org/10.1186/s13054-015-0818-8,Australia,prospective PK study,24,RRT,impaired,CRRT,"meropenem, piperacillin"
creatinine clearance,Physiological parameters,yes,CL,Pokem,2022,https://dx.doi.org/10.3390/antibiotics11070898,Belgium,prospective PK study,19,no,unclear,septic shock,temocillin
serum albumin,Biomarkers,yes,V,Roberts,2015,https://dx.doi.org/10.1093/jac/dku564,Australia,prospective PK study,30,no,normal,trauma,cefazolin
weight,Patient characteristics,yes,V,Roberts,2015,https://dx.doi.org/10.1093/jac/dku564,Australia,prospective PK study,30,no,normal,trauma,cefazolin
GFR,Physiological parameters,yes,CL,Roelofsen,2023,https://dx.doi.org/10.1111/bcp.15487,Netherlands,prospective PK study,92,no,unclear,general ICU,cefotaxime
serum albumin,Biomarkers,yes,CL,Roelofsen,2023,https://dx.doi.org/10.1111/bcp.15487,Netherlands,prospective PK study,92,no,unclear,general ICU,cefotaxime
age,Patient characteristics,no,NA,Roelofsen,2023,https://dx.doi.org/10.1111/bcp.15487,Netherlands,prospective PK study,92,no,unclear,general ICU,cefotaxime
APACHE,Disease severity score,no,NA,Roelofsen,2023,https://dx.doi.org/10.1111/bcp.15487,Netherlands,prospective PK study,92,no,unclear,general ICU,cefotaxime
CRP,Biomarkers,no,NA,Roelofsen,2023,https://dx.doi.org/10.1111/bcp.15487,Netherlands,prospective PK study,92,no,unclear,general ICU,cefotaxime
CRRT,Organ dysfunction/support,no,NA,Roelofsen,2023,https://dx.doi.org/10.1111/bcp.15487,Netherlands,prospective PK study,92,no,unclear,general ICU,cefotaxime
fluid balance,Physiological parameters,no,NA,Roelofsen,2023,https://dx.doi.org/10.1111/bcp.15487,Netherlands,prospective PK study,92,no,unclear,general ICU,cefotaxime
height,Patient characteristics,no,NA,Roelofsen,2023,https://dx.doi.org/10.1111/bcp.15487,Netherlands,prospective PK study,92,no,unclear,general ICU,cefotaxime
serum creatinine,Biomarkers,no,NA,Roelofsen,2023,https://dx.doi.org/10.1111/bcp.15487,Netherlands,prospective PK study,92,no,unclear,general ICU,cefotaxime
sex,Patient characteristics,no,NA,Roelofsen,2023,https://dx.doi.org/10.1111/bcp.15487,Netherlands,prospective PK study,92,no,unclear,general ICU,cefotaxime
SOFA,Disease severity score,no,NA,Roelofsen,2023,https://dx.doi.org/10.1111/bcp.15487,Netherlands,prospective PK study,92,no,unclear,general ICU,cefotaxime
temperature,Vital signs,no,NA,Roelofsen,2023,https://dx.doi.org/10.1111/bcp.15487,Netherlands,prospective PK study,92,no,unclear,general ICU,cefotaxime
weight,Patient characteristics,no,NA,Roelofsen,2023,https://dx.doi.org/10.1111/bcp.15487,Netherlands,prospective PK study,92,no,unclear,general ICU,cefotaxime
white cell count,Biomarkers,no,NA,Roelofsen,2023,https://dx.doi.org/10.1111/bcp.15487,Netherlands,prospective PK study,92,no,unclear,general ICU,cefotaxime
creatinine clearance,Physiological parameters,yes,CL,Roberts,2009,https://dx.doi.org/10.1093/jac/dkp139,Australia,prospective PK study,10,no,unclear,sepsis,meropenem
age,Patient characteristics,no,NA,Rohani,2022,https://dx.doi.org/10.1093/jac/dkac245,USA,retrospective PK study,70,no,unclear,HAP,meropenem
CRRT,Organ dysfunction/support,no,NA,Rohani,2022,https://dx.doi.org/10.1093/jac/dkac245,USA,retrospective PK study,70,no,unclear,HAP,meropenem
height,Patient characteristics,no,NA,Rohani,2022,https://dx.doi.org/10.1093/jac/dkac245,USA,retrospective PK study,70,no,unclear,HAP,meropenem
serum creatinine,Biomarkers,no,NA,Rohani,2022,https://dx.doi.org/10.1093/jac/dkac245,USA,retrospective PK study,70,no,unclear,HAP,meropenem
sex,Patient characteristics,no,NA,Rohani,2022,https://dx.doi.org/10.1093/jac/dkac245,USA,retrospective PK study,70,no,unclear,HAP,meropenem
weight,Patient characteristics,no,NA,Rohani,2022,https://dx.doi.org/10.1093/jac/dkac245,USA,retrospective PK study,70,no,unclear,HAP,meropenem
creatinine clearance,Physiological parameters,yes,CL,Roberts,2011,https://doi.org/10.1128%2FAAC.01543-15,Malaysia,prospective PK study,12,no,normal,sepsis,doripenem
age,Patient characteristics,no,NA,Roos,2006,https://dx.doi.org/10.1093/jac/dkl349,Australia,retrospective PK study,13,no,normal,sepsis,cefepime
APACHE,Disease severity score,no,NA,Roos,2006,https://dx.doi.org/10.1093/jac/dkl349,Australia,retrospective PK study,13,no,normal,sepsis,cefepime
serum creatinine,Biomarkers,no,NA,Roos,2006,https://dx.doi.org/10.1093/jac/dkl349,Australia,retrospective PK study,13,no,normal,sepsis,cefepime
weight,Patient characteristics,no,NA,Roos,2006,https://dx.doi.org/10.1093/jac/dkl349,Australia,retrospective PK study,13,no,normal,sepsis,cefepime
creatinine clearance,Physiological parameters,yes,CL,Roberts,2013,https://dx.doi.org/10.1097/CCM.0b013e31826ab4c4,International,retrospective PK study,31,no,augmented,pneumonia,doripenem
weight,Patient characteristics,yes,V,Roos,2007,https://dx.doi.org/10.1007/s00134-007-0573-7,Australia,prospective PK study,12,no,normal,general ICU,cefpirome
age,Patient characteristics,no,NA,Roos,2007,https://dx.doi.org/10.1007/s00134-007-0573-7,Australia,prospective PK study,12,no,normal,general ICU,cefpirome
APACHE,Disease severity score,no,NA,Roos,2007,https://dx.doi.org/10.1007/s00134-007-0573-7,Australia,prospective PK study,12,no,normal,general ICU,cefpirome
serum creatinine,Biomarkers,no,NA,Roos,2007,https://dx.doi.org/10.1007/s00134-007-0573-7,Australia,prospective PK study,12,no,normal,general ICU,cefpirome
age,Patient characteristics,yes,CL,Sakka,2007,https://dx.doi.org/10.1128/AAC.01318-06,Germany,prospective randomised PK trial,20,no,normal,VAP,imipenem
BSA,Patient characteristics,yes,CL,Sakka,2007,https://dx.doi.org/10.1128/AAC.01318-06,Germany,prospective randomised PK trial,20,no,normal,VAP,imipenem
height,Patient characteristics,yes,CL,Sakka,2007,https://dx.doi.org/10.1128/AAC.01318-06,Germany,prospective randomised PK trial,20,no,normal,VAP,imipenem
weight,Patient characteristics,yes,CL,Sakka,2007,https://dx.doi.org/10.1128/AAC.01318-06,Germany,prospective randomised PK trial,20,no,normal,VAP,imipenem
creatinine clearance,Physiological parameters,yes,CL,Roberts,2015,https://dx.doi.org/10.1093/jac/dku564,Australia,prospective PK study,30,no,normal,trauma,cefazolin
sex,Patient characteristics,no,NA,Sakka,2007,https://dx.doi.org/10.1128/AAC.01318-06,Germany,prospective randomised PK trial,20,no,normal,VAP,imipenem
creatinine clearance,Physiological parameters,yes,CL,Rohani,2022,https://dx.doi.org/10.1093/jac/dkac245,USA,retrospective PK study,70,no,unclear,HAP,meropenem
age,Patient characteristics,no,NA,Sanches,2022,https://dx.doi.org/10.3390/antibiotics11040434,Brazil,retrospective PK study,24,no,normal,general ICU,piperacillin
BMI,Patient characteristics,no,NA,Sanches,2022,https://dx.doi.org/10.3390/antibiotics11040434,Brazil,retrospective PK study,24,no,normal,general ICU,piperacillin
height,Patient characteristics,no,NA,Sanches,2022,https://dx.doi.org/10.3390/antibiotics11040434,Brazil,retrospective PK study,24,no,normal,general ICU,piperacillin
MODS score,Disease severity score,no,NA,Sanches,2022,https://dx.doi.org/10.3390/antibiotics11040434,Brazil,retrospective PK study,24,no,normal,general ICU,piperacillin
SAPS,Disease severity score,no,NA,Sanches,2022,https://dx.doi.org/10.3390/antibiotics11040434,Brazil,retrospective PK study,24,no,normal,general ICU,piperacillin
sepsis,Organ dysfunction/support,no,NA,Sanches,2022,https://dx.doi.org/10.3390/antibiotics11040434,Brazil,retrospective PK study,24,no,normal,general ICU,piperacillin
serum creatinine,Biomarkers,no,NA,Sanches,2022,https://dx.doi.org/10.3390/antibiotics11040434,Brazil,retrospective PK study,24,no,normal,general ICU,piperacillin
sex,Patient characteristics,no,NA,Sanches,2022,https://dx.doi.org/10.3390/antibiotics11040434,Brazil,retrospective PK study,24,no,normal,general ICU,piperacillin
SOFA,Disease severity score,no,NA,Sanches,2022,https://dx.doi.org/10.3390/antibiotics11040434,Brazil,retrospective PK study,24,no,normal,general ICU,piperacillin
weight,Patient characteristics,no,NA,Sanches,2022,https://dx.doi.org/10.3390/antibiotics11040434,Brazil,retrospective PK study,24,no,normal,general ICU,piperacillin
creatinine clearance,Physiological parameters,yes,CL,Roos,2006,https://dx.doi.org/10.1093/jac/dkl349,Australia,retrospective PK study,13,no,normal,sepsis,cefepime
age,Patient characteristics,no,NA,Selig,2022,https://dx.doi.org/10.3390/antibiotics11050618,USA,retrospective PK study,19,no,unclear,trauma,piperacillin
burns,Patient characteristics,no,NA,Selig,2022,https://dx.doi.org/10.3390/antibiotics11050618,USA,retrospective PK study,19,no,unclear,trauma,piperacillin
burns,Patient characteristics,no,NA,Selig,2022,https://dx.doi.org/10.3390/antibiotics11050618,USA,retrospective PK study,19,no,unclear,trauma,piperacillin
serum albumin,Biomarkers,no,NA,Selig,2022,https://dx.doi.org/10.3390/antibiotics11050618,USA,retrospective PK study,19,no,unclear,trauma,piperacillin
urine output,Physiological parameters,no,NA,Selig,2022,https://dx.doi.org/10.3390/antibiotics11050618,USA,retrospective PK study,19,no,unclear,trauma,piperacillin
weight,Patient characteristics,no,NA,Selig,2022,https://dx.doi.org/10.3390/antibiotics11050618,USA,retrospective PK study,19,no,unclear,trauma,piperacillin
weight,Patient characteristics,no,NA,Selig,2022,https://dx.doi.org/10.3390/antibiotics11050618,USA,retrospective PK study,19,no,unclear,trauma,piperacillin
creatinine clearance,Physiological parameters,yes,CL,Roos,2007,https://dx.doi.org/10.1007/s00134-007-0573-7,Australia,prospective PK study,12,no,normal,general ICU,cefpirome
burns,Patient characteristics,yes,V,Selig,2022,https://dx.doi.org/10.1111/bcp.15138,USA,retrospective PK study,23,RRT,impaired,burns,meropenem
age,Patient characteristics,no,NA,Selig,2022,https://dx.doi.org/10.1111/bcp.15138,USA,retrospective PK study,23,RRT,impaired,burns,meropenem
burns,Patient characteristics,no,NA,Selig,2022,https://dx.doi.org/10.1111/bcp.15138,USA,retrospective PK study,23,RRT,impaired,burns,meropenem
burns,Patient characteristics,no,NA,Selig,2022,https://dx.doi.org/10.1111/bcp.15138,USA,retrospective PK study,23,RRT,impaired,burns,meropenem
serum albumin,Biomarkers,no,NA,Selig,2022,https://dx.doi.org/10.1111/bcp.15138,USA,retrospective PK study,23,RRT,impaired,burns,meropenem
urine output,Physiological parameters,no,NA,Selig,2022,https://dx.doi.org/10.1111/bcp.15138,USA,retrospective PK study,23,RRT,impaired,burns,meropenem
weight,Patient characteristics,no,NA,Selig,2022,https://dx.doi.org/10.1111/bcp.15138,USA,retrospective PK study,23,RRT,impaired,burns,meropenem
weight,Patient characteristics,no,NA,Selig,2022,https://dx.doi.org/10.1111/bcp.15138,USA,retrospective PK study,23,RRT,impaired,burns,meropenem
creatinine clearance,Physiological parameters,yes,CL,Sanches,2022,https://dx.doi.org/10.3390/antibiotics11040434,Brazil,retrospective PK study,24,no,normal,general ICU,piperacillin
CRRT,Organ dysfunction/support,yes,CL,Shekar,2014,https://dx.doi.org/10.1186/s13054-014-0565-2,Australia,prospective PK study,11,"ECMO, RRT",impaired,ECMO,meropenem
age,Patient characteristics,no,NA,Shekar,2014,https://dx.doi.org/10.1186/s13054-014-0565-2,Australia,prospective PK study,11,"ECMO, RRT",impaired,ECMO,meropenem
ECMO,Organ dysfunction/support,no,NA,Shekar,2014,https://dx.doi.org/10.1186/s13054-014-0565-2,Australia,prospective PK study,11,"ECMO, RRT",impaired,ECMO,meropenem
serum creatinine,Biomarkers,no,NA,Shekar,2014,https://dx.doi.org/10.1186/s13054-014-0565-2,Australia,prospective PK study,11,"ECMO, RRT",impaired,ECMO,meropenem
sex,Patient characteristics,no,NA,Shekar,2014,https://dx.doi.org/10.1186/s13054-014-0565-2,Australia,prospective PK study,11,"ECMO, RRT",impaired,ECMO,meropenem
weight,Patient characteristics,no,NA,Shekar,2014,https://dx.doi.org/10.1186/s13054-014-0565-2,Australia,prospective PK study,11,"ECMO, RRT",impaired,ECMO,meropenem
CRRT parameters,Extracorporeal parameters,yes,k,Shotwell,2016,https://doi.org/10.2215/cjn.10260915,USA,prospective PK study,68,RRT,impaired,CRRT,piperacillin
weight,Patient characteristics,yes,V,Shotwell,2016,https://doi.org/10.2215/cjn.10260915,USA,prospective PK study,68,RRT,impaired,CRRT,piperacillin
age,Patient characteristics,no,NA,Shotwell,2016,https://doi.org/10.2215/cjn.10260915,USA,prospective PK study,68,RRT,impaired,CRRT,piperacillin
sex,Patient characteristics,no,NA,Shotwell,2016,https://doi.org/10.2215/cjn.10260915,USA,prospective PK study,68,RRT,impaired,CRRT,piperacillin
creatinine clearance,Physiological parameters,yes,CL,Selig,2022,https://dx.doi.org/10.3390/antibiotics11050618,USA,retrospective PK study,19,no,unclear,trauma,piperacillin
weight,Patient characteristics,yes,V,Sime,2019,https://dx.doi.org/10.1128/AAC.01265-19,Australia,prospective PK study,12,no,normal,general ICU,ceftolozane
APACHE,Disease severity score,no,NA,Sime,2019,https://dx.doi.org/10.1128/AAC.01265-19,Australia,prospective PK study,12,no,normal,general ICU,ceftolozane
BMI,Patient characteristics,no,NA,Sime,2019,https://dx.doi.org/10.1128/AAC.01265-19,Australia,prospective PK study,12,no,normal,general ICU,ceftolozane
serum albumin,Biomarkers,no,NA,Sime,2019,https://dx.doi.org/10.1128/AAC.01265-19,Australia,prospective PK study,12,no,normal,general ICU,ceftolozane
serum creatinine,Biomarkers,no,NA,Sime,2019,https://dx.doi.org/10.1128/AAC.01265-19,Australia,prospective PK study,12,no,normal,general ICU,ceftolozane
SOFA,Disease severity score,no,NA,Sime,2019,https://dx.doi.org/10.1128/AAC.01265-19,Australia,prospective PK study,12,no,normal,general ICU,ceftolozane
APACHE,Disease severity score,no,NA,Sime,2020,https://dx.doi.org/10.1128/AAC.01655-19,Australia,prospective PK study,6,RRT,impaired,CRRT,ceftolozane
BMI,Patient characteristics,no,NA,Sime,2020,https://dx.doi.org/10.1128/AAC.01655-19,Australia,prospective PK study,6,RRT,impaired,CRRT,ceftolozane
BSA,Patient characteristics,no,NA,Sime,2020,https://dx.doi.org/10.1128/AAC.01655-19,Australia,prospective PK study,6,RRT,impaired,CRRT,ceftolozane
CRRT parameters,Extracorporeal parameters,no,NA,Sime,2020,https://dx.doi.org/10.1128/AAC.01655-19,Australia,prospective PK study,6,RRT,impaired,CRRT,ceftolozane
CRRT parameters,Extracorporeal parameters,no,NA,Sime,2020,https://dx.doi.org/10.1128/AAC.01655-19,Australia,prospective PK study,6,RRT,impaired,CRRT,ceftolozane
CRRT parameters,Extracorporeal parameters,no,NA,Sime,2020,https://dx.doi.org/10.1128/AAC.01655-19,Australia,prospective PK study,6,RRT,impaired,CRRT,ceftolozane
CRRT parameters,Extracorporeal parameters,no,NA,Sime,2020,https://dx.doi.org/10.1128/AAC.01655-19,Australia,prospective PK study,6,RRT,impaired,CRRT,ceftolozane
height,Patient characteristics,no,NA,Sime,2020,https://dx.doi.org/10.1128/AAC.01655-19,Australia,prospective PK study,6,RRT,impaired,CRRT,ceftolozane
serum albumin,Biomarkers,no,NA,Sime,2020,https://dx.doi.org/10.1128/AAC.01655-19,Australia,prospective PK study,6,RRT,impaired,CRRT,ceftolozane
serum creatinine,Biomarkers,no,NA,Sime,2020,https://dx.doi.org/10.1128/AAC.01655-19,Australia,prospective PK study,6,RRT,impaired,CRRT,ceftolozane
sex,Patient characteristics,no,NA,Sime,2020,https://dx.doi.org/10.1128/AAC.01655-19,Australia,prospective PK study,6,RRT,impaired,CRRT,ceftolozane
SOFA,Disease severity score,no,NA,Sime,2020,https://dx.doi.org/10.1128/AAC.01655-19,Australia,prospective PK study,6,RRT,impaired,CRRT,ceftolozane
weight,Patient characteristics,no,NA,Sime,2020,https://dx.doi.org/10.1128/AAC.01655-19,Australia,prospective PK study,6,RRT,impaired,CRRT,ceftolozane
creatinine clearance,Physiological parameters,yes,CL,Selig,2022,https://dx.doi.org/10.1111/bcp.15138,USA,retrospective PK study,23,RRT,impaired,burns,meropenem
weight,Patient characteristics,yes,V,Sime,2021,https://dx.doi.org/10.1128/AAC.01698-20,Australia,prospective PK study,10,no,normal,EVD,ceftolozane
CSF,Other,yes,V,Sime,2021,https://dx.doi.org/10.1128/AAC.01698-20,Australia,prospective PK study,10,no,normal,EVD,ceftolozane
age,Patient characteristics,no,NA,Sime,2021,https://dx.doi.org/10.1128/AAC.01698-20,Australia,prospective PK study,10,no,normal,EVD,ceftolozane
APACHE,Disease severity score,no,NA,Sime,2021,https://dx.doi.org/10.1128/AAC.01698-20,Australia,prospective PK study,10,no,normal,EVD,ceftolozane
CSF,Other,no,NA,Sime,2021,https://dx.doi.org/10.1128/AAC.01698-20,Australia,prospective PK study,10,no,normal,EVD,ceftolozane
CSF,Other,no,NA,Sime,2021,https://dx.doi.org/10.1128/AAC.01698-20,Australia,prospective PK study,10,no,normal,EVD,ceftolozane
height,Patient characteristics,no,NA,Sime,2021,https://dx.doi.org/10.1128/AAC.01698-20,Australia,prospective PK study,10,no,normal,EVD,ceftolozane
serum albumin,Biomarkers,no,NA,Sime,2021,https://dx.doi.org/10.1128/AAC.01698-20,Australia,prospective PK study,10,no,normal,EVD,ceftolozane
serum creatinine,Biomarkers,no,NA,Sime,2021,https://dx.doi.org/10.1128/AAC.01698-20,Australia,prospective PK study,10,no,normal,EVD,ceftolozane
sex,Patient characteristics,no,NA,Sime,2021,https://dx.doi.org/10.1128/AAC.01698-20,Australia,prospective PK study,10,no,normal,EVD,ceftolozane
SOFA,Disease severity score,no,NA,Sime,2021,https://dx.doi.org/10.1128/AAC.01698-20,Australia,prospective PK study,10,no,normal,EVD,ceftolozane
creatinine clearance,Physiological parameters,yes,CL,Shekar,2014,https://dx.doi.org/10.1186/s13054-014-0565-2,Australia,prospective PK study,11,"ECMO, RRT",impaired,ECMO,meropenem
BP,Vital signs,yes,CL,Sukarnjanaset,2019,https://dx.doi.org/10.1007/s10928-019-09633-8,Thailand,prospective PK study,48,no,normal,general ICU,piperacillin
creatinine clearance,Physiological parameters,yes,CL,Sime,2019,https://dx.doi.org/10.1128/AAC.01265-19,Australia,prospective PK study,12,no,normal,general ICU,ceftolozane
weight,Patient characteristics,yes,V,Sukarnjanaset,2019,https://dx.doi.org/10.1007/s10928-019-09633-8,Thailand,prospective PK study,48,no,normal,general ICU,piperacillin
age,Patient characteristics,no,NA,Sukarnjanaset,2019,https://dx.doi.org/10.1007/s10928-019-09633-8,Thailand,prospective PK study,48,no,normal,general ICU,piperacillin
APACHE,Disease severity score,no,NA,Sukarnjanaset,2019,https://dx.doi.org/10.1007/s10928-019-09633-8,Thailand,prospective PK study,48,no,normal,general ICU,piperacillin
fluid balance,Physiological parameters,no,NA,Sukarnjanaset,2019,https://dx.doi.org/10.1007/s10928-019-09633-8,Thailand,prospective PK study,48,no,normal,general ICU,piperacillin
mechanical ventilation,Organ dysfunction/support,no,NA,Sukarnjanaset,2019,https://dx.doi.org/10.1007/s10928-019-09633-8,Thailand,prospective PK study,48,no,normal,general ICU,piperacillin
serum albumin,Biomarkers,no,NA,Sukarnjanaset,2019,https://dx.doi.org/10.1007/s10928-019-09633-8,Thailand,prospective PK study,48,no,normal,general ICU,piperacillin
serum bilirubin,Biomarkers,no,NA,Sukarnjanaset,2019,https://dx.doi.org/10.1007/s10928-019-09633-8,Thailand,prospective PK study,48,no,normal,general ICU,piperacillin
sex,Patient characteristics,no,NA,Sukarnjanaset,2019,https://dx.doi.org/10.1007/s10928-019-09633-8,Thailand,prospective PK study,48,no,normal,general ICU,piperacillin
SOFA,Disease severity score,no,NA,Sukarnjanaset,2019,https://dx.doi.org/10.1007/s10928-019-09633-8,Thailand,prospective PK study,48,no,normal,general ICU,piperacillin
vasopressor use,Organ dysfunction/support,no,NA,Sukarnjanaset,2019,https://dx.doi.org/10.1007/s10928-019-09633-8,Thailand,prospective PK study,48,no,normal,general ICU,piperacillin
weight,Patient characteristics,no,NA,Sukarnjanaset,2019,https://dx.doi.org/10.1007/s10928-019-09633-8,Thailand,prospective PK study,48,no,normal,general ICU,piperacillin
weight,Patient characteristics,no,NA,Sukarnjanaset,2019,https://dx.doi.org/10.1007/s10928-019-09633-8,Thailand,prospective PK study,48,no,normal,general ICU,piperacillin
creatinine clearance,Physiological parameters,yes,CL,Sime,2021,https://dx.doi.org/10.1128/AAC.01698-20,Australia,prospective PK study,10,no,normal,EVD,ceftolozane
burns,Patient characteristics,no,NA,Swartling,2022,https://dx.doi.org/10.1007/s00228-021-03218-6,Sweden,prospective PK study,51,no,normal,burns,cefotaxime
day of antibiotic therapy,Other,no,NA,Swartling,2022,https://dx.doi.org/10.1007/s00228-021-03218-6,Sweden,prospective PK study,51,no,normal,burns,cefotaxime
SAPS,Disease severity score,no,NA,Swartling,2022,https://dx.doi.org/10.1007/s00228-021-03218-6,Sweden,prospective PK study,51,no,normal,burns,cefotaxime
weight,Patient characteristics,no,NA,Swartling,2022,https://dx.doi.org/10.1007/s00228-021-03218-6,Sweden,prospective PK study,51,no,normal,burns,cefotaxime
APACHE,Disease severity score,no,NA,Tamme,2015,https://dx.doi.org/10.1002/jcph.432,Estonia,prospective PK study,9,RRT,impaired,CRRT,doripenem
CRRT parameters,Extracorporeal parameters,no,NA,Tamme,2015,https://dx.doi.org/10.1002/jcph.432,Estonia,prospective PK study,9,RRT,impaired,CRRT,doripenem
CRRT parameters,Extracorporeal parameters,no,NA,Tamme,2015,https://dx.doi.org/10.1002/jcph.432,Estonia,prospective PK study,9,RRT,impaired,CRRT,doripenem
CRRT parameters,Extracorporeal parameters,no,NA,Tamme,2015,https://dx.doi.org/10.1002/jcph.432,Estonia,prospective PK study,9,RRT,impaired,CRRT,doripenem
serum creatinine,Biomarkers,no,NA,Tamme,2015,https://dx.doi.org/10.1002/jcph.432,Estonia,prospective PK study,9,RRT,impaired,CRRT,doripenem
creatinine clearance,Physiological parameters,yes,CL,Stein,2019,https://dx.doi.org/10.1089/sur.2018.141,USA,prospective PK study,10,no,normal,general ICU,ceftazidime
vasopressor use,Organ dysfunction/support,yes,CL,Thuy,2018,https://dx.doi.org/10.29090/psa.2018.04.017.0042,Vietnam,prospective PK study,30,no,normal,pneumonia,meropenem
age,Patient characteristics,no,NA,Thuy,2018,https://dx.doi.org/10.29090/psa.2018.04.017.0042,Vietnam,prospective PK study,30,no,normal,pneumonia,meropenem
location,Other,no,NA,Thuy,2018,https://dx.doi.org/10.29090/psa.2018.04.017.0042,Vietnam,prospective PK study,30,no,normal,pneumonia,meropenem
mechanical ventilation,Organ dysfunction/support,no,NA,Thuy,2018,https://dx.doi.org/10.29090/psa.2018.04.017.0042,Vietnam,prospective PK study,30,no,normal,pneumonia,meropenem
serum albumin,Biomarkers,no,NA,Thuy,2018,https://dx.doi.org/10.29090/psa.2018.04.017.0042,Vietnam,prospective PK study,30,no,normal,pneumonia,meropenem
sex,Patient characteristics,no,NA,Thuy,2018,https://dx.doi.org/10.29090/psa.2018.04.017.0042,Vietnam,prospective PK study,30,no,normal,pneumonia,meropenem
weight,Patient characteristics,no,NA,Thuy,2018,https://dx.doi.org/10.29090/psa.2018.04.017.0042,Vietnam,prospective PK study,30,no,normal,pneumonia,meropenem
creatinine clearance,Physiological parameters,yes,CL,Sukarnjanaset,2019,https://dx.doi.org/10.1007/s10928-019-09633-8,Thailand,prospective PK study,48,no,normal,general ICU,piperacillin
indwelling catheter,Other,yes,V,Truong,2022,https://dx.doi.org/10.1128/aac.00321-22,Vietnam,prospective PK study,27,no,normal,general ICU,meropenem
age,Patient characteristics,no,NA,Truong,2022,https://dx.doi.org/10.1128/aac.00321-22,Vietnam,prospective PK study,27,no,normal,general ICU,meropenem
diuretic use,Other,no,NA,Truong,2022,https://dx.doi.org/10.1128/aac.00321-22,Vietnam,prospective PK study,27,no,normal,general ICU,meropenem
fluid balance,Physiological parameters,no,NA,Truong,2022,https://dx.doi.org/10.1128/aac.00321-22,Vietnam,prospective PK study,27,no,normal,general ICU,meropenem
sepsis,Organ dysfunction/support,no,NA,Truong,2022,https://dx.doi.org/10.1128/aac.00321-22,Vietnam,prospective PK study,27,no,normal,general ICU,meropenem
sepsis,Organ dysfunction/support,no,NA,Truong,2022,https://dx.doi.org/10.1128/aac.00321-22,Vietnam,prospective PK study,27,no,normal,general ICU,meropenem
serum albumin,Biomarkers,no,NA,Truong,2022,https://dx.doi.org/10.1128/aac.00321-22,Vietnam,prospective PK study,27,no,normal,general ICU,meropenem
sex,Patient characteristics,no,NA,Truong,2022,https://dx.doi.org/10.1128/aac.00321-22,Vietnam,prospective PK study,27,no,normal,general ICU,meropenem
weight,Patient characteristics,no,NA,Truong,2022,https://dx.doi.org/10.1128/aac.00321-22,Vietnam,prospective PK study,27,no,normal,general ICU,meropenem
creatinine clearance,Physiological parameters,yes,CL,Swartling,2022,https://dx.doi.org/10.1007/s00228-021-03218-6,Sweden,prospective PK study,51,no,normal,burns,cefotaxime
weight,Patient characteristics,yes,V,Tsai,2016,https://doi.org/10.1128/aac.01657-16,Australia,prospective PK study,9,no,normal,sepsis,piperacillin
age,Patient characteristics,no,NA,Tsai,2016,https://doi.org/10.1128/aac.01657-16,Australia,prospective PK study,9,no,normal,sepsis,piperacillin
APACHE,Disease severity score,no,NA,Tsai,2016,https://doi.org/10.1128/aac.01657-16,Australia,prospective PK study,9,no,normal,sepsis,piperacillin
BMI,Patient characteristics,no,NA,Tsai,2016,https://doi.org/10.1128/aac.01657-16,Australia,prospective PK study,9,no,normal,sepsis,piperacillin
height,Patient characteristics,no,NA,Tsai,2016,https://doi.org/10.1128/aac.01657-16,Australia,prospective PK study,9,no,normal,sepsis,piperacillin
serum albumin,Biomarkers,no,NA,Tsai,2016,https://doi.org/10.1128/aac.01657-16,Australia,prospective PK study,9,no,normal,sepsis,piperacillin
serum creatinine,Biomarkers,no,NA,Tsai,2016,https://doi.org/10.1128/aac.01657-16,Australia,prospective PK study,9,no,normal,sepsis,piperacillin
sex,Patient characteristics,no,NA,Tsai,2016,https://doi.org/10.1128/aac.01657-16,Australia,prospective PK study,9,no,normal,sepsis,piperacillin
SOFA,Disease severity score,no,NA,Tsai,2016,https://doi.org/10.1128/aac.01657-16,Australia,prospective PK study,9,no,normal,sepsis,piperacillin
vasopressor use,Organ dysfunction/support,no,NA,Tsai,2016,https://doi.org/10.1128/aac.01657-16,Australia,prospective PK study,9,no,normal,sepsis,piperacillin
creatinine clearance,Physiological parameters,yes,CL,Thuy,2018,https://dx.doi.org/10.29090/psa.2018.04.017.0042,Vietnam,prospective PK study,30,no,normal,pneumonia,meropenem
weight,Patient characteristics,yes,V,Tsai,2016,https://dx.doi.org/10.1016/j.ijantimicag.2016.08.015,Australia,prospective PK study,11,no,normal,sepsis,meropenem
age,Patient characteristics,no,NA,Tsai,2016,https://dx.doi.org/10.1016/j.ijantimicag.2016.08.015,Australia,prospective PK study,11,no,normal,sepsis,meropenem
ethnicity,Patient characteristics,no,NA,Tsai,2016,https://dx.doi.org/10.1016/j.ijantimicag.2016.08.015,Australia,prospective PK study,11,no,normal,sepsis,meropenem
serum albumin,Biomarkers,no,NA,Tsai,2016,https://dx.doi.org/10.1016/j.ijantimicag.2016.08.015,Australia,prospective PK study,11,no,normal,sepsis,meropenem
serum creatinine,Biomarkers,no,NA,Tsai,2016,https://dx.doi.org/10.1016/j.ijantimicag.2016.08.015,Australia,prospective PK study,11,no,normal,sepsis,meropenem
sex,Patient characteristics,no,NA,Tsai,2016,https://dx.doi.org/10.1016/j.ijantimicag.2016.08.015,Australia,prospective PK study,11,no,normal,sepsis,meropenem
SOFA,Disease severity score,no,NA,Tsai,2016,https://dx.doi.org/10.1016/j.ijantimicag.2016.08.015,Australia,prospective PK study,11,no,normal,sepsis,meropenem
vasopressor use,Organ dysfunction/support,no,NA,Tsai,2016,https://dx.doi.org/10.1016/j.ijantimicag.2016.08.015,Australia,prospective PK study,11,no,normal,sepsis,meropenem
creatinine clearance,Physiological parameters,yes,CL,Truong,2022,https://dx.doi.org/10.1128/aac.00321-22,Vietnam,prospective PK study,27,no,normal,general ICU,meropenem
BMI,Patient characteristics,yes,CL,Ulldemolins,2010,https://dx.doi.org/10.1093/jac/dkq184,Australia,prospective PK study,10,no,normal,hypoalbuminaemia,flucloxacillin
age,Patient characteristics,no,NA,Ulldemolins,2010,https://dx.doi.org/10.1093/jac/dkq184,Australia,prospective PK study,10,no,normal,hypoalbuminaemia,flucloxacillin
APACHE,Disease severity score,no,NA,Ulldemolins,2010,https://dx.doi.org/10.1093/jac/dkq184,Australia,prospective PK study,10,no,normal,hypoalbuminaemia,flucloxacillin
creatinine clearance,Physiological parameters,yes,CL,Tsai,2016,https://doi.org/10.1128/aac.01657-16,Australia,prospective PK study,9,no,normal,sepsis,piperacillin
serum albumin,Biomarkers,no,NA,Ulldemolins,2010,https://dx.doi.org/10.1093/jac/dkq184,Australia,prospective PK study,10,no,normal,hypoalbuminaemia,flucloxacillin
serum bilirubin,Biomarkers,no,NA,Ulldemolins,2010,https://dx.doi.org/10.1093/jac/dkq184,Australia,prospective PK study,10,no,normal,hypoalbuminaemia,flucloxacillin
serum creatinine,Biomarkers,no,NA,Ulldemolins,2010,https://dx.doi.org/10.1093/jac/dkq184,Australia,prospective PK study,10,no,normal,hypoalbuminaemia,flucloxacillin
SOFA,Disease severity score,no,NA,Ulldemolins,2010,https://dx.doi.org/10.1093/jac/dkq184,Australia,prospective PK study,10,no,normal,hypoalbuminaemia,flucloxacillin
weight,Patient characteristics,no,NA,Ulldemolins,2010,https://dx.doi.org/10.1093/jac/dkq184,Australia,prospective PK study,10,no,normal,hypoalbuminaemia,flucloxacillin
weight,Patient characteristics,no,NA,Ulldemolins,2010,https://dx.doi.org/10.1093/jac/dkq184,Australia,prospective PK study,10,no,normal,hypoalbuminaemia,flucloxacillin
diuresis,Physiological parameters,yes,CL,Ulldemolins,2015,https://dx.doi.org/10.1128/AAC.00712-15,Spain,prospective PK study,30,RRT,impaired,septic shock,meropenem
weight,Patient characteristics,yes,V,Ulldemolins,2015,https://dx.doi.org/10.1128/AAC.00712-15,Spain,prospective PK study,30,RRT,impaired,septic shock,meropenem
age,Patient characteristics,no,NA,Ulldemolins,2015,https://dx.doi.org/10.1128/AAC.00712-15,Spain,prospective PK study,30,RRT,impaired,septic shock,meropenem
APACHE,Disease severity score,no,NA,Ulldemolins,2015,https://dx.doi.org/10.1128/AAC.00712-15,Spain,prospective PK study,30,RRT,impaired,septic shock,meropenem
CRRT parameters,Extracorporeal parameters,no,NA,Ulldemolins,2015,https://dx.doi.org/10.1128/AAC.00712-15,Spain,prospective PK study,30,RRT,impaired,septic shock,meropenem
CRRT parameters,Extracorporeal parameters,no,NA,Ulldemolins,2015,https://dx.doi.org/10.1128/AAC.00712-15,Spain,prospective PK study,30,RRT,impaired,septic shock,meropenem
CRRT parameters,Extracorporeal parameters,no,NA,Ulldemolins,2015,https://dx.doi.org/10.1128/AAC.00712-15,Spain,prospective PK study,30,RRT,impaired,septic shock,meropenem
CRRT parameters,Extracorporeal parameters,no,NA,Ulldemolins,2015,https://dx.doi.org/10.1128/AAC.00712-15,Spain,prospective PK study,30,RRT,impaired,septic shock,meropenem
serum albumin,Biomarkers,no,NA,Ulldemolins,2015,https://dx.doi.org/10.1128/AAC.00712-15,Spain,prospective PK study,30,RRT,impaired,septic shock,meropenem
SOFA,Disease severity score,no,NA,Ulldemolins,2015,https://dx.doi.org/10.1128/AAC.00712-15,Spain,prospective PK study,30,RRT,impaired,septic shock,meropenem
CRRT parameters,Extracorporeal parameters,yes,CL,Ulldemolins,2016,https://dx.doi.org/10.1093/jac/dkv503,Spain,prospective PK study,19,RRT,impaired,MODS,piperacillin
weight,Patient characteristics,yes,CL,Ulldemolins,2016,https://dx.doi.org/10.1093/jac/dkv503,Spain,prospective PK study,19,RRT,impaired,MODS,piperacillin
APACHE,Disease severity score,no,NA,Ulldemolins,2016,https://dx.doi.org/10.1093/jac/dkv503,Spain,prospective PK study,19,RRT,impaired,MODS,piperacillin
CRRT parameters,Extracorporeal parameters,no,NA,Ulldemolins,2016,https://dx.doi.org/10.1093/jac/dkv503,Spain,prospective PK study,19,RRT,impaired,MODS,piperacillin
CRRT parameters,Extracorporeal parameters,no,NA,Ulldemolins,2016,https://dx.doi.org/10.1093/jac/dkv503,Spain,prospective PK study,19,RRT,impaired,MODS,piperacillin
diuresis,Physiological parameters,no,NA,Ulldemolins,2016,https://dx.doi.org/10.1093/jac/dkv503,Spain,prospective PK study,19,RRT,impaired,MODS,piperacillin
serum albumin,Biomarkers,no,NA,Ulldemolins,2016,https://dx.doi.org/10.1093/jac/dkv503,Spain,prospective PK study,19,RRT,impaired,MODS,piperacillin
SOFA,Disease severity score,no,NA,Ulldemolins,2016,https://dx.doi.org/10.1093/jac/dkv503,Spain,prospective PK study,19,RRT,impaired,MODS,piperacillin
serum albumin,Biomarkers,yes,fu,Ulldemolins,2021,https://dx.doi.org/10.1007/s00228-021-03100-5,Spain,prospective PK study,8,RRT,impaired,sepsis,ceftriaxone
weight,Patient characteristics,no,"V, CL",Ulldemolins,2021,https://dx.doi.org/10.1007/s00228-021-03100-5,Spain,prospective PK study,8,RRT,impaired,sepsis,ceftriaxone
age,Patient characteristics,no,NA,Ulldemolins,2021,https://dx.doi.org/10.1007/s00228-021-03100-5,Spain,prospective PK study,8,RRT,impaired,sepsis,ceftriaxone
APACHE,Disease severity score,no,NA,Ulldemolins,2021,https://dx.doi.org/10.1007/s00228-021-03100-5,Spain,prospective PK study,8,RRT,impaired,sepsis,ceftriaxone
CRRT parameters,Extracorporeal parameters,no,NA,Ulldemolins,2021,https://dx.doi.org/10.1007/s00228-021-03100-5,Spain,prospective PK study,8,RRT,impaired,sepsis,ceftriaxone
CRRT parameters,Extracorporeal parameters,no,NA,Ulldemolins,2021,https://dx.doi.org/10.1007/s00228-021-03100-5,Spain,prospective PK study,8,RRT,impaired,sepsis,ceftriaxone
CRRT parameters,Extracorporeal parameters,no,NA,Ulldemolins,2021,https://dx.doi.org/10.1007/s00228-021-03100-5,Spain,prospective PK study,8,RRT,impaired,sepsis,ceftriaxone
diuresis,Physiological parameters,no,NA,Ulldemolins,2021,https://dx.doi.org/10.1007/s00228-021-03100-5,Spain,prospective PK study,8,RRT,impaired,sepsis,ceftriaxone
sex,Patient characteristics,no,NA,Ulldemolins,2021,https://dx.doi.org/10.1007/s00228-021-03100-5,Spain,prospective PK study,8,RRT,impaired,sepsis,ceftriaxone
SOFA,Disease severity score,no,NA,Ulldemolins,2021,https://dx.doi.org/10.1007/s00228-021-03100-5,Spain,prospective PK study,8,RRT,impaired,sepsis,ceftriaxone
BMI,Patient characteristics,no,NA,Vossen,2015,https://dx.doi.org/10.1128/AAC.01801-15,Austria,prospective PK study,14,RRT,impaired,CRRT,doripenem
sex,Patient characteristics,no,NA,Vossen,2015,https://dx.doi.org/10.1128/AAC.01801-15,Austria,prospective PK study,14,RRT,impaired,CRRT,doripenem
weight,Patient characteristics,no,NA,Vossen,2015,https://dx.doi.org/10.1128/AAC.01801-15,Austria,prospective PK study,14,RRT,impaired,CRRT,doripenem
serum albumin,Biomarkers,yes,Bmax,Wallenburg,2021,https://dx.doi.org/10.1093/jac/dkab314,Netherlands,prospective PK study,33,RRT,impaired,general ICU,flucloxacillin
GFR,Physiological parameters,yes,CL,Wallenburg,2021,https://dx.doi.org/10.1093/jac/dkab314,Netherlands,prospective PK study,33,RRT,impaired,general ICU,flucloxacillin
BUN,Biomarkers,no,NA,Wallenburg,2021,https://dx.doi.org/10.1093/jac/dkab314,Netherlands,prospective PK study,33,RRT,impaired,general ICU,flucloxacillin
creatinine clearance,Physiological parameters,yes,CL,Tsai,2016,https://dx.doi.org/10.1016/j.ijantimicag.2016.08.015,Australia,prospective PK study,11,no,normal,sepsis,meropenem
CRRT,Organ dysfunction/support,no,NA,Wallenburg,2021,https://dx.doi.org/10.1093/jac/dkab314,Netherlands,prospective PK study,33,RRT,impaired,general ICU,flucloxacillin
serum bilirubin,Biomarkers,no,NA,Wallenburg,2021,https://dx.doi.org/10.1093/jac/dkab314,Netherlands,prospective PK study,33,RRT,impaired,general ICU,flucloxacillin
creatinine clearance,Physiological parameters,yes,CL,Udy,2015,https://dx.doi.org/10.1186/s13054-015-0750-y,Australia,prospective PK study,48,no,normal,sepsis,piperacillin
GFR,Physiological parameters,no,NA,Wallenburg,2022,https://dx.doi.org/10.1007/s40262-022-01113-6,Netherlands,prospective PK study,39,no,normal,general ICU,piperacillin
CRRT parameters,Extracorporeal parameters,yes,CL,Westermann,2021,https://dx.doi.org/10.1111/bcp.14846,Germany,prospective PK study,25,RRT,impaired,CRRT,meropenem
diuresis,Physiological parameters,yes,CL,Westermann,2021,https://dx.doi.org/10.1111/bcp.14846,Germany,prospective PK study,25,RRT,impaired,CRRT,meropenem
serum creatinine,Biomarkers,yes,CL,Westermann,2021,https://dx.doi.org/10.1111/bcp.14846,Germany,prospective PK study,25,RRT,impaired,CRRT,meropenem
creatinine clearance,Physiological parameters,yes,CL,Wallenburg,2022,https://dx.doi.org/10.1007/s40262-022-01113-6,Netherlands,prospective PK study,39,no,normal,general ICU,piperacillin
CRRT parameters,Extracorporeal parameters,no,NA,Westermann,2021,https://dx.doi.org/10.1111/bcp.14846,Germany,prospective PK study,25,RRT,impaired,CRRT,meropenem
creatinine clearance,Physiological parameters,yes,CL,Young,1997,https://dx.doi.org/10.1093/jac/40.2.269,China,prospective PK study,10,no,normal,pneumonia,ceftazidime
APACHE,Disease severity score,no,NA,Young,1997,https://dx.doi.org/10.1093/jac/40.2.269,China,prospective PK study,10,no,normal,pneumonia,ceftazidime
serum albumin,Biomarkers,no,NA,Young,1997,https://dx.doi.org/10.1093/jac/40.2.269,China,prospective PK study,10,no,normal,pneumonia,ceftazidime
serum bilirubin,Biomarkers,no,NA,Young,1997,https://dx.doi.org/10.1093/jac/40.2.269,China,prospective PK study,10,no,normal,pneumonia,ceftazidime
SOFA,Disease severity score,no,NA,Young,1997,https://dx.doi.org/10.1093/jac/40.2.269,China,prospective PK study,10,no,normal,pneumonia,ceftazidime
GFR,Physiological parameters,yes,CL,Zahr,2022,https://dx.doi.org/10.3390/pharmaceutics14122786,France,retrospective PK study,55,no,unclear,VAP,cefiderocol
weight,Patient characteristics,yes,CL,Zahr,2022,https://dx.doi.org/10.3390/pharmaceutics14122786,France,retrospective PK study,55,no,unclear,VAP,cefiderocol
age,Patient characteristics,no,NA,Zahr,2022,https://dx.doi.org/10.3390/pharmaceutics14122786,France,retrospective PK study,55,no,unclear,VAP,cefiderocol
serum albumin,Biomarkers,yes,NA,Zahr,2022,https://dx.doi.org/10.3390/pharmaceutics14122786,France,retrospective PK study,55,no,unclear,VAP,cefiderocol
sex,Patient characteristics,no,NA,Zahr,2022,https://dx.doi.org/10.3390/pharmaceutics14122786,France,retrospective PK study,55,no,unclear,VAP,cefiderocol
weight,Patient characteristics,yes,NA,Zahr,2022,https://dx.doi.org/10.3390/pharmaceutics14122786,France,retrospective PK study,55,no,unclear,VAP,cefiderocol
uric acid,Biomarkers,yes,"CL, V",Zhao,2022,https://dx.doi.org/10.1007/s40121-021-00551-2,China,prospective PK study,64,no,unclear,pneumonia,meropenem
age,Patient characteristics,no,NA,Zhao,2022,https://dx.doi.org/10.1007/s40121-021-00551-2,China,prospective PK study,64,no,unclear,pneumonia,meropenem
ALT,Biomarkers,no,NA,Zhao,2022,https://dx.doi.org/10.1007/s40121-021-00551-2,China,prospective PK study,64,no,unclear,pneumonia,meropenem
aminotransferase,Biomarkers,no,NA,Zhao,2022,https://dx.doi.org/10.1007/s40121-021-00551-2,China,prospective PK study,64,no,unclear,pneumonia,meropenem
APACHE,Disease severity score,no,NA,Zhao,2022,https://dx.doi.org/10.1007/s40121-021-00551-2,China,prospective PK study,64,no,unclear,pneumonia,meropenem
BUN,Biomarkers,no,NA,Zhao,2022,https://dx.doi.org/10.1007/s40121-021-00551-2,China,prospective PK study,64,no,unclear,pneumonia,meropenem
creatinine clearance,Physiological parameters,yes,NA,Zhao,2022,https://dx.doi.org/10.1007/s40121-021-00551-2,China,prospective PK study,64,no,unclear,pneumonia,meropenem
haemoglobin,Biomarkers,no,NA,Zhao,2022,https://dx.doi.org/10.1007/s40121-021-00551-2,China,prospective PK study,64,no,unclear,pneumonia,meropenem
platelets,Biomarkers,no,NA,Zhao,2022,https://dx.doi.org/10.1007/s40121-021-00551-2,China,prospective PK study,64,no,unclear,pneumonia,meropenem
red cell count,Biomarkers,no,NA,Zhao,2022,https://dx.doi.org/10.1007/s40121-021-00551-2,China,prospective PK study,64,no,unclear,pneumonia,meropenem
serum albumin,Biomarkers,no,NA,Zhao,2022,https://dx.doi.org/10.1007/s40121-021-00551-2,China,prospective PK study,64,no,unclear,pneumonia,meropenem
sex,Patient characteristics,no,NA,Zhao,2022,https://dx.doi.org/10.1007/s40121-021-00551-2,China,prospective PK study,64,no,unclear,pneumonia,meropenem
weight,Patient characteristics,no,NA,Zhao,2022,https://dx.doi.org/10.1007/s40121-021-00551-2,China,prospective PK study,64,no,unclear,pneumonia,meropenem
white cell count,Biomarkers,no,NA,Zhao,2022,https://dx.doi.org/10.1007/s40121-021-00551-2,China,prospective PK study,64,no,unclear,pneumonia,meropenem
